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Abstract
The human endometrium is the site of embryo implantation and is therefore 
responsible for providing a suitable environment for an embryo to grow and develop. 
This is achieved by the endometrium undergoing cyclical changes, under the control 
of steroid hormones. However, it is clear that steroid hormones are not the final 
effectors, but rather initiate a downstream cascade of molecular events through local 
autocrine and paracrine factors, such as cytokines. The role of cytokines in the human 
endometrium still remains to be determined, but they are thought to play an important 
role in the implantation process. This study has therefore focused on the expression of 
pro-inflammatory cytokines in the human endometrium and effects of these cytokines 
on endometrial function.
Immunocytochemistry was used to determine the expression of leukaemia inhibitory 
factor (LIF), interleukin-6 (IL-6), interleukin-la (IL-1 a), interleukin-lp (IL-1 p) and 
tumour necrosis factor a  (TNFa) in the human endometrium of normal fertile women 
throughout the menstrual cycle. The results showed that staining intensity for LIF and 
IL-6 increased in epithelial cells at the time of implantation. IL-1 a  and IL-1 p 
remained relatively constant throughout the cycle, with a slight increase in epithelial 
IL-1 p at the time of implantation. The expression of TNFa could not be determined. 
Staining for LIF, IL-6, IL-1 a  and IL-1 p was then repeated on endometrial sections 
from biopsies obtained from women who suffer recurrent miscarriage at the time of 
implantation and compared to the staining obtained in biopsies from normal fertile 
women. For all four cytokines, there were some biopsies from women who suffer 
recurrent miscarriage, where staining was significantly weaker than that seen in 
normal fertile women at the same time in the menstrual cycle. These results suggest 
that LIF, IL-6, IL-1 a  and IL-1 p may therefore be important for successful 
implantation and subsequently successful pregnancy outcome.
Matrix metalloproteinases (MMPs) are postulated to be involved in the implantation 
process, as they are capable of digesting the components of the extracellular matrix. 
Recent studies have shown that cytokines may be involved in the regulation of MMPs 
in both the endometrium and the invading trophoblast cells. The effects of LIF, IL-6, 
IL-1 a  and TNFa on endometrial MMP production in vitro were therefore
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investigated. MMP-2 was produced by both cultured epithelial and stromal cells, 
MMP-9 was produced mainly by epithelial cells and MMP-7 was only produced by 
epithelial cells. Although LIF and IL-6 had no significant effect on endometrial MMP 
production, IL-1 a  and TNFa did alter MMP-2, MMP-9 and MMP-7 production from 
both epithelial and stromal cells.
More recent studies have suggested the possible role of interleukin-11 (IL-11) in 
endometrial function, particularly decidualisation. Therefore the expression of both 
IL-11 and its receptor, IL-11R, was investigated in endometrial biopsies obtained 
from normal fertile women throughout the menstrual cycle. The results showed that 
both IL-11 and IL-11R were expressed throughout the menstrual cycle, predominantly 
by epithelial cells, however, stromal expression did increase slightly towards the end 
of the cycle.
The effects of cytokines on IL-11 production by cultured endometrial cells were also 
investigated. IL-1 a, TNFa and TGFp caused a significant increase in IL-11 
production from both stromal and epithelial cells. Finally the effects of IL-11 on 
MMP-2, MMP-9, MMP-7, IL-1 p and TNFa produced by cultured endometrial cells 
were studied. No effect of IL-11 on MMP production was seen by either stromal or 
epithelial cells, but IL-11 did cause a concentration dependent decrease in TNFa 
production from cultured epithelial cells.
The results have increased our knowledge on the expression and function of 
endometrial pro-inflammatory cytokines and suggested that although endometrial LIF 
and IL-6 expression is greatest at the time of implantation and is decreased in women 
who suffer recurrent miscarriage, IL-1 and TNFa have a greater effect on endometrial 
function. IL-11 is also expressed by the endometrium and is affected by other 
cytokines. Its positioning within the cytokine networks, which could control 
endometrial function, requires further study.
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Chapter 1 
General Introduction
1.1 Fem ale Reproductive Tract
The female reproductive tract has two distinct reproductive functions. Firstly, it must 
transport gametes to the site of fertilisation and secondly provide the site of 
implantation for the conceptus and a suitable environment for its subsequent 
development. There are four components to the human female reproductive tract, the 
anatomy of which is shown in figure 1.1. The ovaries are the centres of cyclicity, in 
that they release oocytes episodically at ovulation and are also responsible for the 
cyclic release of oestrogen and progesterone, two hormones that control female 
reproductive function. The fallopian tubes (or oviducts) consist of the fimbria, the 
ampulla and the isthmus, the function of which is to transport the oocytes from one 
of the ovaries to the uterus. The ampullary region of the fallopian tube is the site of 
fertilisation; as spermatozoa deposited in the vagina are transported up the female 
reproductive tract into the fallopian tube. The fallopian tube is also the site of early 
embryonic development as the resulting conceptus is transported to the uterus 
(Findlay, 1984: Johnson and Everitt, 1995).
The uterus is the site of implantation and placentation; it is here that growth of the 
embryo/fetus occurs. It consists of an upper expanded portion termed the body; a 
lower cylindrical part termed the cervix, and the fundus, which is the part of the body 
that extends above the point of entry of the fallopian tubes. The uterus is covered 
with a connective tissue layer called the peritoneum that extends laterally as the 
broad ligaments, from which the ovaries are suspended. The uterine wall consists of 
a thick smooth muscle layer, the myometrium and a vascular mucosal layer, the 
endometrium, which varies in thickness with the phases of the menstrual cycle.
The final component of the female reproductive tract is the vagina, which along with 
the cervix is the site of deposition and capacitation of spermatozoa and is also 
responsible for the expulsion of the fully developed infant (Findlay, 1984).
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Figure 1.1: Anatomy of the human female reproductive tract. Taken from Johnson 
and Everitt (1995).
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1.1.1 The ovary
A layer of low columnar epithelial cells, which lines a poorly defined layer of fibrous 
connective tissue called the tunica albuginea, covers the ovary. Within the ovary is 
an inner vascular medulla containing blood vessels, which branch off to form smaller 
blood vessels that then penetrate into the surrounding outer cortex. The cortex of the 
ovary consists of stromal cells and contains the primordial follicles, which constitute 
the fundamental functional units of the ovary (Sadow, 1980).
At birth each ovary contains approximately 2 x 106 primary oocytes, the majority of 
which undergo atresia during infancy. At puberty only 40,000 oocytes remain. They 
are surrounded by a layer of follicular cells, which are in turn surrounded by a layer 
of granulosa cells that secrete a basement membrane, the membrane propria, around 
the outside of the cellular unit which is now termed a primordial follicle. After 
puberty a small number of follicles are recruited daily into further growth, producing 
continuous development of follicles. It is not understood why there is daily 
recruitment of these primordial follicles or how the follicles that do begin to develop 
are selected. Before a primordial follicle can be released (at ovulation) it must pass 
through three stages of development (Findlay, 1984).
The first stage produces a primary or preantral follicle and is characterised by an 
increase in the size of the primary oocyte, secretion and formation of the zona 
pellucida by the oocyte and the development of thecal cells produced by the 
condensation of some of the surrounding stromal cells. The beginning of the next 
phase is characterised by the formation of vacuoles in the granulosa cells, which also 
begin to produce a viscous fluid known as follicular fluid. As the number of vacuoles 
increase, a cavity called the follicular antrum is formed. This increases in size and 
results in the oocyte being connected to the rim of the primordial granulosa cells by 
only a thin "stalk" of cells. The oocyte is however surrounded by a dense mass of 
granulosa cells called the cumulus oophorus (see figure 1.2). This maturing follicle 
also has two distinct thecal cell layers; the inner glandular theca interna and 
surrounding fibrous theca externa and is now termed the secondary or antral follicle. 
The initiation and early progress through the preantral stage is independent of any 
direct extra-ovarian controls but is probably under paracrine control and cytokines 
may be involved (Sadow, 1980).
3
Figure 1.2: Maturation of human ovarian follicles. Taken from Findlay (1984)
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Further on in follicular development, external support is required and this is provided 
endocrinologically by the pituitary gland. If there is no hormonal influence at this 
stage in follicular development then the follicles will undergo atresia. The presence 
of luteinising hormone (LH) and follicular stimulating hormone (FSH) released from 
the pituitary are vital in preventing atresia (Johnson and Everitt, 1995).
During the late preantral and early antral phases of follicular development receptors 
for these hormones appear on the follicular cells. Receptors for LH appear on the 
theca interna cells, whereas FSH receptors appear on the granulosa cells. The binding 
of LH to receptors in the theca internal cells stimulates the production of androgens 
from these cells and there is also a release of oestrogens (Sadow, 1980). The 
oestrogens are produced in one of either two ways. A small amount of oestrogen is 
produced by de novo synthesis from acetate and cholesterol within the cell, but the 
majority is produced by aromatisation of androgens (Sadow, 1980). FSH binds to 
receptors on the granulosa cells and stimulates oestrogen production, however, this 
only occurs in the presence of exogenous androgens, which are then aromatised 
producing oestrogens. Oestrogen, progesterone and androgens are all released into 
the follicular fluid and oestrogens bind to receptors on granulosa cells, stimulating 
the proliferation of increased numbers of oestrogen receptors, therefore providing a 
positive feedback mechanism whereby oestrogen is stimulating an increase in 
oestrogen output (Sadow, 1980). As a result the most advanced follicles provide a 
surge in circulating oestrogen. As oestrogen levels increase, there is an increase in 
LH levels caused by a positive feedback of oestrogen on the pituitary and 
hypothalamus. The increase in LH is rapid and results in a surge in LH that peaks 
approximately 18 hours before ovulation (Johnson and Everitt, 1995). Ovulation 
occurs on approximately day 14 of the menstrual cycle. However, because the length 
of the follicular phase can vary between individuals, the exact day of ovulation is 
also termed day LH + 0 (i.e. no days after the LH surge). Subsequent days in the 
luteal phase are then referred to as day LH + the number of days after the LH surge. 
So if ovulation occurs on day 14 or LH + 0, then day 20 can be referred too more 
exactly as day LH + 6 (Li et aL, 1988).
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The follicle undergoes final maturation to become a preovulatory or Graffian follicle. 
Oestrogen and FSH stimulate the appearance of LH binding sites on the outer layer 
of granulosa cells. This stage is critical for the expanded antral follicle to develop 
into the preovulatory phase of follicular growth (Sadow, 1980). The binding of LH to 
receptors on the granulosa cells causes two important processes to occur. Firstly it 
stimulates the terminal growth changes in the follicle and oocyte in the preovulatory 
follicle resulting in the oocyte rupturing through the follicle and being released, i.e. 
ovulation. Secondly, following the release of the oocyte, the follicle collapses. The 
granulosa cells are thrown into folds and bleeding occurs forming a clot in the centre. 
Capillaries from the theca interna infiltrate towards the centre and the granulosa cells 
proliferate. This whole process transforms the follicle into an endocrine organ called 
the corpus luteum, whose function is to produce progesterone (Johnson and Everitt, 
1995).
The interval between successive ovulations is known as the ovarian cycle. The period 
before ovulation occurs is known as the follicular phase, due to oestrogens being 
secreted from the follicular cells. The period after ovulation is known as the luteal 
phase, due to progesterone being secreted from the corpus luteum (Johnson and 
Everitt, 1995).
1.1.2 The uterus
The human uterus is a pear-shaped organ with two uterine horns and consists of the 
fundus, body and cervix. The uterus is slightly flattened dorso-ventrally and thus 
contains a flattened uterine cavity (Sadow, 1980). The myometrium consists of 
bundles of smooth muscle fibres separated by vascular connective tissue. During 
menstruation the myometrium undergoes low frequency, high amplitude 
contractions. By day 6  of the cycle the contractions are more frequent and by the 
time of ovulation have become high frequency, low amplitude contractions. Towards 
the end of the cycle the contractions decrease in frequency and amplitude, before a 
rapid rise in amplitude just prior to menstruation. The pattern of contractile activity 
results from the combined effects of steroid hormones and prostaglandins (Findlay,
1984). The uterine cavity is lined by a mucous membrane, the endometrium, which is 
where the embryo implants.
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1.1.3 The human endometrium
The human endometrium consists of two major cell types, epithelium and stroma.
The epithelial lay6r is a simple columnar epithelium and is composed of a mixture of 
ciliated and secretory cells. It lines the uterine cavity and is invaginated, which 
results in numerous uterine glands, the morphology of which is continuous with the 
surface epithelium although there are fewer ciliated cells present. The stromal 
compartment of the endometrium can be divided into the stratum functionalis and 
stratum basalis regions (see figure 1.3). It consists mainly of stromal cells and also a 
population of leukocytes that are dispersed throughout the stromal compartment 
(Bulmer et al., 1991).
Blood supply to the endometrium is provided via the uterine artery, which is a branch 
of the internal iliac artery. The uterine arteries, one from each side, run along the 
lateral walls of the uterus from the cervix upwards. The uterine arteries then branch 
off forming between 9 and 14 smaller arteries that penetrate the outer third of the 
myometrium. At this point the uterine arteries anastomose with the terminal branches 
of the ovarian arteries. From the anastomosis a series of arcuate arteries branch off, 
which run within the anterior and posterior myometrial walls thereby encircling it. 
The remaining myometrium is penetrated by radial arteries, which branch off the 
enveloping vasculature. As the radial arteries cross the myometrial-endometrial 
junction, they give off small straight branches called basal arteries, which are 
responsible for blood supply to the stratum basalis. The stratum functionalis requires 
a separate blood supply as it is shed during menstruation. This is provided by the 
spiral arteries, which branch off the basal arteries and pursue a winding course to 
reach the innermost endometrial zone, where they break up into a rich network of 
capillaries. Thin walled veins form an anastomosing network of sinusoids at all 
levels of the endometrium. Veins then follow the route of the arteries back to the 
uterine vein and eventually the internal iliac vein (Rogers, 1992).
1.1.4 The menstrual cycle
The ovarian cycle results in cyclic changes in steroid secretion that bring about 
changes to the endometrium (Figure 1.4). This cycle is termed the menstrual cycle 
and lasts for approximately 28 days, although any length between 25 and 35 days is
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Figure 1.3: Morphology of the human uterus. 
Taken from Sadow (1980)
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Figure 1.4: The menstrual cycle. Taken 
from Sherwood (1994)
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considered to be normal. The menstrual cycle prepares the endometrium to receive 
the blastocyst and subsequently to provide a suitable environment for the continued 
growth and development of the fetus. The cycle is divided into two phases, firstly the 
proliferative or follicular phase (days 0-14), which is then followed by the secretory 
or luteal phase (days 15-28) (Sherwood, 1994; Johnson and Everitt, 1995).
The proliferative phase follows menstruation and during this period the endometrium 
is only 1-2 mm thick. Both the surface and glandular epithelium is made up of 
cuboidal cells and the glands are very narrow and collapsed. Throughout the 
follicular phase of the cycle there is marked proliferation of both epithelial and 
stromal cells under the influence of oestrogens secreted from the ovary, causing 
thickening of the stromal cell layer and an increase in surface area and metabolic 
activity of the surface epithelium, which becomes columnar. The endometrial glands 
increase in number and size, and epithelial secretions containing numerous proteins 
and proteolytic enzymes are increased, reaching a maximum at the time of the 
oestrogen surge (Johnson and Everitt, 1995). Oestrogens act on the proliferative 
endometrium by binding to oestrogen receptors that are abundant in uterine tissue. 
The main functions of oestrogen are to ensure proliferation of the endometrium and 
to "prime" the endometrium so that it will be capable of responding to progesterone 
during the secretory phase of the menstrual cycle. Priming of the endometrium by 
oestrogen results in an increase in the synthesis of intracellular progesterone 
receptors. At the beginning of the proliferative phase there are very few progesterone 
receptors present within the endometrium and as a result progesterone has little effect 
on the endometrium. However, following the surge in oestrogen and ovulation, the 
endometrium is receptive to progesterone and so the secretory phase of the menstrual 
cycle begins (Johnson and Everitt, 1995).
During the secretory phase of the menstrual cycle progesterone stimulates the 
synthesis of secretory material by the glands, which is rich in glycoproteins, sugars 
and amino acids (Johnson and Everitt, 1995). Effects of progesterone on the stromal 
cells are an increase in stromal proliferation resulting in the stromal cells becoming 
larger. Progesterone also stimulates full development of the spiral arteries. These 
changes in endometrial morphology prepare the endometrium for implantation of the 
« blastocyst. If implantation does not occur, levels of the steroid hormones decrease
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towards the end of the secretory phase, causing apoptotic cell death and a collapse of 
the secretory epithelium. The epithelial layer and stratum functionalis are shed via 
the cervix and vagina along with blood from the ruptured spiral arteries, which then 
contract to reduce bleeding. This process is known as menstruation and signifies the 
beginning of the next menstrual cycle (Johnson and Everitt, 1995).
1.1.5 Endometrial leukocyte populations
The human endometrium does not have a classical mucosal immune system; instead 
it contains a specialised population of endometrial leukocytes, which comprise 8 - 
3 5 % of the total endometrial cell number, depending on the time of the menstrual 
cycle (Johnson et al., 1999). Leukocytes that are found in the endometrium include 
CD3+ T cells (approximately two thirds of which are also CD8+), CD14+ 
macrophages and a population of large granular lymphocytes (LGL's). Endometrial 
LGLs vary phenotypically from peripheral LGLs, in that they are mainly CD3‘
CD 16' CD56+ with a small number of CD3' CD16+ CD56+, and constitute the largest 
population of endometrial leukocytes. Studies have suggested the absence of B cells 
in the endometrium at any time in the menstrual cycle (Bulmer et ah, 1991).
During the proliferative and early secretory phases of the menstrual cycle leukocytes 
contribute to less than 1 0 % of total endometrial cell number and this increases to 
greater than 20% by the late secretory phase. This increase in leukocyte number is 
largely due to an increase in the number of LGLs. The factors influencing this 
increase are poorly understood at present, but it is not thought that the numbers are 
increased due to an influx of leukocytes from the peripheral blood system (Bulmer et 
a l, 1991).
During the proliferative phase T cells make up approximately 45% of the 
endometrial leukocyte population. The number of T cells tends to remain constant 
throughout the menstrual cycle, however there is a decrease in the relative number of 
T cells during the secretory phase due to the increase in other leukocyte populations. 
As a result T cells represent the smallest number of endometrial leukocytes, during 
the secretory phase of the menstrual cycle (Vassiliadou and Bulmer, 1996). The 
number of endometrial macrophages is also relatively constant throughout the cycle 
with an increase being seen just prior to menstruation. Macrophages are generally
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found scattered throughout the endometrium but can also be found within aggregates. 
They contain acid phosphatase, non-specific esterase and lysine. Within the 
endometrium they are thought to be involved in scavenging and degradative 
functions associated with menstruation. They are known to produce prostaglandin 
(PG) E2 and PGF2OC and can also produce and respond to a wide range of cytokines 
(Johnson et al., 1999).
The LGLs are the most abundant population of leukocytes during the secretory phase 
of the cycle. By the time of implantation they account for 70-80% of the endometrial 
leukocyte population and if conception occurs and the resulting blastocyst implants, 
the numbers increase further. As with macrophages, the LGLs are found scattered 
singly throughout the endometrium, but during the late secretory phase they tend to 
gather as aggregates particularly around the spiral arteries and endometrial glands. 
They possess granules that contain perforin and granzymes, which suggests that they 
may have the potential to provide an LGL-mediated cytolytic function. They express 
adhesion molecules (CD1 la, CD1 lb and CD1 lc) and integrins (VLA-4), which may 
be involved in the control of LGL recruitment into the endometrium and in 
determining endometrial distribution. The dramatic increase in the numbers of LGLs 
during the secretory phase suggests that they may play a role in implantation and the 
establishment of pregnancy (King et al., 1989).
1.2 Implantation
For implantation to occur there must be a functional normal blastocyst, a receptive 
endometrium and successful communication between the blastocyst and 
endometrium. Development of the embryo to the blastocyst stage occurs 
independently of preparation of the endometrium, but at implantation the two 
become interdependent and the uterine environment regulates further embryonic 
development. The process of implantation is influenced by complex molecular 
interactions between the blastocyst and endometrial surface at the maternal-fetal 
interface (Psychoyos and Martel, 1985).
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1.2.1 Blastocyst Development
Following release of the oocyte into the ampullary region of the fallopian tube, 
providing spermatozoa is present, fertilisation occurs, maternal and paternal 
chromosomes come together and a zygote is formed. Cleavage then occurs to form a 
two-cell stage embryo. The conceptus remains in the fallopian tube for 3-4 days 
where each of the two cells undergoes a series of divisions. Once it reaches the 8-16 
cell stage the morphology of the conceptus changes; it undergoes compaction and 
this results in the formation of a morula. This is achieved by the time the conceptus 
has reached the uterine cavity (see figure 1.5). The process of compaction involves 
minimising intercellular contacts and transforming the morula to that of a highly 
polarised phenotype. The polarisation causes cell cleavage resulting in two cell types, 
which develop into the inner cell mass and the trophectoderm cells. Once the 
distinction of these two cell types has been made, at approximately the 32-64 cell 
stage, the embryo is termed the blastocyst and is ready for implanting into the 
endometrium (Johnson and Everitt, 1995). The trophectoderm forms an outer rim of 
cells, which constitute the first extra-embryonic tissue, giving rise to the trophoblast, 
an accessory fetal membrane. The trophoblastic cells are responsible for the initial 
contact at the maternal-fetal interface and they then continue to develop as the fetal 
component of the placenta. The trophoblastic cells surround the blastocoelic cavity 
which contains blastocoelic fluid and the inner cell mass. The inner cell mass is 
placed within one of the trophoblastic walls and it is this which develops into the 
embryo/fetus. Transfer from the fallopian tube to the uterus occurs at the late morula 
stage around 3-4 days after ovulation. The early blastocyst then floats freely within 
the uterine cavity for approximately 3-4 more days before implanting. Nutritional 
support for the blastocyst is provided by endometrial secretions stimulated by 
progesterone during the secretory phase of the menstrual cycle. Approximately 6  
days after ovulation the zona pellucida comes away from the blastocyst, exposing 
trophoblastic cells. This process occurs due to proteolytic enzymes secreted from 
either the trophoblast itself or uterine secretions. The embryo is now able to implant 
into the epithelium. (Johnson and Everitt, 1995)
Figure 1.5: Diagrammatic representation of follicular growth, ovulation,
fertilisation and embryonic development prior to implantation. 
Taken from Findley (1984).
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1.2.2 Endometrial preparation for implantation
The human endometrium undergoes changes throughout the menstrual cycle in order 
to prepare for blastocyst implantation. These changes are driven by oestrogen and 
progesterone, which act on the endometrium and are thought to initiate a downstream 
cascade of molecular events via local paracrine and autocrine factors such as 
chemokines, cytokines, growth factors, adhesion molecules and invasive proteinases. 
The endometrium is only receptive to implantation for a limited period in the 
menstrual cycle. Psychoyos (1986) first discussed the concept of uterine receptivity 
and this period of receptivity is termed the "implantation window". In humans the 
implantation window is approximately 4 days long, between days 20 and 24 of the 
menstrual cycle, or days LH+7 to LH+10 (Bergh and Navot, 1992).
1.2.3 Morphological markers of implantation
Microscopical studies have shown that endometrial epithelial cells, in particular the 
secretory cells, change considerably during the secretory phase of the cycle (Nikas et 
al., 1999a). During the early proliferative phase (days 4-7) the epithelial surface is 
regenerated following menstruation and is therefore very thin. Most glands are very 
short, straight and narrow and the stromal compartment is compact with spindle- 
shaped stromal cells with large nuclei. As development of the endometrium 
continues into the mid-proliferative phase (days 8 -1 0 ) the surface epithelium 
becomes columnar, the glands become longer and there is evidence of stromal 
oedema. By the late proliferative phase (days 11-14) the glands become more 
tortuous showing active growth and pseudostratification of the epithelium. The 
stroma is moderately dense and actively growing (Noyes et al., 1950).
The secretory epithelial cells are either elongated or polygonal and vary in size. The 
microvilli are short and slender then develop with progression of the proliferative 
phase (Nikas et al., 1999a). By day 16, the glands increase in diameter and tortuosity. 
By day 17 the microvilli are long, thick and upright, and by day 18 the microvilli 
begin to appear swollen. On day 19, the microvilli decrease in number and length, 
fuse and disappear and are replaced by smooth membrane projections, which 
protrude and fold maximally forming pinopodes (Nikas et al., 1999b). By day 20 
there is a peak in the presence of intraluminal secretory material, microvilli are 
virtually absent and pinopodes are fully developed. The pinopodes only last for 24-
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48 hours; by day 21 microvilli reappear on the cell membranes, which are now 
wrinkled in appearance due to regression of the pinopodes. A possible function of 
pinopodes is that they absorb molecules and fluids from the uterine lumen, 
facilitating the proximity between embryo and endometrium. They may also be 
involved in trophoblast adhesion and facilitate penetration of the implanting 
blastocyst into the underlying stroma, because it has been noted that the lateral cell­
cell contacts between epithelial cells become looser in the presence of pinopodes 
(Nikas et al., 1999b). From days 21-22 there is massive stromal oedema, the stromal 
cells increase in size and begin to appear dome-shaped. By day 23 the spiral arteries 
have become more prominent, indicating predecidualisation of the stromal cells. By 
day 24 there are collections of predecidual cells around the arterioles and stromal 
proliferation continues. Differentiation of the predecidua occurs around day 25 and 
by day 26 these cells appear as a solid sheet of well-developed decidual cells. If 
pregnancy has not occurred by day 24 glandular secretions become diminished and 
there is involution of the glandular epithelium. The glands become dilated; the 
previous tall, columnar epithelium is low. Day 27 is characterised by an increased 
population of polymorphonuclear leukocytes (Bulmer et a l , 1991) and areas of focal 
necrosis and haemorrhage that become apparent a few hours preceding menstruation 
(Noyes et al., 1950).
1.2.4 Biochemical markers of implantation
1.2.4.1 Adhesion molecules
Biochemical markers indicating uterine receptivity include adhesion molecules and, 
in particular, integrins. Integrins consist of one a  subunit and one non-covalently 
bound p subunit and these have been shown to be present within the endometrial 
epithelium (Lessey et al., 1992; Tabibzadeh, 1992). Three integrin subunits are 
thought to be important during the period of receptivity. These are a i, 0C4 and p3 as 
there is co-expression of all three during the implantation window, but not at other 
times in the menstrual cycle (Lessey et al., 2000). Expression of the a i and CX4 
subunits is increased following ovulation with a later decrease in a i expression 
during the late secretory phase and P3 expression is known to begin on day 19. The 
implanting blastocyst has the ability to modulate endometrial expression of these 
integrin subunits as it has been shown that a cytokine, interleukin-1 (IL-1), produced
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by the blastocyst mediates the up regulation of p3 in human endometrial epithelial 
cells (Simon et al., 1998).
1.2.4.2 Steroid receptors
Expression of progesterone and oestrogen receptors may be used as markers for 
endometrial maturation as studies have found that these receptors are subject to fine 
hormonal control by ovarian steroid hormones (Garcia et al., 1988; Snijders et al.,
1992). Receptor expression is maximal at the mid-cycle stage in response to 
increased oestradiol secretion. Expression then declines as progesterone-dependent 
down-regulation occurs. During the secretory phase the oestrogen receptor is down 
regulated rapidly in the stroma and more gradually in the glandular epithelium, 
whereas progesterone receptors decline rapidly in the glandular epithelium, but 
persist in the stroma (Garcia et al., 1988; Snijders et al., 1992). These alterations in 
steroid receptor expression could therefore be useful as markers for implantation.
1.2.4.3 Other molecules
Other molecules that could be potential markers of uterine receptivity are the mucin 
MUC-1 and the endometrial protein PPM or glycodelin. The function of MUC-1 in 
the human endometrium is unknown at present, however, it has been shown to be 
present in both glandular and luminal epithelium during the proliferative and 
secretory phases of the menstrual cycle (Hey et al., 1995; Aplin, 1999). The 
expression of MUC-1 is up regulated in human endometrium during the peri- 
implantation period (Hey et al., 1995), suggesting a possible role in implantation. 
Concentrations are increased in uterine flushings from normal fertile women between 
days LH+7 and LH+13 (Hey et al., 1995) and there is strong MUC-1 activity present 
in the luminal epithelium at both the beginning and end of the receptive phase 
(Aplin, 1999). A possible function of MUC-1 is that it may act as a uterine barrier to 
implantation, requiring embryonic signals before it can be removed. As a result this 
may prevent any abnormal blastocysts, incapable of providing these signals, from 
implanting (Aplin, 1999).
Endometrial epithelial cells also produce glycodelin, with maximal expression during 
the secretory phase of the menstrual cycle (Li et al., 1993). Levels in endometrial
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flushings show similar cyclical changes to that of MUC-1 with maximal levels being 
present between days LH+7 and LH+10 (Dalton et al., 1995). The function of 
glycodelin is not known but there are some studies suggesting that it may have 
immunomodulatory properties (Pockley et al., 1988).
1.2.5 The process of implantation
Implantation consists of three separate phases. Firstly apposition of the blastocyst to 
the uterine epithelium, then adhesion and finally invasion through the epithelium into 
the underlying stromal compartment.
Apposition is the first contact between the cellular membranes of the trophectoderm 
and the endometrial luminal epithelium. Apposition requires a direct contact between 
these two cell membranes and therefore must take place where the zona pellucida has 
ruptured or lysed (Psychoyos and Martel, 1985). It is thought that this cell contact is 
made possible by changes in cellular surface charge, which until apposition occurs, is 
negative on both surfaces. At this point there is no establishment of any visible 
connections between the blastocyst and endometrium and the blastocyst can be 
dislodged by washing of the uterine cavity (Bischof, 1997). Functional connections 
are established between the blastocyst and the endometrium during the adhesion 
phase of implantation. Cell surface glycoproteins, oligosaccharides and 
glycosaminoglycans in particular, are considered to be associated with attachment of 
the blastocyst to the endometrium in humans (Rohde and Carson, 1993). More 
recently studies have implicated cell adhesion molecules, such as E-cadherin, and 
integrins, such as ot6pi, to be involved in trophoblast adhesion to the human 
endometrial epithelium (Bischof, 1997).
After attachment, the blastocyst must invade the endometrium by penetrating the 
epithelial lining, basal lamina and underlying stroma. Within a few hours of 
attachment the epithelium beneath the blastocyst becomes eroded and trophoblastic 
processes protrude between the epithelial cells, isolating, dissolving and digesting 
them (Figure 1.6) (Sherwood, 1994). As trophoblastic cells invade the stromal 
compartment some of them fuse to form a syncytium and are referred to as 
syncytiotrophoblasts, whereas others retain their cellularity and are termed
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Figure 1.6: Implantation of the blastocyst into the endometrium, (a) shows the 
attachment phase and (b), (c) and (d) show the stages of the 
invasion phase. Taken from Sherwood (1994).
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cytotrophoblasts, and these continue to generate more trophoblastic cells. As the 
uterine glandular epithelium and underlying stroma is destroyed, the cells release 
large quantities of primary metabolic substrates providing nutrition for the 
implanting embryo (Johnson and Everitt, 1995).
1.2.6 Decidualisation
In humans interstitial implantation occurs, whereby the blastocyst implants deep into 
the maternal stroma and as this occurs the surface epithelium is restored above it.
The blastocyst implants into undecidualised stroma; however, within a few days 
decidualisation occurs and extends throughout the endometrium (Bell, 1985).
Decidualisation is a differentiation of the fibroblast-like stromal cells into epitheloid- 
like cells. In humans a predecidual reaction will occur during the late secretory 
phase, even in the absence of implantation, therefore the initial reaction is not under 
embryonic influence (Noyes et al., 1950). However, if implantation does occur then 
the reaction persists and the stromal cells become the decidua of pregnancy. During 
decidualisation progesterone acts on the oestrogen primed mid-luteal phase stromal 
cells causing numerous changes. The cells change shape, increase in size and there 
are development of organelles involved in protein synthesis. Ultrastructural studies 
on human decidual cells have shown that they possess all the characteristics of a 
secretory cell; euchromatic nucleus, numerous profiles of Golgi cistemae, dilated 
RER and dense membrane bound secretory granules (Kim et al., 1998).
Decidualisation results in localised changes in the composition of the intercellular 
matrix (Aplin, 1996). There is also formation of desmosomes and gap junctions 
between adjacent cell walls, suggesting that decidualisation could facilitate the 
process of trophoblast invasion (Kim et al., 1998). During decidualisation there is 
also an increase in endometrial leukocyte population, mainly due to an increase in 
LGLs and to a lesser extent the macrophages (King et al., 2000). The exact function 
of the decidua is unclear, but it has been postulated that the roles probably include 
nourishing the developing embryo, protecting the maternal tissues from excessive 
trophoblast invasion and protecting the embryo from immunological rejections in 
utero. Once the decidualisation has been completed the decidual cells and 
trophoblastic cells begin to form the placenta.
20
1.2.7 Placentation
Following implantation the growing conceptus is provided with nutritional support 
from the decidual cells. However, as the embryo grows and differentiates this means 
of nutritional support is insufficient and the establishment of a placenta is required in 
order to provide the developing embryo/fetus with all its nutritional requirements. 
Formation of the placenta is completed during the first trimester of pregnancy and 
enables the growing fetus access to the maternal blood supply (Johnson and Everitt,
1995).
Invading trophoblast cells proliferate and differentiate into chorionic villi, which are 
composed of two cell layers, the cytotrophoblasts and syncytiotrophoblasts. 
Cytotrophoblasts are mitotically active mononuclear cells that form the inner layer of 
cells and the surrounding syncytiotrophoblasts are multinucleated masses of cells 
formed by the terminal differentiation and fusion of villous cytotrophoblasts (Boyd 
and Hamilton, 1970). The cytotrophoblasts at the tip of the villi proliferate and 
breach the syncytiotrophoblast layer to form extravillous cytotrophoblasts. A sub­
population of the extravillous cytotrophoblast cells acquires an invasive phenotype 
(Bischof et al., 1995a), which allows the cells to dissociate from the column and 
invade the decidua even deeper where they penetrate the upper portion of the 
myometrium and basal laminae of uterine arterioles. These invasive cytotrophoblasts 
form the anchoring villi and are responsible for anchoring the placenta to the decidua 
(Boyd and Hamilton, 1970). Another sub-population of chorionic villi is the floating 
villi, which float in the maternal blood mediating gas and nutrient exchange 
(Genbacev et al., 1999). Syncytiotrophoblast cells bury through the decidua and 
destroy the walls of maternal uterine blood vessels converting them from muscular 
vessels to flaccid sinusoidal spaces that become filled with maternal blood. Groups 
of cytotrophoblasts from the cell columns invade the lumen of the endometrial spiral 
arteries as endovascular trophoblasts and this ensures that an adequate blood supply 
to the feto-placental unit is established (Johnson and Everitt, 1995).
1.3 Recurrent Miscarriage
Miscarriage, early pregnancy loss or spontaneous abortion is defined as the 
termination of pregnancy before 20 weeks of gestation (dated from the last menstrual
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period) or fetal weight being less than 500g and is the most common complication of 
pregnancy (Timbers and Feinberg, 1997). Approximately 15-20% of clinically 
established pregnancies abort within the first 20 weeks usually within the first 
trimester (weeks 1-12) (Stirrat, 1990). The true figure is likely to be much higher 
than this, nearer 70%, because there is a high rate of miscarriage within the first 2-4 
weeks of pregnancy due to chromosomal abnormalities, that are not recognised 
because it is so early on in the pregnancy (Boklage, 1990). Because a large number 
of miscarriages occur due to chance, investigations into the cause of miscarriage are 
not usually carried out until the woman has been classified as suffering from 
recurrent miscarriage or recurrent spontaneous abortion. Recurrent miscarriage (RM) 
is defined as having 3 or more consecutive miscarriages and affects about 1% of the 
female population (Timbers and Feinberg, 1997). Clinical studies have shown that 
after 3 consecutive miscarriages then the risk of a further pregnancy loss is increased 
to 30-45% and the chance of pregnancy completing to term, resulting in a live birth 
is only 55-60% (Timbers and Feinberg, 1997). However, it is not the number of 
abortions that influences the diagnostic and therapeutic response to a couple 
suffering from RM, it is influenced by the age of the women, the level of anxiety of 
the couple and also any factors readily identifiable in the family/medical history 
(Timbers and Feinberg, 1997). There are many factors known to influence recurrent 
miscarriage.
1.3.1 Genetic Factors
Karyotyping of couples has shown that 3-8% of RM can be explained by a genetic 
abnormality. The most common cause of pregnancy loss, even in recurrent aborters, 
due to cytogenetic abnormalities is sporadic aneuploidies, the largest group of which 
is trisomic pregnancies. Other abnormalities include balanced translocation of part of 
a chromosome, sex chromosome mosaicism and ring chromosomes. Karyotyping 
shows a percentage of pregnancies lost to genetic abnormalities. However, 
karyotyping will not detect single gene defects, and therefore these could account for 
a number of RM (Timbers and Feinberg, 1997).
1.3.2 Anatomical factors
Approximately 5-10% of first trimester RMs are caused by abnormalities in uterine 
anatomy (Timbers and Feinberg, 1997). These abnormalities include both congenital
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and acquired changes to normal uterine anatomy. Congenital Mullerian abnormalities 
such as a septate or bicornate uterus were originally thought to be associated with 
late second trimester miscarriages; however it is now recognised that these factors 
can also cause earlier miscarriages (Patton and Novy, 1988). The effect of congenital 
Mullerian abnormalities on recurrent miscarriage is not completely understood at 
present, but it is possible that they may result in compromised implantation and 
insufficient decidual and placental growth due to poor vascularisation of the 
endometrium (Portuondo et al., 1986). Acquired Mullerian abnormalities include 
uterine synechiae (Asherman syndrome), submucosal leiomyomata and 
abnormalities seen following in utero exposure to diethylstilbestrol (DES). Uterine 
leiomyomatas have varying effects on pregnancy loss depending on the size and 
location of the fibroid (Rock and Murphy, 1986). If submucosal and myometrial 
myomas are large enough there are alterations in endometrial vascularisation or a 
possible reduction in uterine size. In utero exposure to DES causes abnormalities 
associated with the upper genital tract. These only contribute to a small percentage of 
miscarriages; however, in females exposed to DES the first or second trimester 
miscarriage rate is 18-48% (Patton and Novy, 1988). Another factor that is thought to 
contribute to recurrent miscarriage in the late second trimester is cervical 
incompetence. This is characterised by painless dilation and prolapse with ballooning 
of the membranes into the vagina, followed by rupture of the membranes and 
expulsion of the immature fetus (Rock and Murphy, 1986).
At present there are no studies proving that surgical correction for uterine anomalies 
results in a successful outcome. However, 70-85% of women suffering from 
recurrent miscarriage that have undergone surgery for septate or bicomate utems 
have had successful live births (Rock and Murphy, 1986).
1.3.3 Endocrinological factors
The most common endocrinological factor known to cause miscarriage is luteal 
phase defect (LPD) and this affects approximately 25% of women who suffer from 
recurrent miscarriage (Lee, 1987). LPD is a condition whereby progesterone 
production from the corpus luteum is diminished and results in inadequate 
endometrial development; therefore the endometrium is unable to support early 
pregnancy. Although LPD is well recognised there is no direct evidence that it is a
23
cause of recurrent miscarriage and there is no consensus regarding its underlying 
mechanisms, diagnosis or possible treatment. However, studies have shown that 
progesterone supplementation is likely to increase the chance of achieving successful 
pregnancy (Daya, 1989).
Other endocrine factors include thyroid disease and badly controlled diabetes 
mellitus. These conditions have been associated with an increased risk of fetal loss, 
but studies have failed to show a relationship between these conditions and recurrent 
miscarriage (Rock and Zancur, 1983).
1.3.4 Autoantibodies
The most recognised immunological causes of recurrent miscarriage are autoimmune 
reactions, where the cellular or humoral response is directed against a specific site 
within the host. The most common autoimmune disease is antiphospholipid 
syndrome (APS), which can occur as either a secondary condition in patients 
suffering from other immune disorders such as systemic lupus erythematosus (SLE), 
or as a primary condition in women with no previous recognised autoimmune disease 
(Branch et al, 1992). APS is characterised by the presence of increased 
antiphospholipid antibodies and one or more of three clinical features; pregnancy 
loss, thrombosis and thrombocytopenia (Branch et al., 1992). APS is directed against 
platelets and vascular epithelium and results in vascular damage, thrombosis and 
placental destruction. Lupus anticoagulant (LAC) and anticardiolipin antibodies 
(ACA) are the two major antiphospholipid antibodies present in APS. The presence 
of these antibodies has been shown to be associated with second trimester and 
occasional first trimester recurrent miscarriages (Dudley and Branch, 1989). APS can 
be treated with low dose aspirin, heparin, glucocorticoids and intravenous gamma 
globulin or a combination of these and has resulted in 55-85% successful pregnancy 
outcome (Rai et al., 1997).
Other antibodies have been implicated as a possible cause of recurrent miscarriage, 
including antinuclear antibodies, thyroid antibodies and anti-SSA. However, further 
work is required before the effects of these antibodies on recurrent miscarriage can 
be understood (Timbers and Feinberg, 1997).
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1.3.5 Immunological mechanisms
Other immunological influences on recurrent miscarriage include allogenic factors. 
The theory is that unexplained recurrent miscarriage may be due to an abnormal 
maternal immune response to fetal antigens of paternal origin. However, the 
mechanisms that allow maternal tolerance to the semiallogenic conceptus are not 
completely understood at present and as a result it is difficult to assess the 
association between allogenic immunological factors and recurrent miscarriage 
(Scott and Branch, 1994).
1.3.6 Microbiological factors
Infections are thought to be a possible cause of recurrent miscarriage, but studies 
have failed to show an increased incidence of infections in women suffering from 
recurrent miscarriage when compared to normal fertile women. The most common 
infection of the human female reproductive tract is chlamydia trachomatis, but 
studies have shown that it is unlikely to be a cause of recurrent miscarriage (Harrison 
et al., 1983). Two other infections, mycoplasma hominis and ureaplasma 
urealyticum, although present in normal, assymptomatic women have been shown to 
be more frequent in women suffering from recurrent miscarriage (Stray-Pederson et 
al., 1978). However, elimination of these mycoplasmas has not improved subsequent 
pregnancy outcome and they are therefore unlikely to be a significant cause of 
recurrent miscarriage.
Other possible causes include viral and parasitic infections such as cytomegalovirus 
and herpes simplex virus. Although there is no evidence that they are associated with 
recurrent miscarriage it is still considered that they may possibly be linked to first 
trimester losses (Timbers and Feinberg, 1997).
1.3.7 Unexplained RM
Even though the understanding of possible causes of recurrent miscarriage has 
improved greatly over the past twenty years, the majority (>50%) of recurrent 
miscarriage cases still remain unexplained (Timbers and Feinberg, 1997). A greater 
understanding of the paracrine and autocrine cascade of events that occurs during 
implantation may result in an explanation as to a possible cause for some of this 
group of recurrent miscarriage women. Recent evidence has suggested that along
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with LPD other endometrial defects could provide an explanation for some 
unexplained recurrent miscarriages.
1.3.8 The endometrium and recurrent miscarriage
A recent study (Ogasawara et al., 2000) found that the frequency of normal 
embryonic karyotype is significantly increased with the number of previous 
miscarriages, suggesting that the maternal factor of implantation and pregnancy 
becomes increasingly responsible for pregnancy failure as the number of previous 
miscarriages increases. Investigations into the cause of unexplained recurrent 
miscarriage have recently focused on these endometrial factors that may be involved 
in interactions at the maternal-fetal interface. Possible factors include morphological 
abnormalities (Serle et al., 1994), altered endometrial secretions (Hey et al., 1995; 
Dalton et al., 1995), abnormal endometrial leukocyte distributions (Clifford et al., 
1999; Quenby et al., 1999) and abnormal endometrial cytokine expression (Lim et 
al., 2000).
Morphological evidence to support this has been provided by studies, which have 
shown that there was a high incidence of endometrial defect in women who suffer 
recurrent miscarriage (Tulppala et al., 1991; Li et al, 1998). Morphometrical analysis 
of the endometrium has also shown significant differences in a subgroup of women 
suffering from RM compared to normal fertile women (Serle et al., 1994; Saleh et 
al., 1995).
The use of immunohistochemistry has provided evidence that a possible cause of RM 
in some women may be due to changes in the composition of certain molecules in 
endometrial secretions. Expression of four mucin-related secretory epitopes is 
decreased in RM women (Searle et al., 1994), and a decrease in epithelial secretion 
of MUC-1 in RM women has also been demonstrated (Hey et al., 1995). The 
concentrations of MUC-1 and the endometrial secretory protein, placental protein 14 
(PPM or glycodelin) have also been shown to be decreased in the uterine flushings 
from women who suffer recurrent miscarriage compared to normal controls (Dalton 
et al., 1995; Hey et al., 1995; Aplin et al., 1996). The plasma concentrations of 
glycodelin in RM women have also been investigated and found to be decreased 
when compared to normal controls (Tuppala et al., 1995).
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Changes in the population of leukocytes present in the endometrium, particularly 
during the secretory phase of the menstrual cycle, has also been suggested as a 
possible factor that may contribute to some unexplained recurrent miscarriages. 
Quenby et al. (1999) showed that there was a significant increase of endometrial 
leukocytes that were CD4+, CD14+, CD16+, CD56+ and MHC Class II+ in a group of 
RM women compared to controls. They also found that in this group of RM women, 
women who had a further subsequent miscarriage following the study, had an 
increased number of CD56+ staining cells than those whose subsequent pregnancy 
resulted in a live birth. The increase in endometrial CD56+ cells in RM women 
compared to controls has been confirmed by similar results from another group 
(Clifford et al., 1999). This study also showed that there was no correlation between 
the number of CD56+ cells and other factors that may influence a further miscarriage 
such as; maternal age, number of previous miscarriages, past history of a live birth 
and time since last miscarriage.
The importance of the role of endometrial cytokines in implantation and pregnancy 
has also been suggested. Lim et al. (2000) showed, using RT-PCR, that endometrial 
expression of IFNy, IL-2, IL-12 and TNFp was significantly increased in women 
suffering from RM when compared to normal fertile women, whereas the expression 
of IL-6 was significantly decreased. These results suggest that the endometrial 
cytokine profile is altered in some women who suffer unexplained RM and could 
therefore be a contributory factor to the cause of these miscarriages.
Results from the studies described above, support the notion that endometrial defects 
are associated with recurrent miscarriage, particularly where no other cause can be 
determined.
1.4 Cytokines
Cytokines are regulatory proteins secreted by cells in response to a variety of stimuli. 
They are a diverse group of molecules that are secreted into the extracellular medium 
and then influence target cells. Their action is similar to that of peptide hormones, 
except they are not produced by specific endocrine organs, but instead are produced
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by more than one cell type in a number of different tissues. They were originally 
described as products of immune cells (Clemens, 1991). They generally act in a 
paracrine or autocrine manner but, although it is more unusual, they can also target 
cells in other parts of the body therefore acting in a similar way to endocrine 
stimulation produced by classical hormones (Hamblin, 1993).
Cytokines are relatively small molecules with a typical molecular mass of 15-30kDa. 
They can produce a wide variety of effects and most share common structural and 
functional features. Some cytokines are modified before they are secreted by the 
addition of a carbohydrate side chain and are therefore secreted as glycoproteins, 
whereas others are synthesised as large precursors and therefore require to be cleaved 
before they can become biologically active. The synthesis and secretion of cytokines 
is not constant, but instead dependent upon many factors that are capable of inducing 
and suppressing cytokine production (Clemens, 1991).
Cytokines have pleiotropic properties and are known to produce numerous 
physiological actions. The physiological roles of cytokines include cell proliferation 
and differentiation, regulation of hematopoiesis, immune responses, inflammatory 
responses and fever, control of host defences and cytotoxic/phagocytic cells, wound 
healing, tissue remodelling, bone formation and influences on cellular metabolism 
(Hamblin, 1993).
1.4.1 Cytokine receptors
Cytokines are all proteins/glycoproteins and cannot penetrate the plasma cell 
membrane. They must therefore exert their cellular functions via interactions with 
specific membrane-bound receptors. Generally cytokine receptors consist of three 
domains. Firstly the extracellular domain, which provides the binding site for the 
cytokine and also creates specificity for that particular ligand. Next is the 
transmembrane domain, which spans the phospholipid bilayer of the plasma 
membrane, and finally the intracellular or cytoplasmic domain that has either 
enzymatic activity or binds other molecules in order to deliver a signal inside the cell 
in response to binding of the cytokine ligand. The extracellular domains of cytokine 
receptors can be cleaved to produce soluble forms of the receptor (Hilton, 1994).
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Most cytokine receptors signal through another molecule and this signalling 
molecule is often used by more than one cytokine. For example, gpl30 is used by all 
members of the IL-6 family of cytokines, including LIF, IL-11, oncostatin M and IL- 
6 itself (Taga, 1997). Cytokine activity can be regulated by changes in cytokine 
concentration and also by modulation of receptors. Following binding of a cytokine 
to its receptor there is a decrease in the number of cell surface receptors caused by 
internalisation of the ligand-receptor complexes by endocytosis. This results in a 
temporary desensitisation to further stimulation and provides a mechanism whereby 
over-stimulation is prevented by internalisation, limiting the magnitude and duration 
of the response (Clemens, 1991). It also provides a possible mechanism by which the 
cytokine produces its effects. The specific responses of a cell to cytokines are 
controlled by signal transduction mechanisms. These pathways are central to the 
regulatory actions of cytokines.
1.4.2 ThI and Tr2 cytokines
CD4+ T-helper cells are a major source of cytokines in the immune system. The 
production of cytokines from CD4+ T-helper cells varies between two subgroups of 
T-helper cells. Cytokines that are produced by T helper type-1 cells (ThI cytokines) 
include IL-2, IFNy and TNFp whereas T helper type-2 cells produce cytokines such 
as IL-4, IL-5, IL-6 and IL-10 (Th2 cytokines). IFNy and IL-2 promote the 
development of cytotoxic lymphocytes and NK cells, as well as inhibiting the 
development of B-cells in response to Th2 cells, while IL-4, IL-5 and IL-6 are 
involved in B-cell development (Mosmann and Coffman, 1989).
1.4.3 Cytokines and pregnancy
The presence of numerous cytokines at the maternal-fetal interface has been shown 
and the receptors for these cytokines are present on trophoblast cells, suggesting that 
they may play a role in the growth and survival of the fetoplacental unit (Sharkey, 
1998). The exact role of cytokines in maternal-fetal interactions is still poorly 
understood, particularly in humans, but experiments in mice led Wegmann et al. 
(1993) to propose that "since ThI cytokines compromise pregnancy and Th2 
cytokines are produced at the maternal-fetal interface, we hypothesise that these 
cytokines inhibit ThI responses, improving fetal survival but impairing responses
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against some pathogens". This has led to numerous further studies into the role of 
cytokines at the maternal-fetal interface, particularly in mice.
Wegmann's initial experiments showed that injection of IL-10 into abortion-prone 
mice decreased the abortion rate (Chaouat et al., 1990), while injection of IL-2 and 
IFNy into normal mice increased the likelihood of abortion (Chaouat et al., 1990). It 
was therefore considered possible that excessive ThI-type cytokines could mediate a 
cellular response, which would lead to activation of the uterine NK cell population, 
whereas the Tn2-type cytokines from the fetoplacental unit could divert the maternal 
response away from ThI-type responses.
It has also been shown that murine fetoplacental unit tissue in vitro spontaneously 
released IL-4, IL-5 and IL-10 during all three trimesters of pregnancy, whereas the 
only ThI -type cytokine present were small levels of IFNy during the earliest phase 
of gestation (Wegmann et al., 1993). These cytokine patterns reflect the ThI and Th2 
profiles defined by T-cell clones, however it is likely that at least some, if not the 
majority, of cytokines synthesised at the maternal-fetal interface are derived from 
non-T cells. Further studies have since provided more information for a possible role 
of cytokines at the maternal-fetal interface. IL-10 has been localised to the maternal 
decidua in mice on day 6 of pregnancy (Lin et al., 1993). IFNy has been shown to 
inhibit the secretion of GM-CSF from uterine epithelium (Robertson et al., 1994). 
Also injections of TNFp, as well as IL-2 and IFNy, terminated normal murine 
pregnancies (Chaouat et al., 1990).
1.4.4 Evidence for the Th1-Th2 response in humans
The expression of ThI and Tn2-type cytokines at the matemo-fetal interface has been 
studied in humans, to determine if the balance between these two groups of cytokines 
is critical for successful pregnancy outcome. As in mice, it was hypothesised that a 
decreased expression of Tn2-type cytokines would result in an increase of ThI-type 
cytokines at the matemo-fetal interface and would lead to impaired fetal growth 
(Hayes and Smith, 1997).
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An increased expression of Th2 cytokines has been reported in the endometrium, 
during the mid-secretory phase of the menstrual cycle (Krasnow et al., 1996). This 
suggests that Tj^-type cytokines are important in the implantation process. There is 
also evidence to show that both ThI and Tn2-type cytokines are present in the 
developing placenta during human pregnancy (Vince and Johnson, 1996), which 
suggests that the balance between the expression of these cytokines is important in 
ensuring successful implantation and pregnancy. Haimovici et al. (1991) showed that 
IFNy and TNFa inhibited embryonic and fetal development, as well as the 
proliferation of human trophoblast cell lines in vitro, providing further evidence that 
over expression of ThI-type cytokines could be detrimental to successful 
implantation.
The role of ThI and Tn2-type cytokines in implantation has been investigated further 
by studies, which have looked at the expression of ThI and Tn2-type cytokines in 
women who suffer recurrent miscarriage. These studies have shown that there is a 
significant increase in Tn2-type cytokines and significant decrease in ThI-type 
cytokines in normal fertile women when compared to women who suffer recurrent 
miscarriage (Vives et al., 1999; Makhseed et al., 1999; Lim et al., 2000). Work has 
also demonstrated that the TH2-type cytokine IL-4, upregulates production of LIF 
from decidual T cells, whereas ThI-type cytokines downregulate LIF production 
(Piccinni et al., 1998), which is important because LIF is thought to play a role in 
successful implantation. This study also showed that decidual T cell production of 
LIF and Tn2-type cytokines was decreased in women suffering recurrent 
miscarriages. Taken together, the results from these studies provide evidence to 
suggest that the expression of ThI and Tn2-type cytokines is important in human 
implantation and pregnancy and that it is the balance between ThI and Tn2-type 
cytokines, which is critical for implantation to be successful.
As well as ThI and Tn2-type cytokines there are a number of other cytokines that do 
not fit into these categories but may also have a role in successful pregnancy 
outcome.
31
1.5 Leukaemia inhibitory factor (LIF)
LIF is a secreted glycoprotein with a molecular mass of 32-62kDa depending on its 
state of glycosylation, which depends on the cellular source. The molecular mass 
following deglycosylation is 20-25kDa and glycosylation of LIF does not appear to 
affect the biological activity either in vitro or in vivo. LIF has an anti parallel up-up- 
down-down four-alpha-helix bundle topology, which is common to haemopoietic 
growth factors and contains 6 cysteine residues and 3 disulphide bonds (Robinson et 
al., 1994). The LIF gene has 6290bp, consists of 3 exons and 2 introns (Stahl et al., 
1990) and is positioned on chromosome 22 at position 22ql2 (Sutherland et al., 
1989), with transcription giving rise to 4.2Kbp mRNA (Stahl et al., 1990). LIF was 
first described as a factor that induced the differentiation of murine myeloid 
leukaemic Ml cells into macrophages (Tomida et al., 1984) and was later shown to 
inhibit the proliferation of Ml cells (Gearing et al., 1987). The original source of LIF 
was alloreactive T cells, but it is now known that other cells are capable of producing 
LIF. The in vitro biological effects of LIF are numerous and include suppression of 
embryonic stem cell differentiation, enhancement of the survival and proliferation of 
primitive germ cells, stimulation of acute phase proteins, induction of a cholinergic 
phenotype in adrenergic neurones, stimulation of the proliferation of factor- 
dependent haemopoietic cells and enhancement of the generation of megakaryocytes 
by IL-3 (Hilton, 1992).
Signalling of LIF is mediated via interaction with a specific LIF receptor (LIF-R) 
(Gearing et al., 1991). The signal is transduced through the 130-kDa membrane 
glycoprotein gpl30, which associates with the LIF receptor following binding of LIF 
(Robinson et al., 1994). Gpl30 is a common signal transducing receptor component 
known to be involved in signalling from the IL-6 family of cytokines including LIF, 
IL-11, oncostatin M (OSM) and ciliary neurotrophic factor (CNTF), that are all 
pleiotropic and exhibit overlapping biological functions (Taga, 1997). Gpl30 
comprises a 597 amino acid extracellular domain, a 22 amino acid transmembrane 
domain and an intracellular domain of 277 amino acids (Hibi et al., 1996). Gpl30 
has no LIF binding capacity by itself, but does play an important role in the 
formation of high-affinity binding sites by associating with the LIF/LIF-R complex 
in transduction of the LIF signal. Binding of LIF to LIF-R triggers the
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heterodimerisation of the LIF/LIF-R complex with gpl30 and together they initiate 
intracellular signalling, which involves activation of members of the JAK family of 
cytoplasmic tyrosine kinases (Lutticken, 1994; Stahl et al., 1994). Although gpl30 
possesses no intrinsic tyrosine kinase domain, the dimerisation of gpl30 leads to the 
activation of associated cytoplasmic tyrosine kinases and subsequent modification of 
transcription factors (Taga and Kishimoto, 1997).
1.5.1 Role of LIF in implantation
The importance of LIF in implantation was recognised in 1992 (Stewart et al.), who 
showed that knockout mice for the LIF gene produced normal blastocysts, but these 
blastocysts failed to implant. However, when LIF was administered to these mice the 
blastocysts implanted normally and developed fully to term, as they did when 
transferred to psuedopregnant mice. In mice, endometrial LIF expression is greatest 
in the endometrial glands, on day 4 of pregnancy, which is the time that implantation 
occurs (Bhatt et al., 1991). The expression of LIF, LIF-R and gpl30 has also been 
shown in the mouse uterus during pregnancy (Yang et al., 1995) further suggesting a 
role for LIF in murine pregnancy.
1.5.2 Expression of LIF in humans
Expression of LIF by the human endometrium both in vitro (Chen et al., 1995; Laird 
et al., 1997) and in vivo has been shown, with an increase in expression during the 
mid-secretory phase of the cycle (Chamock-Jones et al., 1994; Cullinan et al., 1996; 
Laird et al., 1997). LIF mRNA has also been localised to the endometrium (Kojima 
et al., 1994; Vogiagis et al., 1996) as has the LIF-R (Sharkey et al., 1999). All of 
these studies have shown that expression of LIF is predominantly by endometrial 
epithelial cells, with little, if any production by stromal cells. Endometrial LIF 
production has also been shown to be increased by other cytokines (Arici et al, 1997) 
and in vivo production has been shown to be stimulated by steroids such as 
progesterone (Cameron et al., 1997).
LIF is also expressed by human decidua cells in vitro (Sharkey et al., 1999; 
Hambartsoumian, 1998a) and production by these cells is also under the control of 
other cytokines and hormones (Sawai et al., 1997). The importance of LIF in human 
implantation has been further suggested by studies of LIF in women with
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reproductive failure. These studies have shown that endometrial LIF expression is 
decreased in women with unexplained infertility (Laird et al., 1997;
Hambartsoumian, 1998b; Giess et al., 1999). One important possible role for LIF 
within human implantation may be in controlling trophoblast invasion. It has been 
shown that LIF inhibits the differentiation of cytotrophoblasts to an invasive 
phenotype by inhibiting the secretion of metalloproteinases and increasing the 
production of hCG and fibronectin (Bischof et al., 1995a).
1.6 Interleukin-6 (IL-6)
Interleukin-6 is secreted as a glycoprotein with a molecular mass of 21-26kDa, 
depending upon its cellular source. IL-6 is a member of the same family of cytokines 
as LIF and has a similar structure. The precursor for IL-6 has 212 amino acids, with a 
signal sequence of 28 amino acids and the mature IL-6 molecule being a 184 amino 
acid protein with 2 glycosylation sites (Narazaki and Kishmoto, 1994a). The gene 
encoding IL-6, situated on chromosome 7 at position 7p21, is 5Kbp in length and 
consists of 5 exons and 4 introns. Transcription gives rise to 1.2Kb mRNA. The 
tertiary structure of IL-6 is a four-alpha-helix bundle containing four cysteine 
residues within the central portion and therefore 2 disulphide bridges (Narazaki and 
Kishimoto, 1994a). Numerous cells produce IL-6, including T and B-lymphocytes 
(following stimulation), monocytes, fibroblasts, bone marrow stromal cells, 
mesangial cells, keratinocytes and endothelial cells. IL-6 is one of the most 
ubiquitously active cytokines. It is a factor required for terminal differentiation of 
activated B cells and is also required by B cells to induce antibody secretion. It is a 
pro-inflammatory cytokine and acts on resting T cells as an activation factor (Taga 
and Kishimoto, 1997). Other biological actions include the stimulation of acute phase 
protein synthesis in hepatocytes, a growth factor for B cell tumours such as 
myelomas, plasmacytomas and hybridomas and the induction of cytotoxic T- 
lymphocyte differentiation (Hamblin, 1993). IL-6 also plays a central role in 
megakaryocyte maturation, neuronal differentiation and osteoclast activation 
(Narazaki and Kishimoto, 1994a).
IL-6 elicits its effect via interaction with the IL-6 receptor (IL-6R), a member of the 
immunoglobulin superfamily, and the signal transducing molecule gpl30. IL-6R has
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a molecular weight of approximately 80kDa and consists of 449 amino acids 
(Narazaki and Kishimoto, 1994b). Binding of IL- 6  to IL-6 R triggers the association 
of the IL-6 /IL-6 R complex with gpl30, which then mediates IL- 6  function via gpl30 
generating the IL- 6  signal.
1.6.1 IL-6 and reproduction
Studies have shown that IL-6  is produced by the human endometrium in vitro and 
that production may be controlled by other cytokines and hormones (Tabibzadeh et 
al., 1989; Laird et al. 1993; Tseng et al., 1996). Epithelial cells are the major source 
of IL-6 , but stromal cells prepared from the secretory phase of the menstrual cycle 
have also been shown to produce this cytokine (Laird et al., 1993; Tabibzadeh et al., 
1995a). In vivo studies have shown that both IL- 6  mRNA (Vandermolen and Yang,
1996) and protein (Tabibzadeh et al., 1995a) is expressed in the endometrium and 
expression appears to increase at the time of implantation, particularly within the 
epithelial glands. Decidualised stromal cells also produce IL-6  (Montes et al., 1995). 
The IL- 6  receptor and gpl30 have also been localised to the human endometrium 
(Tabibzadeh et al., 1995a) and IL-6 R has also been shown to be present in the human 
embryo (Sharkey, 1998).
1.7 Interleukin-1 (IL-1)
The interleukin-1 family consists of three polypeptides; IL-1 alpha (IL-1 a), IL-1 beta 
(IL-1 p ) and IL-1 receptor antagonist (IL-lra) that play a central role in the regulation 
of immune and inflammatory responses. All three cytokines have a molecular weight 
of approximately 17.5kDa and predominantly have a beta-sheet topology. The 
precursor forms of IL-1 a  and IL-1 p have an amino acid length of 271 and 269 
respectively, however, following proteolytic cleavage the mature forms are both 153 
amino acids in length. IL-lra is translated as a precursor with a conventional signal 
sequence of 25 amino acids and the mature form consisting of 152 amino acid 
residues. The precursor forms of IL-1 a  and IL-1 p are not secreted, but instead 
accumulate in the cytoplasm where IL-1 a  precursor is active but the IL-1 (3 precursor 
is not. The active form of IL-1 a  is not secreted, whereas active IL-1 p is secreted 
(Mosley et al., 1987). Both IL-1 a  and IL-1 p are known to be produced by 
monocytes, keratinocytes, B lymphocytes, astrocytes, kidney mesangial cells and
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endothelial cells, as well as activated macrophages, which also produce IL-lra 
(Dower, 1992). However if the conditions are appropriate almost every cell in the 
body is capable of producing IL-1 (Clemens, 1991).
The gene encoding IL-1 a  is approximately 1 lKbp, has 7 exons and 6  introns, is 
situated at chromosome 2ql3 and transcribes a 2.1Kbp mRNA. The gene encoding 
IL-ip is 7.5Kbp, has 7 exons and 6  introns, is situated at 2ql3-2q21 and has mRNA 
of approximately 1.6 Kbp. IL-lra gene is 15Kbp but with only four exons and three 
introns on chromosome 2ql4-2q21 and gives rise to a 1.8Kbp mRNA (Dower and 
Sims, 1994).
The biological effects of IL-1 are numerous and diverse. IL-1 causes proliferation of 
fibroblasts and can also suppress the expression of matrix protein mRNAs in these 
cells. IL-1 also causes proliferation of smooth muscle cells and keratinocytes, 
induces TNF release and adhesion molecule expression and activation in endothelial 
cells, activates proton pumping in osteoclasts leading to bone resorption and induces 
metalloprotease secretion in chondrocytes. IL-1 can induce the secretion of acute 
phase proteins in hepatocytes; induce differentiation of B-cells and proliferation of 
Th2 cells in combination with stimulation through the T cell antigen receptor. It can 
also induce proliferation of mature B-cells, induce cytokine secretion from 
monocytes and neutrophils and induce insulin secretion and cell death (over a slow 
period of time) in islet cells (Dinarello, 1991).
1.7.1 Interleukin -1 receptors
Interleukin-1 acts via two receptors, interleukin-1 receptor type I (IL-lRtI) and 
interleukin-1 receptor type II (IL-lRtll). IL-lRtI is the only functional receptor and 
IL-lRtll is thought to act as a decoy receptor (Stylianou et al., 1992; Sims et al.,
1993), as IL-1 a  and IL-1 p can bind to IL-lRtll but no signal is produced because the 
intracellular domain of this receptor is much shorter than that of IL-lRtI. Both IL-1 a  
and IL-1 p act as agonists for both receptor types, whereas IL-lra acts as an 
antagonist for both receptors, possibly providing a mechanism whereby the 
biological effects of IL-1 can be suppressed. IL-lRtI consists of 569 amino acids 
made up of a 2 0  amino acid signal peptide, a 317 amino acid extracellular domain,
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containing three immunoglobulin-like domains, a 2 2  amino acid transmembrane 
domain and a 210 amino acid intracellular domain. It has a molecular weight of 
80kDa because all of its six potential glycosylation sites are used. The gene encoding 
IL-lRtI is situated on chromosome 2 at position 2ql2 and transcribes a 5Kbp 
mRNA. IL-lRtll consists of 398 amino acids, consisting of a 13 amino acid signal 
peptide and a 334 amino acid extracellular domain, which shares 28% homology to 
the amino acid sequence of the IL-lRtI extracellular domain. It has a molecular 
weight of 60kDa and consists of a 22 amino acid transmembrane domain and a 29 
amino acid intracellular tail, both of which show no similarity to these regions of the 
IL-lRtI. The lower molecular weight is due to a shorter cytoplasmic region. The 
gene encoding IL-lRtll is situated on chromosome 2 at position 2ql2-2ql3 (Sims 
and Dower, 1994).
The mature forms of IL-1 have affinity for both receptors, although IL-lra binding 
has the highest affinity for IL-lRtI and IL-1 p binding has highest affinity for IL- 
lRtll. The precursor form of IL-1 p does not bind to IL-lRtI, which explains why 
proIL-ip has no biological activity. However, the receptor binding and biological 
activities of the mature and pro forms of IL-1 a  appear indistinguishable (Mosley et 
al., 1987). The effects of both IL-1 a  and IL-1 p are similar despite having only 28% 
homology, but their similarity in biological activity is due to the fact that they both 
signal through the same receptors.
1.7.2 IL-1 in reproduction
The IL-1 family of cytokines has been shown to be expressed by the human 
endometrium and they may have a role to play in implantation. Fukuda et al. (1995) 
demonstrated, using ELISA and RT-PCR, that all three members of the IL-1 family 
of cytokines were expressed by human endometrial cells in vitro. Expression of IL- 
la , IL-1 p and IL-lra protein has also been demonstrated in the human endometrium 
in vivo (Tabibzadeh and Sun, 1992; Kauma et al., 1990; Simon et al., 1993a; Simon 
et al., 1994a; Simon et al., 1995a). Work in mice has shown that implantation is 
prevented by blocking IL-lRtI with IL-lra, suggesting that IL-1 plays an important 
role in the implantation process (Simon et al., 1994b). IL-lRtI has been shown to be 
present in the human endometrium throughout the menstrual cycle (Simon et al.,
37
1993a; Simon et al., 1993b) and also within decidual glands and syncytiotrophoblast 
cells (Simon et al., 1994a). Maternal decidua and villous cytotrophoblast and 
syncytiotrophoblast cells are also known to express IL-1 p and IL-lra (Simon et al., 
1994a). In vitro studies have also shown that IL-1 is capable of stimulating epithelial 
and stromal IL- 6  production (Tabibzadeh et al., 1989; Laird et al., 1994; 
Vandermolen and Yang, 1996) and stromal and decidual LIF production (Arici et al., 
1995; Sawai et al., 1997). This, taken together with the findings that the complete IL- 
1 family is expressed by the human embryo (De los Santos et al., 1996), supports an 
autocrine/paracrine role for the IL-1 system in human implantation.
1.8 Tumour Necrosis Factor - alpha (TNFa)
TNFa is a 157 amino acid long polypeptide that is not glycosylated in humans. It has 
a molecular weight of 17kDa under denaturing conditions but exists as a trimer with 
a molecular weight of 45-55kDa under native conditions (Aggarwal and Reddy, 
1994). It has a trimeric crystal structure consisting of an antiparallel beta-sheet 
sandwich with edge-to-face "jelly roll" structural motif (Aggarwal, 1992). The gene 
encoding TNFa is approximately 3.6Kbp with 4 exons and 3 introns, is situated on 
chromosome 6p21.1-6p21.3 and transcribes a 1.7Kbp mRNA. TNFa was originally 
identified as a factor produced in bacillus Calmette-Guerin primed mice in response 
to endotoxin and found to be responsible for necrosis of various tumours in vivo and 
is cytotoxic for transformed cell lines in vitro (Hamblin, 1993). It is produced by a 
wide variety of cells in response to bacterial, viral and various other parasitic 
infections. The major source of TNFa is from macrophages, but it is also produced 
by other cells including natural cytotoxic cells, T and B-lymphocytes, granulocytes, 
fibroblasts, mast cells, smooth muscle cells, breast, ovarian and glial tumour cells, 
astrocytes, Kupffer cells, adipocytes and granulosa cells (Aggarwal and Reddy,
1994).
Biological actions of TNFa include protection of cells from viral infection, activation 
of granulocytes and macrophages, promotion of bone resorption by osteoclasts and 
inhibition of collagen synthesis. TNFa also induces cytokine secretion (in particular 
IL-2 and IL-6 ) and is known to co-stimulate T cell proliferation and enhance B-cell 
differentiation and immunoglobulin secretion. It also activates vascular endothelial
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cells, promotes angiogenesis, stimulates proliferation of fibroblasts, stimulates acute 
phase protein synthesis by hepatocytes and induces fever (Hamblin, 1993).
1.8.1 TNFa receptors
There are two receptors for TNFa, TNFa receptor type 1 or type B (p60) and TNF 
receptor type 2 or type A (p80). The p80 receptor is 461 amino acids in length and 
consists of a 235 amino acid extracellular domain, a 30 amino acid transmembrane 
domain and a 174 amino acid intracellular domain. The gene is 17Kbp long, has 10 
exons and 9 introns, is situated on chromosome 12pl3 and its mRNA is 3Kbp long. 
The p60 receptor is 455 amino acids long, consisting of a 182 amino acid 
extracellular domain, a 21 amino acid transmembrane domain and a 233 amino acid 
intracellular domain. Its gene is situated on chromosome 12pl and transcribes a 
4.5Kbp mRNA. The p60 receptor is primarily expressed on epithelial cells whereas 
the p80 receptor is primarily expressed on myeloid cells. The extracellular domains 
of both receptors are rich in cysteine and they have a 25% homologous amino acid 
sequence. In contrast, the intracellular domains have no homology to each other, or 
to any other receptors. The majority of functions are mediated through the p60 
receptor and this may be due to the fact that the intracellular domain of p60, and not 
that of p80, contains potential phosphorylation sites for cAMP-dependent protein 
kinase, protein kinase C and tyrosine kinases. Following binding of TNFa to its 
receptor it is quickly internalised and degraded. Although it is not clear which signals 
are mediated through each receptor, it is known that both p60 and p80 activate the 
transcriptional factor nuclear factor kappa B (NF^B) (Aggarwal and Reddy, 1994).
1.8.2 TNFa and endometrial function
TNFa has been shown to be present in the human endometrium in vitro (Tabibzadeh, 
1991). However there are contrasting reports about its presence in the stromal and 
epithelial compartments throughout the menstrual cycle. Two studies have shown 
that expression of both mRNA and protein is strong in the stromal compartment 
during the proliferative phase and becomes variable during the secretory phase. 
Whereas there was no TNFa present in the glandular epithelium in the proliferative 
or early secretory phase, but expression was seen during the mid-late secretory 
phases (Tabibzadeh, 1991; Phillippeaux and Piguet, 1993). However, other studies
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have detected TNFa mRNA and protein throughout the menstrual cycle with 
glandular epithelial TNFa mRNA being high during the proliferative phase, then 
decreasing in the early proliferative phase before increasing again during the mid-late 
secretory phases (Hunt et al., 1992; von Wolff et al., 2000). This pattern of TNFa 
expression has also been shown by cultured endometrial epithelial cells in vitro 
(Laird et al., 1996). Both TNFa receptors (p60 and p80) have been shown to be 
present in the human endometrium throughout the menstrual cycle (Tabibzadeh et al. 
1995b) suggesting that TNFa is functional within the endometrium. A role for 
endometrial TNFa in implantation and formation of the feto-placental unit has been 
further implicated by work that has shown that TNFa mRNA is decreased in women 
who suffer RM (von Wolff et al., 2000). TNFa production by human endometrial 
epithelial cells is influenced by IL-1 and steroids (Laird et al., 1996) suggesting that 
it may have a role in the mediation between cytokines and steroids in the 
endometrium.
1.9 Interleukin-11 (IL-11)
Interleukin 11 is a multifunctional cytokine with a molecular weight of 19kDa and is 
178 amino acids in length. The IL-11 precursor is 199 amino acids in length and has 
a molecular mass of 23kDa (Trepicchio and Dorner, 1998). IL-11 has a similar four- 
alpha-helix bundle topology to IL-6  and LIF. It lacks any glycosylation sites or 
cysteine residues, but is a highly stable molecule (Du and Williams, 1997). IL-11 
was first identified as a soluble factor released by PU-34 primate bone marrow 
stromal cells that has the ability to stimulate the proliferation of IL- 6  dependent cells 
(Paul et al., 1990). Human IL-11 cDNA was later cloned from a human fetal lung 
fibroblast cell line (Paul and Schendel, 1992). The gene for human IL-11 is 7Kbp in 
size, contains 5 exons and 4 introns and is located on chromosome 19ql3.3-19ql3.4. 
Transcription gives rise to two mRNA transcripts of 2.5Kbp and 1.5Kbp (Paul et al., 
1990; Du and Williams, 1997), the difference resulting from the presence of 
additional 3’ noncoding sequences within the larger transcript.
1.9.1 IL-11 receptor alpha
IL-11 is another cytokine that signals through gpl30 in association with its own 
receptor interleukin-11 receptor alpha (IL-1 IRa). IL-1 IR a is a 422 amino acid
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protein that has a genomic region of 9Kbp, consists of 12 exons and 12 introns and is 
located on chromosome 9pl3 (Du and Williams, 1997). IL-11 has similar biological 
actions to IL- 6  in that it acts synergistically with other cytokines (in particular IL-3) 
in supporting growth of primitive haemopoietic progenitors (Musashi et al., 1991), 
directly promotes megakaryocyte maturation (Burstein et al., 1992), acts with IL-3 in 
promoting megakaryocyte colony formation (Yonemura et al., 1992), promotes 
synthesis of acute phase proteins in hepatocytes and inhibits adipocyte development 
(Kawashima et al., 1991). Also, like IL- 6  but unlike LIF, IL-11 does not prevent 
embryonic stem cell development but does promote haemopoietic differentiation by 
developing embryoid bodies in culture (Keller et al., 1993). However, in contrast to 
IL- 6  it does not interact with T-cells (Clark, 1994).
1.9.2 IL-11 and endometrial function
Studies in mice showing that IL-1 IR a is essential for normal decidual development 
have suggested that IL-11 is important in implantation and pregnancy (Bilinski et al., 
1998; Robb et al., 1998). Female mice with either an inactive or null mutation for the 
IL-1 IR a chain are fertile and their blastocysts implant and elicit an initial decidual 
response. However only small decidua form, which subsequently degrade and lead to 
unsuccessful implantation and therefore pregnancy. These results suggest the 
importance of IL-11 in murine endometrial function.
1.10 Matrix metalloproteinases (MMPs)
Matrix metalloproteinases are a family of zinc dependent enzymes that are capable of 
degrading all components of the extracellular matrix (ECM). They are secreted in a 
latent form and are then activated by proteolytic cleavage. They can be divided into 
subgroups depending on their size and substrate specificity into collagenases, 
gelatinases, stromelysins and membrane-type MMPs (Salamonsen, 1996).
The collagenases include: MMP-1 (interstitial collagenase 1), MMP- 8  (interstitual 
collagenase 2) and MMP-13 (collagenase 3). The gelatinases are: MMP-2 (72kD- 
metalloproteinase, gelatinase A) and MMP-9 (92kD-metalloproteinase, gelatinase 
B). The stromelysins include: MMP-3 (stromelysin 1), MMP-10 (stromelysin 2),
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MMP-11 (stromelysin 3), MMP-12 (metalloelastase) and MMP-7 (matrilysin) and 
the membrane type MMPs are: MMP-14 (MT1-MMP), MMP-15 (MT2-MMP), 
MMP-16 (MT3-MMP) and MMP-17 (MT4-MMP) (Birkedal-Hansen et a l, 1993).
1.10.1 Structure of matrix metalloproteinases
All MMPs contain three functional domains, the pre domain at the amino-terminal, 
followed by the pro domain and then the catalytic domain. With the exception of 
MMP-7, all other MMPs also contain a fourth functional domain, the haemopexin- 
like domain, at the carboxy-terminal (Hulboy et al., 1997). The pre domain is the 
leader sequence, which signals for cellular export. The pro domain consists of 80-90 
amino acids and contains a cysteine residue within a highly conserved sequence 
(PRCGVPDV), adjacent to the active site, which binds zinc. It is the cleavage and 
removal of this domain that activates the latent, or proMMPs, into their active form 
(Matrisian, 1990). The catalytic domain contains conserved histidine residues and is 
the zinc-binding domain. The haemopexin-like domain is involved in mediating 
associations with ECM components and inhibitors (Hulboy et a l, 1997). There is 
also a short, but variable, hinge region present in MMPs that connects the 
haemopexin-like domain to the catalytic domain, which has been shown to play a 
role in substrate binding and in interactions with inhibitors (Massova et al., 1998).
The gelatinases (MMP-2 and MMP-9) possess fibronectin-like sequences within 
their catalytic domain, which facilitate gelatin binding by these enzymes (Hulboy et 
al., 1997). The MT-MMPs contain an extra domain, consisting of approximately 25 
amino acids, near the carboxy-terminal that localises the enzymes to the plasma 
membrane (Massova et al., 1998).
1.10.2 Control of MMP activity
MMP activity is regulated at multiple levels including transcription, secretion, 
activation and inhibition. Inhibition is accomplished by a family of tissue inhibitors 
of metalloproteinases (TIMPs), of which there are four, TIMP-1, TIMP-2, TIMP-3 
and TIMP-4. In general they are widely expressed and are frequently regulated in co­
ordination with MMPs (Hulboy et al., 1997). TIMP-1 is a ubiquitous 28.5 kDa 
secreted glycoprotein that forms tight stoichiometric non-covalent complexes with 
the active forms of all MMPs and also with proMMP-2. TIMP-2 is a 21.5 kDa non-
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glycosylated protein that has 40% homology to TIMP-1 and similar inhibitory 
activity against active MMPs, but it preferentially binds proMMP-2. TIMP-3 is a 24 
kDa glycoprotein that is different to other TIMPs in that it has an affinity for the 
ECM (Zhang and Salamonsen, 1997). TIMP-3 and TIMP-4 are not as well 
characterised at present, but have been shown to inhibit MMP activity (Hulboy et al.,
1997).
Transcription of some MMPs, in particular MMP-1, MMP-3, MMP-7 and MMP-9 is 
regulated by growth factors, cytokines and hormones (Birkedal Hansen et al., 1993). 
Most cytokines and growth factors tested have been shown to induce MMP 
transcription, with the exception of TGFp, which decreases transcription (Birkedal 
Hansen et al., 1993). Glucocorticoids inhibit MMP synthesis by decreasing 
transcription (Salamonsen, 1996), and progesterone has been shown to decrease 
proMMP-1, proMMP-3 and proMMP-7, but increase TIMP-1 and TIMP-2 in 
progesterone dependent tissues (Salamonsen, 1996). Thyroid hormone, angiotensin II 
and FSH have all been implicated in the control of MMP activation (Salamonsen, 
1996).
1.10.3 MMP production by the endometrium
The presence of MMPs within the endometrium is well documented. MMP-7 has 
been shown to be present in epithelial cells during the proliferative, late secretory 
and menstrual phases of the menstrual cycle (Rogers et al., 1993; Rogers et al.,
1994), but is not produced by stromal cells. The expression of MMP-2 and MMP-9 
in both epithelial and stromal cells in vivo and in vitro has been reported (Martelli et 
al., 1993; Rogers et al., 1994; Freitas et al., 1999; Skinner et al., 1999). Other studies 
have shown the presence of MMP-1 (Salamonsen, 1994; Marbaix et al., 1995), 
MMP-3 (Jeziorska et al., 1996), MMP-10 and MMP-11 (Rogers et al., 1994) in the 
endometrium. The exact role of each of these MMPs in endometrial function remains 
unclear, but increased levels of some MMPs are seen at the time of menstruation 
suggesting that they may play a role in the degradation of the endometrium at this 
time (Salamonsen, 1994).
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1.10.4 MMPs and implantation
MMPs are also postulated to be involved in the endometrial remodelling associated 
with embryo implantation. MMP-9 production by the endometrium is increased 
during the mid-secretory phase of the menstrual cycle (Skinner et al., 1999), which 
coincides with the implantation window (Johannisson, 1991). Although the 
expression of TIMPs by the endometrium does not alter dramatically through the 
menstrual cycle (Zhang and Salamonsen, 1997) the expression of TIMPs is increased 
in decidualised stromal cells (Zhang and Salamonsen, 1997). The invasive 
trophoblast cells invading the maternal decidual cells also produce MMP-9 (Bischof 
et al., 1995a;), MMP-2 (Bischof et al., 1991; Fernandez et al., 1992) and MMP-14 
(Nawrocki et al., 1995; Hurskainen et al., 1996). This is in contrast to the non- 
invasive trophoblast cells, which do not produce MMPs. These results suggest that 
MMPs do play an important role in the implantation process.
1.10.5 Control of endometrial MMP production
The control of MMP production by human endometrium is less well understood. 
Several studies have suggested that progesterone and oestrogen suppress MMP 
production (Osteen et al., 1994; Osteen et al., 1997; Singer et al., 1997; Skinner et 
al., 1999) and that the reduction of steroid hormone levels at the end of the cycle 
results in the increased MMP production associated with menstruation. More recent 
work has suggested that the expression of endometrial and trophoblastic MMPs are 
regulated by various cytokines (Rawdanowicz et al., 1994; Bischof et al., 1995a; 
Singer et al., 1999; Meisser et al., 1999a), particularly IL-1, TNF-a and LIF. These 
cytokines in particular are known to be important in the control of endometrial 
function and embryo implantation (Stewart et al., 1992; Hunt et al., 1992; Sharkey, 
1998; Simon et al., 1998); thus one of their roles in implantation may be to control 
MMP production.
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Chapter 2 
Materials and Methods
2.1 Human subjects
2.1.1 Normal fertile women
Endometrial biopsies were obtained, using a Sharman's curette (Dawns Surgical Ltd, 
Sheffield, U.K.), from women attending the Jessop Hospital for Women, Sheffield, 
U.K. for non-endometrial pathology. All subjects gave their informed consent to 
participate in the study and local ethical committee approval was obtained. All of the 
women were aged between 25 and 40 and had regular menstrual cycles of between 
25 and 35 days.
Endocrinological investigation showed evidence of ovulation. All subjects had 
normal uterine anatomy, had no steroid treatment for at least 2  months prior to the 
study and were all of proven fertility. The day of the cycle in which the biopsy was 
taken was calculated from the date of the last menstrual period.
2.1.2 Women with unexplained recurrent miscarriage
Endometrial biopsies were obtained, using a Pipelle sampler (Unimar, Nevilly-en- 
Thelle, France), from women attending the recurrent miscarriage clinic at Jessop 
Hospital for Women, Sheffield, U.K. All subjects gave their informed consent to 
participate in the study and local ethical committee approval was obtained. All 
women had suffered at least three or more consecutive miscarriages, were aged 
between 25 and 40 and had menstrual cycles of between 25 and 35 days. They all 
had normal uterine anatomy and showed no evidence of anticardiolipin or lupus 
antibodies. The day in the cycle that the biopsies were obtained were all calculated 
from the day of the LH surge and were all obtained between days LH+ 6  and LH+10.
2.1.3 Collection of biopsies
Endometrial biopsy samples were collected directly from the operating theatre or 
outpatients clinic and taken to the laboratory. Samples used for 
immunocytochemistry or RT-PCR analysis were snap frozen in liquid nitrogen.
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Samples used for cell culture were collected in Hanks balanced salt solution (Sigma, 
Poole, U.K.) and used immediately.
2.2 Cryostat sectioning
All reagents were obtained from Sigma, Poole, U.K. Biopsies were transported from 
storage in liquid nitrogen to ensure that they did not thaw. A Leica cryostat was used 
to cut the sections and a temperature of -20°C was maintained throughout the entire 
procedure. Each biopsy was removed from liquid nitrogen and attached to a holder 
using Cryo-M-Bed embedding compound (Bright Instrument Company Ltd, 
Huntington, U.K.). Once the embedding compound had frozen, serial cryostat 
sections of 15 pm were obtained from each biopsy. Serial sections were placed on 
each microscope slide and the duplicate section used as a negative control. After 
cutting, the sections were immediately fixed in 3.7% (w/v) paraformaldehyde in 
phosphate buffered saline (PBS) for 15 min at room temperature. The sections were 
then washed twice for 5 min in PBS and fixed in methanol for 4 min then acetone for 
2 min, both at -20°C, before being washed again for 2 x 5min in PBS and stored in 
8 % (w/v) sucrose solution at -20°C until they were used.
2.3 Immunocytochemistry
2.3.1 Principles of immunocytochemistry
Immunocytochemistry uses antibodies to specifically bind to antigens present within 
a cell. A substrate is then used to visualise where the antibodies have bound. The 
immunostaining technique used in these studies is known as the PAP procedure 
(figure 2.1). Sections of tissue are incubated with a primary antibody, which will 
bind specifically to any antigen that is present within the cells. The sections are then 
incubated with a secondary antibody specific for the primary antibody in order to 
amplify the binding. Peroxidase anti-peroxidase (PAP) is then applied to the sections, 
which will bind to the secondary antibody. The sections are then incubated with a 
substrate that can be identified due to its colour, which in this case was 
diaminobenzadinetetrachloride (DAB) that produces a brown colouring. This step 
allows the binding to be visualised. A counterstain is then used to visualise any cells 
that do not contain the antigen.
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Figure 2.1: Principles of immunocytochemistry using the PAP procedure
Incubate with primary antibody I
Cell expressing antigen
Incubate with secondary antibody I
Incubate with PAP I
Incubate with DAB I -  peroxidase
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2.3.2 Immunocytochemistry procedure
All reagents were obtained from DAKO, Ely, U.K., unless otherwise stated. Sections 
were washed twice for 5 min in PBS to remove sucrose solution and then quenched 
in 3% (v/v) hydrogen peroxide (Sigma, Poole, U.K.) in methanol (Sigma, Poole, 
U.K.) for lOmin at room temperature, before being blocked with 10% (v/v) normal 
rabbit serum in PBS (Sigma, Poole, U.K.) for 30 min at room temperature. Sections 
were then incubated with a primary antibody for each of the cytokines either 
overnight at +4°C or for lh  at room temperature. The sections were then incubated 
with secondary antibody for 30 min at room temperature. Primary and secondary 
antibodies were all diluted in 1 0 % normal rabbit serum.
Sections were then incubated with a 1:100 dilution of mouse or goat peroxidase-anti- 
peroxidase (PAP), in PBS, for 30 min at room temperature. Both the secondary 
antibody and PAP stages were then repeated when staining for LIF, IL- 6  IL-11 and 
IL-1 IRa, in order to amplify the staining. Diaminobenzadine tetrachloride (DAB) 
substrate (Vector Laboratories, Peterborough, U.K.) was then used to visualise 
antibody binding and the sections counterstained with haematoxylin (Vector, U.K). 
Sections were then dehydrated through 50%, 70% and 90% alcohol (BDH, Poole, 
U.K.) for 5min each and then 95% and 2 x absolute alcohol for 10 min each before 
being cleared in Xylene (BDH, Poole, U.K.) overnight and mounted with a cover slip 
using DePeX (BDH, Poole, U.K.). All incubations were carried out in a humid 
chamber and two five-minute washes in PBS were carried out between each of the 
incubations. A negative control was run parallel to each section where the primary 
antibody had previously been neutralised following an overnight incubation with a 
blocking peptide (Santa Cruz Biotechnology, Inc., U.K.). For each antibody staining 
was repeated on at least 3 different sections from each biopsy.
2.4 Quantification of staining
Two methods were used to quantify the amount and intensity of staining obtained 
using immunocytochemistry.
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2.4.1 Semi-quantitative analysis
Two investigators, independent of one another, assessed all staining semi- 
quantitatively. Intensity of staining was graded on a scale of 0 (-) to 4 (++++), where 
-  represented negative staining, -/+ represented negative to weak staining, + 
represented weak staining, +/++ represented weak to moderate staining, ++ 
represented moderate staining, ++/+++ represented moderate to strong staining, +++ 
represented strong staining, +++/++++ represented strong to very strong staining and 
++++ represented very strong staining. Overall there was good agreement on the 
grade given for each section by each assessor. On the rare occasion that differences 
occurred these sections were re-examined and a grade was obtained by consensus.
2.4.2 Quantification using image-capture analysis
Staining for LIF, IL- 6  and IL-1 was also assessed using digital image software. For 
each section five fields were captured using a Neotech Image Grabber (version 1.2). 
Three epithelial and three stromal areas were then marked in each field and the 
average intensity for each area calculated using Jandel Sigma Scan Image 
Measurement Software. The average intensity was calculated as the total intensity of 
the area divided by the number of pixels that the area covered. This provided fifteen 
intensities for epithelial staining and fifteen intensities for stromal staining in each 
section. The mean intensity for epithelial and stromal staining was then calculated for 
each section. This method is described in more detail in chapter 3.
2.5 Tissue culture
All materials were obtained from Sigma, U.K. unless otherwise stated. Endometrial 
epithelial and stromal cells were prepared and cultured using an established method 
(Laird et a l , 1993; Laird et a l , 1994; Laird et al., 1997). Endometrial tissue was 
collected immediately into Hanks balanced salt solution containing streptomycin 
(lOOpg/ml) and penicillin (lOOpg/ml). The tissue was then chopped finely and 
incubated in Dulbecco’s modified Eagle’s medium containing 0.1% (w/v) type la  
collagenase (DMEMC), for 45 min at 37°C with gentle pippetting every 15 min to 
disperse the cells. The cell suspension was then centrifuged for 10 min at 100 x g, 
leaving a pellet containing epithelial cells and supernatant containing the stromal 
cells. The epithelial cells were then incubated and pipetted for a further 45 min at
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37°C in DMEMC before repeating the centrifugation. Following centrifugation the 
epithelial cells were resuspended in 2 ml DMEM (containing 2% (w/v) glutamine, 
streptomycin/penicillin (100 pg/ml) and 10% (v/v) foetal bovine serum) (CDMEM). 
The supernatants containing stromal cells were centrifuged for 5 min at 300 x g. The 
resulting supernatant was discarded and the pellet of stromal cells was resuspended 
in 2 ml CDMEM.
For each cell type a density gradient was performed where the cell suspensions were 
layered over 8 ml CDMEM and left for 30 min, allowing the larger epithelial cells 
and gland fragments to fall to the lower 2  ml and the smaller stromal cells to remain 
in suspension in the upper 8 ml. For the epithelial cells the upper 8  ml was discarded 
and the lower 2  ml used for cell culture, whereas for the stromal cells the upper 8  ml 
were used for cell culture and the lower 2 ml discarded. Each cell type was plated out 
at a density of 1 x 105 cells/ml into 96 well plates, to study the effects of cytokines on 
cultured cells, or 2.5 x 105 cells/ml into tissue culture flasks, for mRNA studies using 
RT-PCR analysis. Cells were then incubated at 37°C in an atmosphere containing 
5% CO2 and 95% air until confluent. This was usually 48 h when cultured in plates 
and 5-7 days when cultured in flasks.
When the stromal and epithelial cells cultured in 96 well plates reached confluency 
media was replaced with CDMEM containing either no additions (controls) or 
cytokines (0.1-10 ng/ml) in replicate wells for each concentration. After a further 
period of 48 h the media was removed and stored at -20°C for analysis by 
zymography or ELISA. The number of plates of stromal and epithelial cells prepared 
from a single biopsy varied depending on the size of the biopsy; between 1-3 plates 
of epithelial and 1 -2  plates of stromal cells were normally obtained for each biopsy. 
Therefore, cells prepared from a single biopsy could be incubated with more than 
one different type of cytokine.
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2.6 Preparation of endometrial biopsy material and cultured 
endometrial cells for analysis of cytokines using RT-PCR
2.6.1 Principles of RT-PCR
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) is a two-step process 
that can be used to identify the presence of messenger RNA (mRNA). The first step 
uses reverse transcriptase (RT) to make a DNA sequence that is complementary 
(cDNA) in base sequence to the mRNA. This step is required because the 
polymerase used in PCR will only amplify DNA. PCR is then used to selectively 
amplify the defined cDNA produced from the RT step. To enable specific 
amplification of cDNA, two oligonucleotide primer sequences are designed that, 
when added to the cDNA, will bind specifically to complementary DNA sequences 
immediately flanking the desired target region. The new DNA strands, which are 
complementary to the original cDNA, are synthesised in the presence of DNA 
polymerase and four deoxynucleoside triphosphates (dATP, dCTP, dGTP and 
dTTP). This technique is termed "chain reaction" because the newly synthesised 
DNA strands then act as a template for further DNA synthesis in subsequent cycles. 
After about 30 cycles, the amount of DNA synthesised is about 105 copies of the 
original cDNA sequence targeted by the primers, which is then enough to visualise 
as a band of a specific size when run on agarose gel electrophoresis.
2.6.2 Preparation of cells for RNA extraction
Endometrial cells were grown in flasks as described, until confluent. Once confluent 
the media was removed from the cells and PBS added to the flask to wash the cells. 
The PBS was then removed and cell dissociation solution (containing EDTA, 
glycerol and sodium citrate in PBS) (Sigma, Poole, U.K.) added for 10 min at 37°C. 
The cell dissociation fluid is a gentler method than trypsin and EDTA for removing 
cells. The cell dissociation solution was then discarded and CDMEM was pipetted 
gently over the cells removing them from the bottom of the flask into cell 
suspension. The cell suspension was then centrifuged at 300 x g for 5 min and the 
supernatant discarded.
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2.6.3 Preparation of endometrial biopsies for RNA extraction
Endometrial biopsies were treated with a dismembranator, where tissue and a ball 
bearing are placed inside a Teflon tube, which is held tightly in place and shaken 
vigorously until the tissue is broken up. This ensured the biopsies were broken up, 
without thawing, in preparation for the RNA extraction. Thawing would cause 
mRNA breakdown because of the action of RNAases. The biopsies were moved 
directly from liquid nitrogen into Teflon tubes that had been chilled in liquid 
nitrogen. A ball bearing, also chilled in liquid nitrogen, was also added to the tube 
and the top replaced. The tube was then placed in the dismembranator and vigorously 
shaken for approximately 1 min. 1 ml of TRIzol reagent (Sigma, Poole, U.K.) was 
then added to the homogenised biopsy and mixed thoroughly before being frozen and 
stored in liquid nitrogen.
2.6.4 RNA extraction
Following preparation, 1 ml of TRIzol Reagent was added to the endometrial cell 
pellets and left on ice for 5 min. Endometrial biopsies previously prepared with 
TRIzol reagent were thawed on ice. 100 pi of ice-cold chloroform was then added to 
the tubes and mixed well before sitting on ice for 10 min. The tubes were then 
centrifuged at 12000 rpm for 15 min at +4°C. The top aqueous layer (approximately 
500 pi) was then removed and placed into a new tube with an equal amount of ice- 
cold isopropanol and left on ice for 1 h. The centrifugation was then repeated at 
12000 rpm for 15 min at +4°C, the supernatant was discarded and the pellet was 
resuspended in 250 pi 80% ethanol. The resuspended pellets were then centrifuged at 
12000 rpm for 5 min at +4°C and the supernatant removed. The pellets were then air- 
dried for approximately 10 min and resuspended in 20-50 pi sterile H2O.
2.6.5 Analysis of endometrial mRNA
The RNA concentration for each sample was calculated by measuring the optical 
density at 260 nm. The resulting figure was then put into the following equation to 
give the RNA concentration:
RNA concentration (pg/pl) = (optical density at 260 nm x dilution factor) x 0.04
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The samples were then diluted to ensure an RNA concentration of approximately 1 
pg/pl was obtained.
The ratio of the optical density at 260 nmioptical density at 280 nm was also 
calculated. This value reflected the purity of the mRNA in the sample, with a value 
of 2 .0  being the purest.
2.7 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
2.7.1 RT
All materials were obtained from Gibco, U.K. For each sample a 36 pi mastermix 
consisting of 8 pi 5 x RT buffer, 8 pi 5 x KC1, 16 pi dNTP’s (containing equal 
amounts of dGTP, dATP, dCTP and dTTP), 1.2 pi oligo dT, 1.2 pi RT and 1.6 pi 
sterile H2O was added to 4 pi of RNA (1 pg/pl). The mixture was then overlaid with 
40 pi of mineral oil and thermocycled at 37.5°C for 1 h, 99°C for 5 min and finally 
4°C. The samples were then removed and stored at -20°C. Two controls were run 
parallel to each sample. The first contained only sterile H2O in replacement of RNA 
(negative control) and the second contained sterile H2O in replacement of the RT 
enzyme (no RT control).
2.7.2 PCR
All materials were obtained from Gibco, U.K. PCR was used to detect any mRNA 
present in the endometrial cells and biopsies for LIF, IL-6 , IL-ip and TNFa. Initial 
analysis was carried out using the housekeeping gene 7B6, to detect whether the 
RNA extraction was successful and if there was any genomic DNA contamination 
and also to ensure that adequate mRNA had been obtained. All primers were 
synthesised in-house. The sequences for all primers, with the exception of those for 
LIF, were obtained from previous studies (Francis and Duff, 1993; Estdale et al., 
1996). The primer sequences for LIF were designed using Oligo™ Primer Analysis 
Software (version 3.4). This software enables the generation of primer sequences at 
specific points along the DNA sequence of interest and subsequent calculation of the 
optimum annealing temperature for the PCR reaction. Furthermore it predicts the 
potentially negative effects of complementary annealing between primers and the
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possibility of primer hairpin loops forming. The sequences for all of the primers used 
are as follows:
7B6 Forward 5' AGC CGT AGA CGG AAC TTC CA 3'
Reverse 5' CTA AAA CAG CGG AAG CGG T 3'
LIF Forward 5' GAG TTG TGC CCC TGC TGT TG 3'
Reverse 5' ATC CCT CCG TTC ACA GCA CA 3'
IL-6 Forward 5' CCA CAC AGA CAG CCA CTC ACC 3
Reverse 5' GGC TTG TTC CTC ACT ACT CTC 3'
IL-lp Forward 5' CGA CAC ATG GCA TAA CGA GC 3'
Reverse 5' CAT CTT TCA ACA CGC AGG AC 3'
TNFa Forward 5' GAG TGA CAA GCC TGT AGC CC 3'
Reverse 5' CCC AGA TAG ATG GGC TCA TA 3'
All primers were used at a concentration of 20 pM. For each sample a 20 pi 
mastermix was added to 5 pi cDNA. However, the amounts of reagents varied for 
each PCR. The mastermix for 7B6 consisted of 15.25 pi sterile H2O, 2.5 p i 10 x PCR 
buffer, 0.5 pi MgCl2, 0.75 pi forward primer, 0.75 pi reverse primer and 0.25 p i Taq 
polymerase. The mastermixes for LIF and IL-6  consisted of 15.85 pi sterile H2O, 2.5 
pi 10 x PCR buffer, 0.4 pi MgCL, 0.5 pi forward primer, 0.5 p i reverse primer and
0.25 pi Taq polymerase and the mastermixes for IL-lp and TNFa consisted of 15.75 
pi sterile H2O, 2.5 p i 1 0  x PCR buffer, 0.5 pi MgCfe, 0.5 pi forward primer, 0.5 p i 
reverse primer and 0.25 pi Taq polymerase. The samples containing the mastermix 
were then overlaid with 40 pi mineral oil and thermocycled. For each pair of primers 
the thermocycle program was optimised. This involved repeating the program using 
different annealing temperatures and variations in the number of cycles used in each 
program.
The optimum thermocycle programs used were as follows:
7B6 U F IL- 6  IL-1P TNFa
1. Denaturation of DNA
5 min 95°C 95°C 95°C 95°C 95°C
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7B6 LIF IL- 6  IL-13 TNFa
2. Denaturation of DNA
lmin 95°C 95°C 95°C 95°C 95°C
3. Primer reannealing
lmin 57°C 62°C 53°C 55.9°C 59.9°C
4. DNA synthesis
lmin 72°C 72°C 72°C 72°C 72°C
Cycles of 2,3 and 4 x35 x35 x35 x35 x35
5. Completion of synthesis
5min 72°C 72°C 72°C 72°C 72°C
6 . Completion of annealing
5 min 55°C 55°C 55°C 55°C 55°C
7. Holding Temperature 4°C 4°C 4°C 4°C 4°C
2.7.3 Electrophoresis
Agarose gel electrophoresis was used to separate the PCR products on the basis of 
fragment size, lg agarose was dissolved in 50ml 1 x TBE (10.8% w/v Tris, 5.5% w/v 
boric acid and 0.93% EDTA) and 2jnl ethidium bromide added. The gel mixture was 
then poured into the gel plate and left to set around a comb, giving a set number of 
wells that are required. The gel was then placed in a tank containing 1 x TBE and the 
PCR products added to the wells. Each PCR product (lOpl) was mixed with 6 pi 
loading buffer, and lOpl of this mixture added to the appropriate well. A marker 
[(|)F 174-HaeIII] (Sigma, Poole, U.K.) was run parallel to the PCR products in every 
gel, and was used to determine the size of any product seen. Gels were run at 100- 
110V for 40-50 min.
The gels were visualised under an ultraviolet trans-illuminator. Bands could be seen 
due to the ethidium bromide being intercalated within the DNA fragments and 
fluorescing under the UV light. Images were recorded using a Polaroid film camera.
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2.8 Analysis of MMP secretion into media
MMP production by cultured stromal and epithelial cells was assessed using 
zymography and ELISA.
2.8.1 Zymography
Zymography is a technique that can identify enzymes by separating them according 
to their size, using SDS-PAGE (Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis). SDS is an anionic detergent that disrupts nearly all non-covalent 
interactions in naive proteins. Following denaturation with SDS, the larger the 
protein is, the more SDS they bind and the more negatively charged they become. An 
electrical current is passed through the gel and proteins are fractionated according to 
their overall charge, the smaller the protein, the further it will travel down the gel. In 
zymography a protein substrate specific for the enzyme that is to be detected, is 
incorporated into the gel. MMP-2 and MMP-9 are gelatinases, so gelatin is added to 
the gel. Once the gel has been run, the SDS is washed out of the gel to prevent the 
enzymes from being denatured and the gel is incubated overnight. This allows the 
gelatinases to digest the gelatin, leaving an area where the gelatin has been digested. 
When the gel is then stained with Coomassie blue, all of the gel is dyed blue except 
the areas where there is no gelatin present, indicating the presence of the gelatinases.
All materials were obtained from Sigma, UK., unless otherwise stated. A 7% 
acrylamide lower gel solution was prepared containing 1.4 ml Bis (2.6% w/v) 
acrylamide (40% w/v) (BDH, Poole, U.K.), 1.8 ml Tris buffer solution (1.5M Tris, 
0.4% SDS, pH 8 .8 ), 0.8 ml gelatin (1% w/v) and 4 ml distilled H2O. 15 pi TMED 
and 50pl ammonium persulphate (10% w/v) was then added and the gel solution 
poured between two glass plates. TMED and ammonium persulphate cause the Bis 
acrylamide to polymerise forming a polyacrylamide gel matrix. Once the gel has set, 
an upper gel solution was poured on top of the lower gel. The upper gel solution 
contained 0.59 ml Bis (2.6% w/v) acrylamide (40% w/v), 0.75 ml Tris buffer 
solution (0.5M Tris, 0.4% SDS, pH 6 .8 ). 1.69 ml distilled H2O, 15 pi TMED and 50 
pi ammonium persulphate (10% w/v). A comb with 10 wells was then placed in the 
top of the gel and the gel left to set around it. Once the gel had set, the comb was 
removed leaving 10 wells at the top of the gel. The gels (still in glass plates) were
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then placed into a tank containing a running buffer (2M glycine, 1% SDS, 0.25M 
Tris HC1).
5 pi of conditioned cell culture media was added to 5 pi of non-reducing buffer and 
added to each well. A molecular weight marker was run parallel to each of the 
samples containing bands between 205kDa and 36kDa. Supernatants from the D3X 
human melanoma cell line (a gift from Dr A. Cross, Sheffield Hallam University) 
were used as a positive control for MMP-2 and MMP-9 and were also run in each 
gel. After electrophoresis the gels were incubated in 2.5% (v/v) Triton-X-100 for 3 x 
30min washes at 37°C before being incubated in 0.25 M Tris buffer containing 1M 
NaCl and 25mM CaCl2 for 24h. The gels were then stained with 0.5% (w/v) 
Coomassie blue R-250 in 7% (v/v) acetic acid, 50% (v/v) methanol and destained in 
7% (v/v) acetic acid, 30% (v/v) methanol. Individual gels were run with supernatants 
taken from cells incubated with each concentration of cytokine. Zymography was 
repeated at least 3 times for each of twelve different experiments to ensure a 
consistent result was obtained.
2.8.2 Densitometry
Bands representing MMP-2 and MMP-9 in the zymography gels were measured 
quantitatively using densitometric analysis. The net intensity of each band was 
measured using Kodak Digital Science™ ID Image Analysis Software. The intensity 
of the band for each different concentration of cytokine was compared to the control 
band on each gel. As intensities for the control band varied greatly between 
experiments the results were recorded as a percentage change from the control value. 
For each of the cytokines tested a minimum of 3 gels for each experiment were run. 
This was repeated for each of the 3 different biopsies and the mean results for each 
cytokine concentration was calculated.
2.8.3 ELISA for MMPs
The amounts of MMP-2, MMP-9 and MMP-7 produced by cultured endometrial 
epithelial and stromal cells was measured quantitatively using commercially 
available BIOTRA ELISA kits (Amersham Life Sciences, U.K.) according to the 
manufacturer’s instructions. The MMP-2 assay kit detected latent, active and TIMP-
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bound forms of MMP-2 while the MMP-9 kit did not detect active MMP-9 but did 
detect latent and TIMP-bound forms and the MMP-7 kit only detected the latent 
form. The sensitivity of the assays was 0.37 ng/ml for MMP-2, 0.6 ng/ml for MMP-9 
and 0.16 ng/ml for MMP-7. The intra-assay variation range was 5.7%, 5.2% and 
3.5% while the inter-assay variation was 10.0%, 8 .8 % and 6.9% for MMP-2, MMP-9 
and MMP-7 respectively. As these experiments were carried out in CDMEM 
containing non-heat inactivated serum, CDMEM was run as a control parallel to the 
samples tested using ELISA. Samples were diluted 1:50 for MMP-2 and 1:20 for 
MMP-7 in assay buffer to ensure the metalloproteinase concentration was within the 
range of the standard curve. The absorbance was measured using a Wallac 1420 
multilabel counter at 450nm, as instructed by the manufacturer. ELISA 
measurements were performed on each of four replicate samples for both epithelial 
and stromal cell cultures, for each concentration of cytokine.
2.9 ELISA for IL-11
The amount of IL-11 produced from cultured epithelial and stromal cells was 
measured quantitatively using a commercially available Quantikine® ELISA kit 
(R+D Systems, Abingdon, U.K.). The kit used an anti-human IL-11 antibody 
conjugated to horseradish peroxidase to detect IL-11 and the colour reagent used was 
tetramethylbenzadine. The sensitivity of the assay was 8.0 pg/ml with an intra-assay 
variation range of 2.4% and an inter-assay variation of 6.9%. Again, CDMEM was 
run as a parallel control to the samples tested using ELISA. Epithelial samples were 
diluted 1:10 and stromal samples diluted 1:5 in calibration diluent to ensure the 
cytokine concentration was within the range of the standard curve. The absorbance 
was measured at 450 nm and 550 nm using a Wallac 1420 multilabel counter, as 
instructed by the manufacturer. The total values were calculated as absorbance at 450 
nm minus the absorbance at 550 nm in order to correct for optical imperfections in 
the plate.
2.10 ELISA for TNFa and IL-1 (3
The amount of TNFa and IL-lp produced from cultured epithelial and stromal cells 
was measured quantitatively using commercially available Duoset ELISA 
Development systems (R+D Systems, Abingdon, U.K.). A 96 well plate was coated
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with the capture antibody provided (mouse anti-human TNFa or IL-1 P) and 
incubated overnight at room temperature. The wells were then washed with wash 
buffer (0.05% Tween 20 in PBS) before adding 300 pi block buffer (1% BSA, 5% 
sucrose in PBS with 0.05% NaNs) into each well for lh  at room temperature. 
Following another wash, 100 pi of cell culture supernatant was then added to each 
well and incubated for 2 h at room temperature. For TNFa the cell culture 
supernatants were diluted 1:50 in assay diluent to ensure that the values fell on the 
standard curve. The wells were then washed again and 100 pi of detection antibody 
(biotinylated goat anti-human TNFa or IL-lp) was added to each well and incubated 
for 2 h at room temperature. The wells were then washed again, before adding 100 pi 
of streptavadin (conjugated to horseradish-peroxidase) to each well for 2 0  min at 
room temperature. Following a final wash, 100 pi of substrate solution (1:1 mixture 
of H2O2 and tetramethylbenzidine) was added to each well for 2 0  min at room 
temperature before adding 50 pi of stop solution (2M H2SO4). The absorbance was 
measured at 450 nm using a Wallac 1420 multilabel counter. Absorbance at 550nm 
was not measured in this case as it was not advised by the manufacturer. Excellent 
standard curves and duplication of results was obtained by measurement at 450nm 
only.
2.11 Bioassay for TNFa
TNFa production from cultured epithelial and stromal cells was also measured 
quantitatively using cytotoxic bioassay. This assay utilises the cytotoxic action of 
TNFa on pre-sensitised murine aneuploid fibrosarcoma cells (L929). These cells are 
sensitised to TNFa by treatment with actinomycin D.
L929 cells were plated into the wells of a 96-well plate at 2 x 105 cells/ml. The cells 
were then incubated at 37°C in an atmosphere of 5% CO2 for 24 h, until confluency 
had almost been reached. Nine TNFa standards between 0.91 and 0.0018 ng/ml were 
prepared and 100 pi of each added to 3 replicate wells. Supernatants from cultured 
epithelial cells were added in duplicate. The supernatants were diluted 1:5 in cell 
culture media to ensure that the values fell on the standard curve. 4 pi of actinomycin 
D (0.1 mg/ml) was then added to every well to give a final concentration of 2 pg/ml
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in each well. The plates were then incubated for a further 24 h at 37°C under an 
atmosphere of 5% CO2. The cell media was then removed from each well and the 
cells washed with 200 pi PBS. Cells were then fixed with 200 pi methanol for 15 
min. The methanol was then removed and the plates air dried. The plates were then 
stained with crystal violet (0.1% solution in 200 mM boric acid), 200 pl/well for 20 
min. The plates were then washed three times in distilled H2O and the stained cell 
layer solublised in 50 pi 10% (v/v) glacial acetic acid. The plate was then incubated 
for 30 min in a gas incubator to achieve dissolution. The absorbance of each well 
was then read at 570 nm.
The absorbance readings were inversely proportional to the amount of TNFa present. 
Higher amounts of TNFa caused a greater cytotoxic effect on the cells and therefore 
less crystal violet staining was seen, due to the presence of fewer cells, resulting in a 
lower absorbance reading.
2.12 Statistical analysis
Data was expressed as group means ± SEM (n = 4, number of replicate wells from a 
single experiment). Results shown are those obtained from cells prepared from a 
single biopsy and are typical of those obtained on each of the 3 occasions that the 
experiment was repeated. Differences in the amounts of MMP produced in the 
presence of different cytokines were analysed using ANOVA.
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Chapter 3
Endometrial cytokine expression in normal fertile women
3.1 Introduction
The exact role of cytokines in human endometrial function still remains to be 
determined, but it is thought that the paracrine and autocrine action of cytokines 
provides local specificity to the regulation of implantation and uterine function. The 
actions of cytokines allows different cell types within the endometrium to have 
separate but co-ordinated growth and differentiation and also provides a means of 
mediating the embryonic-maternal interactions required for successful development 
and implantation of a blastocyst. Although many cytokines have been shown to be 
present within the endometrium this work has focused on LIF, IL-6, IL-1 and TNFa.
3.1.1 Leukaemia Inhibitory Factor
LIF has been shown to be essential for implantation in mice (Stewart et al., 1992) 
and more recent work has suggested that it may also be important in implantation in 
humans. LIF is known to be expressed by endometrial epithelial and stromal cells 
(Charnock-Jones et al., 1994; Vogiagis et al., 1996; Cullinan et al., 1996), decidual 
cells (Sawai et al., 1997) and villous and extravillous trophoblast cells (Sharkey et 
al., 1999). It has also been detected in endometrial flushings (Laird et al., 1997) and 
mRNA for both LIF and its receptor has been identified in pre-implantation 
blastocysts (Charnock-Jones et al., 1994; Chen et al., 1999) suggesting an important 
role of LIF in human implantation.
3.1.2 Interleukin-6
IL-6 has also been shown to be present in human endometrial epithelial and stromal 
cells (Tabibzadeh et al., 1995a; Vandermolen and Yang., 1996; Laird et al., 1993), 
but expression is greater in epithelium. IL-6 is also produced by decidual cells 
(Montes et al., 1995) and the IL-6 receptor is present in both the human embryo and
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glandular epithelium with mRNA expression being increased at the time of 
implantation (Sharkey, 1998).
3.1.3 Interleukin-1
IL-1 a  and IL-lp protein and mRNA have been shown to be expressed by human 
endometrial cells (Kauma et al., 1990; Tabibzadeh and Sun, 1992; Simon et al., 
1993a), decidual cells (Simon et al., 1994a), placental cells (Simon et al., 1994a; 
Simon et al., 1995b) and pre-implantation embryos (De los Santos et al., 1996). The 
antagonist for these cytokines, IL-lra, has also been reported to be produced by 
endometrial cells (Fukuda et al., 1995; Simon et al., 1995a), decidual cells (Simon et 
al., 1994a), trophoblast cells (Simon et al., 1994a) and pre-implantation embryos (De 
los Santos et al., 1996). It has also been shown that endometrial cells (Simon et al., 
1993a; Simon et al., 1993b), decidual and trophoblast cells (Simon et al., 1994a) and 
embryos (De los Santos et al., 1996) express the functional receptor IL-1R tl. Overall 
this work has demonstrated that the IL-1 system is present in both embryonic and 
maternal tissues, particularly around the time of implantation, and this may also be 
involved in signalling between the embryo and endometrium.
3.1.4 Tumour Necrosis Factor
TNFa is another cytokine that has been localised in and produced by the human 
endometrium (Hunt et al., 1992; Phillippeaux and Piguet, 1993; Tabibzadeh, 1991, 
Laird et al., 1996). The receptors for TNFa are also expressed by the human 
endometrium (Tabibzadeh et al., 1995b).
We wanted to confirm the pattern of expression of these cytokines in the 
endometrium, throughout the menstrual cycle in vivo. This could then be compared 
to cytokine expression in women with impaired fertility, such as recurrent 
miscarriage, and used to determine if abnormal cytokine expression could be a 
contributing factor to unsuccessful pregnancy in these women. The aim of this study 
was therefore to determine the pattern of protein and mRNA expression of LIF, IL-6, 
IL-1 a, IL-1 p and TNFa throughout the menstrual cycle using immunocytochemistry 
and RT-PCR.
62
3.2 Materials and Methods
3.2.1 Endometrial sections
Cryostat sections were obtained from endometrial biopsies from normal fertile 
women as described in the materials and methods section. Staining obtained for LIF 
was performed on sections from biopsies from 26 different women during the early 
proliferative (n=2), mid proliferative (n=l), late proliferative (n=2), early secretory 
(n=10), mid secretory (n=8) and late secretory (n=3) phases of the menstrual cycle. 
Staining for IL-6 was performed on sections from biopsies from 24 different women 
obtained during the early proliferative (n=l), mid proliferative (n=4), late 
proliferative (n=4), early secretory (n=4), mid secretory (n=9) and late secretory 
(n=2) phases of the menstrual cycle. Staining obtained for IL-1 a  was performed on 
sections from biopsies from 19 different women during the early proliferative (n=l), 
mid proliferative (n=2), late proliferative (n=5), early secretory (n=3), mid secretory 
(n=7) and late secretory (n=l) phases of the menstrual cycle. Staining obtained for 
IL-lp was performed on sections from biopsies from 24 different women during the 
mid-proliferative (n=4), late proliferative (n=4), early secretory (n=4), mid secretory 
(n=10) and late secretory (n=2) phases of the menstrual cycle. Staining obtained for 
TNFa was performed on sections from biopsies from 10 different women during the 
mid-proliferative (n=2), late proliferative (n=2), early secretory (n=2), mid secretory 
(n=2) and late secretory (n=2) phases of the menstrual cycle.
Dating of the biopsies was calculated from the time of the last menstrual period. 
Biopsies obtained between days 0-4 were termed the early proliferative phase; days 
5-9, the mid-proliferative phase; days 10-14, the late proliferative phase; days 15-19 
the early secretory phase; days 20-24, the mid-secretory phase and days 25+, the late 
secretory phase of the menstrual cycle.
3.2.2 Immunocytochemistry
All sections were stained according to the protocol described in the materials and 
methods section. The protocol for each antibody was optimised, by initially using 
varying concentrations of both primary and secondary antibody to identify the 
optimal combination for visualisation of the antigen. The primary and secondary
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antibodies used in these experiments were sold specifically for immunocytochemical 
studies and are summarised in tables 3.1 and 3.2 respectively. The binding was 
visualised using PAP antibodies and DAB substrate.
3.2.3 Quantification of staining
All staining was assessed semi-quantitatively as described in chapter 2.
The intensity of staining for LIF, IL-6, IL-1 a  and IL-lp was also assessed using a 
quantitative image analysis method that was developed as part of my studies. This 
method of analysis was used in an attempt to provide a more robust method for 
quantification of immunocytochemical staining.
From one section from each biopsy, 5 fields were chosen at random and digitally 
captured using Neotech Image Grabber (version 1.2). The images were then 
converted into greyscale images before the intensity of staining could be measured. 
This was necessary because the software used to measure the intensity of staining 
could not differentiate between different colours. Therefore, all colour was converted 
into greyscale so that the intensity could be determined. The overall intensity 
observed in positive staining therefore included intensities from both positive 
staining (i.e. from DAB substrate) and the counterstain (i.e. haematoxylin). The 
intensity of staining seen in the negative controls, where only haematoxylin is 
present, was therefore subtracted from the total intensity seen in the positive sections, 
in order to correct for this. For each field, 3 areas containing glandular epithelial 
cells and 3 areas containing stromal cells were highlighted and the intensity of each 
area measured using Jandel Sigma Scan image measurement software. This produced 
intensity values for 15 glandular epithelial and 15 stromal areas from each section. 
Each area was chosen at random and encompassed between 5 and 20 cells. Glandular 
epithelial and stromal staining was then assessed separately. For each cell type the 
average intensity of each area was calculated by dividing the total intensity of the 
area by the number of pixels present within the selected area. Intensity was measured 
on a scale of 0-255, where 0=black and 255=white. The average intensity
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Table 3.1: Primary antibodies used when staining for LIF, IL-6, IL-la, IL-ip 
and TNFa with concentrations and incubation times used for each 
antibody. The antibodies were obtained from R+D Systems, 
Abingdon, U.K. (♦), Genzyme Diagnostics, West Mailing, U.K. (v)  
and Santa Cruz Technology Inc, U.K. (*).
Antibody Concentration Incubation
LIF Goat anti-human LIF ♦ 1:50 (2 (ig/ml) 24h
IL-6 Mouse anti-human IL-6 v 1:20 (50 jig/ml) 24h
IL -la Goat anti-human IL -la  * 1:100 (2 jig/ml) 24h
IL-lp Goat anti-human IL-1 p * 1:100 (2 fag/ml) 24h
TNFa Mouse anti-human TNFa * 1:50 (4 jag/ml) 48h
Table 3.2 : Secondary antibodies used when staining for LIF, IL-6, IL-la, IL-ip  
and TNFa with concentrations and incubation times for each 
antibody. All antibodies were obtained from DAKO (Ely, U.K.).
Antibody Concentration Incubation
LIF Rabbit anti-goat Ig 1:200 (9 ng/ml) 30min
IL-6 Rabbit anti-mouse Ig 1:25 (140 ng/ml) 30min
IL -la Rabbit anti-goat Ig 1:100 (18 ng/ml) 30min
IL-lp Rabbit anti-goat Ig 1:100(18 ng/ml) 30min
TNFa Rabbit anti-mouse Ig 1:25 (140 ng/ml) 30min
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results were then inverted by subtracting each value from 255 to allow higher results 
to represent higher intensities of staining. This also prevented the values becoming 
negative once the background staining was subtracted from the intensity values. This 
was repeated on the negative controls run parallel to each section, in each of the 
experiments. For LIF and IL-6, all positive sections and negative controls had been 
counterstained with haematoxylin, so the staining on the negative controls was 
quantified so that it could then be used to adjust the positive staining results to allow 
for background staining. For IL -la  and IL-lp intensity of staining on two types of 
negative control needed to be quantified. Firstly where haematoxylin had been used, 
to allow for background in the positive staining when a counterstain was used and 
also where no haematoxylin had been used to allow for background when no 
counterstain had been used on the positive sections.
For each cytokine, the mean average intensity of the negative controls was calculated 
(mean of the 15 average intensities obtained from each of the 15 areas). This mean 
intensity was then subtracted from each of the 15 results from the positive staining 
results for each section. The mean intensity and standard error of the mean was then 
calculated from these 15 results for each section/biopsy and plotted on a graph. To 
determine if there was any significant difference in staining throughout the cycle, the 
mean results from each biopsy were divided into the phases of the cycle that they 
were obtained from and assessed using ANOVA.
3.2.4 RT-PCR
RT-PCR analysis for expression of LIF, IL-6, IL-1 P and TNFa mRNA in 
endometrial biopsies was attempted. We first performed this on cultured stromal and 
epithelial cells, as this has previously been successful for IL-6, IL-1 p and TNFa 
(Estdale et al., 1996).
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3.3 Results
3.3.1 Semi-quantification of staining
3.3.1.1 Leukaemia inhibitory factor
Figure 3.1 shows examples of LIF staining in sections obtained during the mid- 
proliferative (figure 3.1a), late proliferative (figure 3.1b), early secretory (figure 
3.1c), mid-secretory (figure 3. Id) and late secretory (figure 3.1e) phases of the 
menstrual cycle. A negative control is included, where a serial section had been 
incubated with primary antibody, which had been neutralised before being added to 
the section (figure 3. If). The results show that, throughout the cycle, epithelial 
staining was more intense than that seen in the stromal compartment of the 
endometrium. Glandular epithelial staining was moderate in the early-mid 
proliferative phases of the menstrual cycle (figure 3.1a), but increased in intensity 
throughout the late proliferative (figure 3.1b) and secretory phases (figure 3.1c,d and 
e) of the menstrual cycle, peaking during the mid-secretory phase (figure 3. Id), at the 
time of implantation. Luminal epithelium was not present in every section, but when 
it was present showed similar staining to that seen in the glandular epithelium. 
Stromal intensity was relatively weak and remained relatively constant throughout 
the menstrual cycle, but overall showed greater intensity during the secretory phase 
compared to the proliferative phase of the menstrual cycle.
Table 3.3 summarises the semi-quantitative analysis for LIF throughout the 
menstrual cycle in the sections from biopsies from 26 different normal fertile 
women.
3.3.1.2 Interleukin-6
Figure 3.2 shows IL-6 staining in sections obtained from endometrial biopsies during 
the mid-proliferative (figure 3.2a), late proliferative (figure 3.2b), early secretory 
(figure 3.2c), mid-secretory (figure 3.2d) and late secretory (figure 3.2e) phases of 
the menstrual cycle. A negative control is included, where a serial section had been 
incubated with primary antibody, which had been neutralised before being added to
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Figure 3.1: Immunocytochemical staining for LIF in sections obtained from 
endometrial biopsies during the (a) mid-proliferative, (b) late 
proliferative, (c) early secretory, (d) mid-secretory and (e) late 
secretory phases of the menstrual cycle. A negative control is also 
included (f).
(c) (d)
(f)
% .* 0 - >
v  V ' S > , '
«►» 3 • *** *■»»*,
'  ^  a *  o ^  ’Wv 3lL -r '
,
he--' /  t  *& ' ’ -t*  \U * *w  * &
J '  ^ * 2 3
■ , **■
•y  1 t
V ,  * r  * Jf. *2... *  #  >* ■ ■<N 'l!**
f
68
Magnification = X400
Table 3.3:Semi quantitative analysis of staining intensity for LIF in
26 endometrial biopsies throughout the menstrual cycle.
Biopsy Day of cycle Epithelial staining Stromal staining
1 3 ++ -/+
2 3 ++/+++ -/+
3 5 +++ +
4 12 +++ +
5 12 ++/+++ +
6 15 ++ -/+
7 15 ++/+++ +
8 15 +++ +/++
9 16 +++ -/+
10 16 +/++ -/+
11 18 +++ ++
12 18 +++/++++ -/+
13 18 +++/++++ ++
14 19 +++/++++ -/+
15 19 ++/+++ +/++
16 20 +++ ++
17 20 ++/+++ +
18 21 +++ ++
19 21 +++ +
20 21 +++/++++ +/++
21 22 ++++ +/++
22 23 ++++ +
23 24 ++++ +
24 26 +++ +/++
25 29 ++/+++ +/++
26 30 ++ -/+
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Figure 3.2:Immunocytochemical staining for IL-6 in sections obtained from 
endometrial biopsies during the (a) mid-proliferative, (b) late 
proliferative, (c) early secretory, (d) mid-secretory and (e) late 
secretory phases of the menstrual cycle. A negative control is also 
shown (f).
(a) (b)
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the section (figure 3.2f). The pattern of staining through the cycle, was similar to that 
seen for LIF. Glandular epithelial staining was weak in the early-mid proliferative 
phases of the menstrual cycle (figure 3.2a), but increased in intensity throughout the 
late proliferative (figure 3.2b) and secretory phases (figure 3.2c,d and e) of the 
menstrual cycle, peaking during the mid-secretory phase (figure 3.2d). Luminal 
epithelium was not present in every section, but when it was present showed similar 
staining to that seen in the glandular epithelium. Only very pale staining was seen in 
the stromal compartment at any time in the menstrual cycle, and no attempt was 
made to analyse this semi-quantitatively.
Table 3.4 summarises the semi-quantitative analysis of IL-6 in the sections from 
biopsies from 24 different normal fertile women.
3.3.1.3 Interleukin-la
Figure 3.3 shows examples of IL -la  staining in sections obtained during the mid- 
proliferative (figure 3.3a), late proliferative (figure 3.3b), early secretory (figure 
3.3c), mid-secretory (figure 3.3d) and late secretory (figure 3.3e) phases of the 
menstrual cycle. A negative control is included, where a serial section had been 
incubated with primary antibody, which had been neutralised before being added to 
the section (figure 3.3f). The results show that IL -la  was expressed by epithelial and 
stromal endometrial cells. Glandular epithelial staining remained relatively constant 
throughout the menstrual cycle, with a slight increase in intensity during the 
secretory phase (figure 3.3c,d and e). Luminal epithelium was not present in every 
section, but when it was present showed increased staining to that seen in the 
glandular epithelium (figure 3.3a). Stromal intensity was moderate throughout the 
menstrual cycle, but increased in intensity during the secretory phase, in particular 
the late secretory phase (figure 3.3e).
Table 3.5 summarises the semi-quantitative analysis for IL -la  in the sections from 
biopsies from 19 different normal fertile women.
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Table 3.4: Semi quantitative analysis of staining intensity for IL-6 in
24 endometrial biopsies throughout the menstrual cycle.
Biopsy Day of cycle Epithelial staining Stromal staining
1 3 + -
2 5 + -
3 6 + -
4 7 + -
5 9 + -
6 10 + -
7 12 ++ -
8 13 ++ -
9 14 ++ -
10 15 ++ -
11 16 +++ -
12 18 +++ -
13 19 +++ -
14 20 +++/++++ -
15 21 +++/++++ -
16 22 +++/++++ -
17 23 +++/++++ -
18 23 ++++ -
19 23 ++++ -
20 24 ++++ -
21 24 ++++ -
22 24 ++++ -
23 29 ++/+++ -
24 31 ++/+++ -
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Figure 3.3: Immunocytochemical staining for IL-la  in sections obtained from 
endometrial biopsies during the (a) mid-proliferative, (b) late 
proliferative, (c) early secretory, (d) mid-secretory and (e) late 
secretory phases of the menstrual cycle. A negative control is also 
shown (f).
(a) (b)
(c) (d)
(t)
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Table 3.5: Semi quantitative analysis of staining intensity for IL-1 a  in
19 endometrial biopsies throughout the menstrual cycle.
Biopsy Day of cycle Epithelial staining Stromal staining
1 3 ++/+++ +
2 7 +++ +/++
3 8 +++ +/++
4 10 ++/+++ +/++
5 11 +++ +/++
6 12 ++/+++ +/++
7 14 +++/++++ +/++
8 14 +++ +
9 16 +++/++++ +/++
10 19 +++ ++
11 19 +++ ++
12 20 +++ ++
13 20 +++ +/++
14 20 +++ ++
15 21 +++ +/++
16 21 +++ ++
17 23 ++++ ++/+++
18 24 +++/++++ ++/+++
19 31 +++ ++/+++
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3.3.1.4 Interleukin-1 p
Figure 3.4 shows examples of IL-lp staining in sections obtained during the mid- 
proliferative (figure 3.4a), late proliferative (figure 3.4b), early secretory (figure 
3.4c), mid-secretory (figure 3.4d) and late secretory (figure 3.4e) phases of the 
menstrual cycle. A negative control is included, where a serial section had been 
incubated with primary antibody, which had been neutralised before being added to 
the section (figure 3.4f). The results show that throughout the cycle, epithelial 
staining was more intense than that seen in the stromal compartment of the 
endometrium. Glandular epithelial staining was strong in the early-mid proliferative 
phases of the menstrual cycle (figure 3.4a) and remained relatively constant 
throughout the late proliferative (figure 3.4b) and secretory phases (figure 3.4c,d and 
e) of the menstrual cycle, but did show highest intensity during the mid-secretory 
phase (figure 3.4d). Luminal epithelium was not present in every section, but when it 
was present, showed similar staining to that seen in the glandular epithelium (figure 
3,4b and d). Stromal intensity was moderate throughout the menstrual cycle, but was 
strong in the late secretory phase.
Table 3.6 summarises the semi-quantitative analysis for IL-lp in the sections from 
biopsies from 24 different normal fertile women.
3.3.1.5 Tumour necrosis factor a
The expression of TNFa in sections from endometrial biopsies could not be 
determined using immunocytochemistry. Varying concentrations of primary and 
secondary antibodies were used, and for different incubation times. However, the 
staining obtained was very non-specific (figure 3.5a) and this could not be reduced, 
even after numerous attempts to try and decrease the non-specific staining. This 
included using different concentrations of the primary and secondary antibodies, 
increasing the time that the sections were quenched and increasing the number of 
washes between each step of the protocol. The negative control for TNFa, where the 
antibody had been neutralised prior to incubation on the section, also showed non­
specific binding (figure 3.5b) confirming that the staining which was obtained in the 
positive sections was non-specific.
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Figure 3.4: Immunocytochemical staining for IL-lP in sections obtained from
endometrial biopsies during the (a) mid-proliferative, (b) late proliferative,
(c) early secretory, (d) mid-secretory and (e) late secretory phases 
of the menstrual cycle. A negative control is also shown (f).
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Table 3.6: Semi quantitative analysis of staining intensity for IL-1p in
24 endometrial biopsies throughout the menstrual cycle.
Biopsy Day of cycle Epithelial staining Stromal staining
1 5 ++++ +
2 5 +++ +
3 7 +++ +/++
4 8 +++ ++
5 10 ++++ ++
6 10 +++ ++
7 12 +++ ++
8 14 +++ ++
9 15 +++ ++
10 15 +++ +
11 16 +++/++++ +/++
12 19 +++ ++
13 20 +++ +/++
14 20 ++++ +
15 20 +++/++++ +
16 21 ++++ ++
17 21 ++++ +/++
18 21 ++++ +/++
19 21 ++++ +
20 22 ++++ +
21 23 +++ ++
22 24 +++ ++
23 25 +++ +++
24 31 +++ ++/+++
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Figure 3.5: Examples of immunocytochemical staining for TNFa. Staining 
for TNFa is shown in (a) and (b) shows a negative control.
(a)
(b)
Magnification = X400
78
3.3.2 Quantification of results
Quantification of the staining did not confirm the pattern of cytokine expression seen 
when using the semi-quantitative method. This lack of correlation was demonstrated 
by the results obtained from quantification of immunocytochemical staining for LIF 
in sections from biopsies obtained from 26 different normal fertile women using the 
method that was developed. Intensity of epithelial LIF staining is shown in figure 3.6 
(a). These results suggest that epithelial staining for LIF varies throughout the 
menstrual cycle, but the pattern of expression does not confirm that obtained when 
using semi-quantitative analysis. The staining intensity readings were relatively 
constant in biopsies obtained throughout the cycle, but is increased on day 21 of the 
cycle in two biopsies and is low in the late secretory phase. Analysis of staining 
intensity in this way showed no significant difference in epithelial staining in 
biopsies grouped according to the phases of the menstrual cycle (figure 3.6b).
Figure 3.7 (a) shows the staining intensities for LIF in stromal cells from 26 different 
normal fertile women throughout the menstrual cycle, obtained using quantitative 
analysis. The values obtained for the staining intensity are lower in the stromal than 
in the epithelial compartment of the endometrium at all times in the menstrual cycle, 
as was suggested by the semi-quantitative method. Overall these results suggest that 
staining is slightly higher in the proliferative phase of the menstrual cycle compared 
to the secretory phase. Figure 3.7 (b) suggests that the staining in the mid- 
proliferative phase is significantly higher than in the other phases. However, this 
result is unfairly influenced by the single high reading of day 5 of the cycle.
These results suggest that this quantitative method is not suitable as a means of 
measuring staining intensity. The problems shown in the results for LIF are typical of 
that seen when using this method to quantify the staining for IL-6, IL-loc and IL-lp 
and therefore the results of the quantification for IL-6, IL -la  and IL-ip staining 
intensity have not been included in this work.
3.3.3 RT-PCR analysis
Table 3.7 shows the optical density readings and A260/280 ratios for RNA extracted 
from 8 epithelial and 5 stromal cell cultures and 8 endometrial biopsies. The
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Figure 3.6: Quantitative analysis of staining intensity for epithelial LIF in 
sections from biopsies from 26 different women throughout 
the menstrual cycle, (a) individually and (b) grouped into 
phases of the menstrual cycle. EP = early proliferative, MP = 
mid proliferative, LP = late proliferative, ES = early secretory, 
MS = mid secretory and LS = late secretory phases of the 
menstrual cycle.
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Figure 3.7: Quantitative analysis of staining intensity for stromal LIF in 
sections from biopsies from 26 different women throughout 
the menstrual cycle, (a) individually and (b) grouped into 
phases of the menstrual cycle. EP = early proliferative, MP = 
mid proliferative, LP = late proliferative, ES = early secretory, 
MS = mid secretory and LS = late secretory phases of the 
menstrual cycle.
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Table 3.7: Optical density readings and absorbance at 260nm and 
280nm ratios for RNA extracted from 8 epithelial and 5 
stromal cell cultures and 8 endometrial biopsy samples
Optical density reading A260:280
Epithelial cell cultures
1 0.376 1.736
2 0.276 1.775
3 0.391 1.663
4 0.607 1.354
5 0.178 1.84
6 0.183 1.813
7 0.147 1.844
8 0.119 1.821
Stromal cell cultures
1 0.063 1.839
2 0.558 1.048
3 0.359 1.096
4 0.615 1.053
5 0.555 1.053
Endometrial biopsies
1 0.284 1.427
2 0.587 1.875
3 0.194 1.552
4 0.2 1.6
5 0.163 1.304
6 0.147 1.869
7 0.255 1.877
8 0.317 1.744
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absorbance readings suggested that RNA was successfully extracted from the 
majority of both cell cultures and endometrial biopsies. However, the A260/280 
ratios were quite low (<1.8 jig/pl) for a lot of the samples suggesting that RNA was 
not as pure as it could be. It is likely that genomic DNA is also present in these 
samples, which would account for the impurity of some of the samples. RT-PCR for 
the housekeeping gene 7B6 confirmed that RNA extraction had been successful. 
Figure 3.8 shows the RT-PCR product representing 7B6, in cDNA obtained from 
cultured epithelial cells (lane 3), stromal cells (lane 4) and in endometrial biopsies 
(lanes 5, 6 and 7). Lanes 8-12 are negative controls where no RT was added to the 
PCR mastermix, however, bands are present in these lanes at approximately 1300bp 
and these bands are likely to represent products from genomic DNA.
In contrast to this, only limited success was achieved in the analysis of mRNA for 
LIF, IL-6, IL-lp and TNFa in the mRNA extracted from both cultured endometrial 
cells and biopsy samples, by RT-PCR, despite numerous attempts to optimise primer 
concentrations, annealing temperatures and MgCk concentrations. Figure 3.9 (a) 
shows that a PCR product of the expected size for LIF was seen in mRNA prepared 
from cultured epithelial cells. However, this could not be repeated for mRNA 
extracted from 8 endometrial biopsy samples obtained at any time in the menstrual 
cycle. The higher molecular weight bands are again likely to represent products from 
genomic DNA.
Figure 3.9 (b) again shows that a PCR product could be obtained for IL-6 from 
mRNA prepared from cultured epithelial cells, but that when the same reaction was 
carried out with mRNA extracted from endometrial biopsies, no specific bands were 
seen. There are numerous non-specific bands present in this gel, which suggest that 
contamination of the mastermix, via impurities in one of the components of the 
mastermix, has occurred.
Figure 3.10 shows that, as for LIF and IL-6, PCR products for IL-ip and TNFa 
could be obtained from cultured endometrial epithelial cells and bands were also 
obtained from mRNA extracted from at least 2 of the endometrial biopsies. However, 
consistent positive results for all four cytokines were only obtained for a very few
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Figure 3.8 : Gel showing bands for 7B6 in cDNA from cultured epithelial cells (lane
3), cultured stromal cells (lane 4) and endometrial biopsies (lanes 5, 6 and 
7). Lane 1 contains the marker, lane 2 is the negative control (no RNA 
added and lanes 8-12 are negative controls (no RT added).
1 2 3 4 5 6 7 8 9  10 11 12
1353bp
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Figure 3.9 : Gels to show PCR products for (a) LIF and (b) IL-6. In both gels, lane 1 = 
marker, lane 2 = negative control. In figure (a) lanes 3, 5, 7, 9 and 11 = 
cultured epithelial cells and lanes 4, 6, 8,10 and 12 = negative controls (no 
RT). In figure (b) lanes 3 and 4 = cultured epithelial cells and lanes 5-12 = 
endometrial biopsies. The expected band sizes are arrowed.
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Figure 3.10: Gels to show PCR products for (a) IL-ip and (b) TNFa. In both gels 
lane 1 = marker, lane 2 = negative control, lanes 3 and 4 = cultured epithelial cells 
and lanes 5-10 = different endometrial biopsies.
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biopsies and cultured cells, despite the RT-PCR reactions being repeated numerous 
times.
Figure 3.10 (a) shows a band for IL-ip present in samples from cultured epithelial 
cells and also 2 of the endometrial biopsies. The higher molecular weight bands in 
lanes 8-10 are likely to represent products from genomic DNA and the lower 
molecular weight bands in lanes 4-10 are a result of dimerisation of the primers.
Figure 3.10 (b) shows bands representing TNFa mRNA at 436bp. Again the higher 
molecular weight bands are likely to represent products from genomic DNA. The 
other bands that are present in some lanes at lower molecular weights are non­
specific bands could be a result of contamination or the primers binding non- 
specifically.
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3.4 Discussion
The control of human endometrial function by steroids is well understood, however it 
is now believed that the actions of local autocrine/paracrine factors needs to be 
determined in order to understand the exact mechanisms involved in human 
endometrial function. To gain further insights into the potential autocrine and 
paracrine regulation of endometrial function, in particular implantation, the 
expression of the cytokines LIF, IL-6, IL-1 and TNFa has been studied in the normal 
human endometrium throughout the menstrual cycle. The aim was to develop 
immunocytochemical and RT-PCR methods using endometrium from normal fertile 
women, so that we could then compare expression in women who suffer recurrent 
miscarriage.
3.4.1 RT-PCR
It was hoped that use of RT-PCR would show the presence of mRNA transcripts for 
LIF, IL-6, IL-1 p and TNFa in endometrial biopsies obtained throughout the 
menstrual cycle. Similar methods for analysis of cytokine mRNA in cultured 
epithelial cells had previously been used in the laboratory (Estdale et al., 1996). 
Consistent evidence for the presence of mRNA for these cytokines in endometrial 
biopsy samples could not be obtained. However, RT-PCR for 7B6 on RNA extracted 
from both cultured endometrial cells and endometrial biopsies was successful. This 
suggests that the RNA extraction procedure used did result in good quality RNA 
being obtained from both the cultured cells and the biopsies. Thus it would appear 
that the RT-PCR technique was inadequate. This is however unlikely, because some 
PCR products for LIF, IL-1 p and TNFa, particularly from cultured endometrial 
epithelial cells, were obtained, which would not have happened if the PCR method 
was not working. Attempts were made to optimise the PCR conditions used for all 
primers. This included optimising the concentrations of primers, magnesium and Taq 
polymerase in each of the mastermixes, as well as optimising the annealing 
temperature and number of cycles used for each reaction. The sequences of the 
primers were all checked to ensure that they were suitable for the reactions.
However, PCR using nested primers was not attempted and this may have produced 
more specific results. The most probable explanation for the inconsistency of the
results is that the RNA quality extracted from the endometrial biopsies was not good 
enough to detect these cytokines. The reason for successful RT-PCR for 7B6 and 
failure for the cytokines may be due to differences in abundance of mRNA in the 
tissue. Previous studies have shown that it is possible to analyse cytokine mRNA 
from endometrial biopsies obtained from the operating theatre at Jessop Hospital for 
Women (Lim et al., 2000). However, the subsequent analysis was not carried out in 
our laboratory and although similar methods are described, there may be subtle 
differences. A modification of our collection procedure for endometrial biopsies and 
RNA extraction procedure would be required to proceed further with this type of 
analysis. This might include addition of RNAase inhibitors at an early stage of RNA 
extraction or even during collection of the sample.
3.4.2 Quantification of staining
The method used in this study to quantify the intensity of staining obtained has been 
developed specifically for this study. It was hoped that it would provide a more 
robust numerical method for comparing staining intensities in different biopsy 
samples than the semi-quantitative scoring systems that have traditionally been used. 
It would also allow statistical comparison between staining seen at different times in 
the cycle. However the attempt to quantify staining intensity in this way was not 
successful.
One of the reasons for the lack of success with the quantitative method is likely to be 
a result of using a counterstain. Although this allows visualisation of cells that do not 
stain positively, it provides background intensity that interferes with the 
measurement of the positive brown staining, even after the results have been 
corrected for negative staining, by subtracting the intensity of the negative sections. 
The quantification of staining was also carried out on sections that were not run in 
parallel to one another. Therefore inter experimental variations could also be a factor 
influencing the results. Another reason is the need to convert the image to greyscale 
for analysis. An image analysis method that detects specific colour would be a better 
method to use. Another difficulty is the variation in cellular density. A more intense 
signal is obtained when the cells are closely packed together. Hence a comparison of 
the densely packed epithelial cells and sparsely packed stromal cells is difficult.
89
Although the results achieved using this method of quantification were invalid, this 
method is one that could prove to be useful for future work. However, it would be 
essential to ensure that no counterstain was included in the immunocytochemistry. 
Also, the results should be analysed at the end of each separate staining run and not 
compared between different slides prepared on different occasions, because although 
the results may show similar staining patterns, the intensity of the staining, even the 
counterstain alone, can vary between different experiments.
3.4.3 Leukaemia Inhibitory Factor
LIF is a cytokine that has previously been shown to be essential for implantation in 
mice (Stewart et al., 1992). It has therefore been postulated that LIF may be an 
important factor in human implantation. The results from this study clearly show that 
LIF is expressed by the human endometrium throughout the menstrual cycle.
Analysis of the staining semi-quantitatively shows that epithelial LIF protein 
expression is higher than stromal expression throughout the menstrual cycle agreeing 
with previous observations by other groups (Charnock-Jones et al., 1994; Chen et al., 
1995; Arici et al., 1995). Glandular epithelial expression is moderate to strong during 
the proliferative phase and increases in intensity during the secretory phase, peaking 
at the time of implantation, whereas stromal staining was weak to moderate 
throughout the cycle, with little cyclical variation. This pattern of expression is 
similar to that reported by Vogiagis et al. (1996), Cullinan et al. (1996) and Yang et 
al. (1996), although Yang et al. (1996) detected only minimal stromal LIF expression 
during the late proliferative and secretory phases of the menstrual cycle. Another 
study (Charnock-Jones et al., 1994) also showed that expression of LIF protein was 
maximal in the epithelium during the mid-late secretory phase, but did not detect any 
LIF in the epithelial cells during the proliferative phase and found no stromal 
expression throughout the menstrual cycle. These differences may be accounted for 
by the fact that goat anti-human LIF antibodies from different manufacturers were 
used in each study. In this study, luminal epithelium was not present in all sections, 
but when present LIF expression was similar to that seen in the glandular epithelium 
which again agrees with previous results (Vogiagis et al., 1996). The most important 
observation from this and previous studies is the increased expression of epithelial
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LIF during the mid-secretory phase, at the time when implantation occurs in humans 
(Charnock-Jones et al., 1994; Kojima et al., 1994; Arici et al., 1995; Vogiagis et al., 
1996; Laird et al., 1997). LIF receptor mRNA has been identified in luminal 
epithelium throughout the menstrual cycle (Cullinan et al., 1996) and also in pre­
implantation blastocysts (Charnock-Jones et al., 1994), suggesting that human 
blastocysts are capable of responding to a maternal LIF signal prior to implantation. 
Taken together, these results suggest that LIF does play a role in human endometrial 
function and is likely to be important in the human implantation process.
3.4.4 Interleukin-6
The function of IL-6 in implantation in mice has not yet been determined, however, 
it is not considered as important as LIF, as knockout mice for the IL-6 gene have 
been shown to have normal fertility (Poli et al., 1994; Kopf et al., 1994). However, 
IL-6 does share the signal transducing receptor component gpl30 with LIF and it 
may therefore play a similar role to LIF in human endometrial function. The results 
from this study show that IL-6 is expressed in the endometrium throughout the 
menstrual cycle. Analysis using the semi-quantitative method showed that epithelial 
expression varied considerably with the time in the cycle. Expression was very low 
in the early-mid proliferative phases and increased gradually throughout the cycle, 
with maximal intensity during the mid-late secretory phases. When luminal 
epithelium was present within the sections, expression of IL-6 was similar to that 
seen in the glandular epithelium. This study confirms the presence of IL-6 within the 
human endometrium as shown previously, using RT-PCR (Tabibzadeh and Sun,
1992; Vandermolen and Yang, 1996) and immunocytochemistry (Tabibzadeh et al., 
1995a). Tabibzadeh et al. (1995a) showed a similar pattern of staining for IL-6 as 
shown in this study, with predominant epithelial expression throughout the cycle and 
increased expression at the time of implantation. In addition, they showed that IL-6 
was expressed in the upper functionalis of the stromal cells, but only during the late 
secretory phase of the menstrual cycle. Production of IL-6 by endometrial cells in 
culture has previously been reported (Laird et al., 1993) and also showed that stromal 
IL-6 was only detected in supernatants of cells prepared from late secretory 
endometrium. Only two biopsies were obtained from the late secretory phase in this 
study, which may explain why no IL-6 staining was observed. The increased
91
expression of IL-6 at the time of implantation suggests that IL-6 may also play a role 
in implantation.
3.4.5 Interleukin-1
The interleukin-1 system is known to be present in both fetal and maternal tissues at 
the time of implantation (Simon et al., 1996). The results from this study agree with 
these previous studies and show that both IL-1 a  and IL-1 p are expressed by the 
human endometrium throughout the menstrual cycle. The results of the semi- 
quantitative analysis showed that both epithelial and stromal cells express IL-1 a  with 
little variation throughout the cycle. However, epithelial expression is more intense 
than stromal expression at all times in the menstrual cycle, except the late secretory 
phase when IL-1 a  expression appears to increase in the stromal cells. Expression of 
IL-1 p is similar to that of IL-1 a, in that, it is expressed throughout the menstrual 
cycle, by both epithelial and stromal cells. As with IL-1 a, expression of IL-1 p is 
more intense in epithelial cells than stromal cells at all times, except the late 
secretory phase when stromal expression is similar to that in the epithelium.
Epithelial IL-1 p expression, although strong throughout the cycle, did appear to be 
greatest during the mid-secretory phase of the menstrual cycle. IL-1 p is the secreted 
form of IL-1, while IL-1 a  is thought to be retained within the cell (Dower and Sims, 
1994). The technique of immunocytochemistry will not detect the secreted form of 
IL-1 P; therefore a similar expression of IL-1 a  and IL-1 p is to be expected. These 
results agree with previous work that has shown ubiquitous expression of IL-1 a  and 
IL-1 p mRNA in epithelial and stromal cells throughout the menstrual cycle 
(Tabibzadeh and Sun, 1992). The mRNA for IL-lRtI is expressed in the 
endometrium throughout the menstrual cycle, reaching maximal levels at the early 
and late secretory phases and epithelial mRNA expression of IL-1 p is increased 
during the secretory phase (Simon et al., 1993a). De los Santos et al. (1996) 
demonstrated the presence of the complete IL-1 system in pre-implantation embryos. 
Further work from this group (Simon et al., 1998), has demonstrated that embryonic 
IL-1 may interact with its endometrial receptor to upregulate the expression of the 
integrin p3, which is thought to be a marker for uterine receptivity (Lessey et al., 
1992; Lessey et al., 1994). Taken together these results suggest the importance of the
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IL-1 system in human endometrial function and the increased expression of epithelial 
IL-1 p at the time of implantation, seen in this study, provides further evidence for the 
importance of this cytokine system, particularly during implantation.
3.4.6 Tumour Necrosis Factor a
In this study, the expression of TNFa by endometrial cells could not be determined 
using immunocytochemistry. Although some of the staining observed may have 
indicated the presence of TNFa within endometrial sections, there was also a lot of 
non-specific staining seen, which despite much effort, could not be removed. The 
reason for this is unclear as neutralisation of the primary antibody for use as a 
negative control was attempted, but still resulted in non-specific staining. In an 
attempt to remove the non-specific staining, the concentrations of both primary and 
secondary antibodies were reduced, the concentration of peroxidase used to quench 
the sections was increased and the length and number of washes between each step in 
the protocol was increased. No attempt was made to localise TNFa using other anti­
human TNFa antibodies due to time constrictions, but it is likely that the use of other 
TNFa antibodies would have produced more specific results.
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Chapter 4
Endometrial cytokine expression in RM women
4.1 Introduction
Previous reports from our laboratory have shown that a proportion of women who 
suffer recurrent miscarriage have an abnormal endometrial development (Dalton et 
al., 1995; Hey et al., 1995). Several studies have shown the importance of cytokines 
in the development of the feto-placental unit and the prevention of miscarriage. 
Therefore it is possible that abnormal endometrial cytokine production during the 
peri-implantation period may lead to subsequent abnormal development of the feto­
placental unit and miscarriage. Relatively few studies have examined the expression 
of endometrial cytokines in women who suffer recurrent miscarriages and compared 
the findings to those seen in normal fertile women. Decreased endometrial 
expression of IL-1 p and IL-6 mRNA transcripts during the mid-secretory phase of 
the menstrual cycle has been reported in women with habitual abortion, when 
compared to normal fertile women (von Wolff et al., 2000). Another study has 
shown that endometrial expression of IFNy, IL-2 and IL-12 mRNA and protein is 
increased in women with recurrent miscarriage when compared to normal fertile 
women, whereas IL-6 expression is significantly decreased (Lim et al., 2000). 
Altered IFNy, IL-10, TNFa and TGFp mRNA expression by decidual and 
trophoblast cells in women who had a successful pregnancy outcome compared to 
those who have had a failed pregnancy has also been reported (Vives et al., 1999). 
LIF has also been implicated as a cytokine that may be particularly involved in 
implantation and in vitro LIF production by decidual T-cells from unexplained 
recurrent miscarriage women is reportedly lower than that produced by decidual T 
cells from normal fertile women (Piccinni et al., 1998).
Having determined the expression of LIF, IL-6, IL-1 a  and IL-1 p in the endometrium 
of normal fertile women throughout the menstrual cycle, this study was performed to 
determine if endometrial expression of these cytokines during the peri-implantation 
period is altered in women who suffer unexplained recurrent miscarriage. The 
expression of LIF, IL-6, IL-1 a  and IL-1 p in endometrium of normal fertile, at the
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time of implantation, was therefore compared to that in normal fertile women at the 
same time in the menstrual cycle.
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4.2 Materials and Methods
Expression of LIF, IL-6, IL-1 a  and IL-1 p protein was analysed in biopsies obtained 
from recurrent miscarriage women at the time of implantation. The staining 
intensities were analysed quantitatively and compared to staining seen at the same 
times in the menstrual cycle of normal fertile women (data shown in chapter 3).
4.2.1 Endometrial biopsies
Biopsies from women suffering unexplained recurrent miscarriage were timed from 
the LH surge and obtained between days LH+6 and LH+10. Each biopsy was then 
assessed according to Noyes et al. (1950) to determine the morphology of the biopsy. 
This was required to ensure that any biopsies that had retarded development were 
accounted for. Expression of LIF was investigated in sections from 24 biopsies. IL-6 
expression was assessed in sections from 15 biopsies. Expression of IL-1 a  was 
investigated in sections from 12 biopsies and IL-1 p expression was investigated in 
sections from 11 biopsies.
4.2.2 Immunocytochemistry
Immunocytochemical staining was carried out according to the protocol described in 
chapter 2. The staining procedure and antibodies used for all four cytokines were the 
same as those in chapter 3. All staining was repeated on at least three sections from 
each biopsy. A negative control was run parallel to each section where the next serial 
section was incubated with primary antibody, which had been neutralised for 24 h 
prior to the experiment. For each experiment, sections obtained from biopsies from 
normal fertile women at the same time in the cycle, were run parallel to the recurrent 
miscarriage sections.
4.2.3 Semi-quantitative analysis
All staining was assessed semi-quantitatively according to the method described 
previously.
96
4.3 Results
The results for the morphological analysis of the biopsies used in staining for each of 
the cytokines is shown in table 4.1. The results show that although all samples were 
obtained between days LH+6 and LH+10, 5 biopsies stained for LIF and 2 biopsies 
stained for IL-6 had the morphology of day LH+3 or LH+4, suggesting that these 
women had retarded endometrium.
4.3.1 Leukaemia Inhibitory Factor
Staining for LIF in sections from biopsies obtained from women suffering recurrent 
miscarriage showed that LIF protein was present in all endometrial biopsies, and as 
in normal fertile women, staining was predominantly seen in epithelial cells. 
However, the intensity of staining for LIF was highly variable between different 
individuals. Semi-quantitative analysis of the staining intensity for each biopsy is 
shown in table 4.2. The results show that 13 of the biopsies had similar staining to 
that seen in normal fertile women at the same time in the menstrual cycle, but 
staining was decreased, particularly in the epithelial cells, in sections from biopsies 
from 11 different women with recurrent miscarriage (biopsies 7, 11, 12, 13, 14, 16, 
17, 19, 22, 23 and 24). Figure 4.1 shows examples of the staining obtained for LIF, 
where staining was similar to that seen in normal fertile women (figure 4 .1a and b) 
and weaker than that seen in normal fertile women (figure 4.1 c and d).
4.3.2 Interleukin-6
Immunocytochemical staining for IL-6 was seen in all 15 biopsies from recurrent 
miscarriage women. The staining again varied greatly between individuals. The 
semi-quantitative analysis in all recurrent miscarriage biopsies stained for IL-6 is 
shown in table 4.3. The results showed that very little, if any IL-6 was present in the 
stromal compartment in any of the biopsies, agreeing with that seen in normal fertile 
women. This semi-quantitative assessment showed that epithelial staining was 
weaker in 9 of the biopsies (biopsies 1, 4, 5, 7, 9, 10, 11, 12 and 13) from recurrent 
miscarriage women, when compared to staining seen in normal fertile women at the 
same time in the cycle. Figure 4.2 shows the intensity of staining seen in four 
biopsies from women who suffer unexplained recurrent miscarriage, two of which
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Table 4.1: Morphological dating of the recurrent miscarriage 
biopsies stained for LIF, IL-6, IL-1a and IL-1 p
Cytokine
IL-1 pIL-1 aIL-6LIFLH Day
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Table 4.2:Semi quantitative analysis of staining intensity for LIF in 
normal fertile women and in 24 endometrial biopsies from 
women with recurrent miscarriage. All biopsies were obtained 
during the implantation period. The LH days shown are those 
calculated from the morphological appearance of the tissue.
Biopsy Day of cycle Epithelial staining Stromal staining
N 20 +++ ++
0 20 ++/+++ +
R 21 +++ ++
M 21 +++ +
A 21 +++/++++ +/++
L 22 ++++ +/++
S 23 ++++ +
24 ++++ +
1 LH+3 +++/++++ +/++
2 LH+3 +++ +
3 LH+3 +++ +
4 LH+4 ++++ +
5 LH+4 +++ +
6 LH+6 +++ +
7 LH+6 ++ +/++
8 LH+7 +++ +
9 LH+7 ++++ +/++
10 LH+7 +++ +
11 LH+8 ++ +/++
12 LH+8 + +
13 LH+8 ++/+++ +
14 LH+8 +/++ +
15 LH+8 +++ +
16 LH+8 + -/+
17 LH+8 ++ +/++
18 LH+9 +++ +
19 LH+9 ++ +/++
20 LH+9 ++++ ++
21 LH+9 ++++ +/++
22 LH+10 ++/+++ +
23 LH+10 ++ ++
24 LH+10 + +
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Figure 4.1: Staining for LIF in endometrial biopsies from women who
suffer unexplained recurrent miscarriages. Examples of
(a and b) normal and (c and d) weak staining.
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Table 4.3: Semi quantitative analysis of staining intensity for IL-6 in 
normal fertile women and in 15 endometrial biopsies from 
women with recurrent miscarriage. All biopsies were 
obtained during the implantation period. The LH days 
shown are those calculated from the morphological 
appearance of the tissue.
Biopsy Day of cycle Epithelial staining Stromal staining
20 +++/++++ -
N 21 +++/++++ -
0 22 +++/++++ -
R 23 +++/++++ -
M 23 ++++ -
A 23 ++++ -
L 24 ++++ -
S 24 ++++ -
24 ++++ -
1 LH+3 ++ -
2 LH+4 ++++ -
3 LH+6 +++/++++ -
4 LH+7 ++ -
5 LH+8 ++ -
6 LH+8 ++++ -
7 LH+8 + -
8 LH+8 ++++ -
9 LH+8 ++ -
10 LH+8 ++ -
11 LH+8 + -
12 LH+8 + -
13 LH+8 ++ -
14 LH+9 ++++ -
15 LH+9 +++/++++ -
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Figure 4.2: Staining for IL-6 in endometrial biopsies from women
who suffer unexplained recurrent miscarriages. Examples
of (a and b) normal and (c and d) weak staining.
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show similar staining to that seen in normal fertile women (figure 4.2a and b), and 
two of which show weaker staining than that seen in normal fertile women (figure 
4.2c and d).
4.3.3 Interleukin-la
Staining for IL -la  was assessed in 12 biopsies from recurrent miscarriage women 
and compared to staining seen in 7 biopsies from normal fertile women obtained at 
the time of implantation. All recurrent miscarriage biopsies showed positive staining 
for IL -la  although the intensity varied between individuals. Table 4.4 shows the 
semi-quantitative analysis of IL -la  intensity in the recurrent miscarriage biopsies. Of 
the 12 biopsies assessed, 5 showed decreased stromal and epithelial staining when 
compared to normal fertile women (biopsies 1, 2, 5, 6 and 12) and another 2 biopsies 
showed a slight decrease in stromal staining only (biopsies 8 and 9). Examples of 
staining for IL -la  in biopsies from recurrent miscarriage women are shown in figure 
4.3, where (a) and (b) show similar staining and (c) and (d) show weaker staining 
than that seen in normal fertile women at the time of implantation.
4.3.4 Interleukin-1 p
Staining for IL-ip was assessed in 11 biopsies from recurrent miscarriage women 
and compared to that seen in 10 biopsies from normal fertile women at the time of 
implantation. Staining for IL-ip was apparent in all recurrent miscarriage biopsies, 
but again varied between individuals. The semi-quantitative analysis of staining 
intensity is shown in table 4.5. Staining for IL-lp was weaker in both the epithelial 
and stromal cells of 2 of the recurrent miscarriage biopsies (biopsies 1 and 4), when 
compared to staining in normal fertile women. However, epithelial staining in some 
biopsies was very variable throughout the section. In some biopsies only parts of 
glands stained, whereas in others some glands showed positive staining and others 
showed no staining. Even when glandular epithelial staining appeared variable 
throughout the sections staining in the luminal epithelium was always strong. This 
pattern of staining was not seen in normal fertile women, where epithelial staining
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Table 4.4: Semi quantitative analysis of staining intensity for IL-1a in 
normal fertile women and in 12 endometrial biopsies from 
women with recurrent miscarriage. All biopsies were 
obtained during the implantation period. The LH days 
shown are those calculated from the morphological 
appearance of the tissue.
Biopsy Day of cycle Epithelial staining Stromal staining
N 20 +++ ++
O 20 +++ +/++
R 20 +++ ++
M 21 +++ +/++
A 21 +++ ++
L 23 ++++ ++/+++
S 24 +++/++++ ++/+++
1 LH+6 ++ +
2 LH+7 ++ -/+
3 LH+7 +++/++++ +/++
4 LH+8 +++ ++
5 LH+8 +/++ -/+
6 LH+8 + -
7 LH+8 ++++ ++
8 LH+9 +++/++++ +
9 LH+9 +++ +
10 LH+10 +++ +/++
11 LH+10 +++ +
12 LH+10 -/+ -
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Figure 4.3: Staining for IL -la  in endometrial biopsies from women who
suffer unexplained recurrent miscarriages. Examples of
(a and b) normal and (c and d) weak staining.
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Table 4.5: Semi quantitative analysis of staining intensity for IL-1 p in 
normal fertile women and in 11 endometrial biopsies from 
women with recurrent miscarriage. All biopsies were obtained 
during the implantation period. The LH days shown are 
those calculated from the morphological appearance of the 
tissue.
Biopsy Day of cycle Epithelial staining Stromal staining
20 +++ +/++
N 20 ++++ +
O 20 +++/++++ +
R 21 ++++ ++
M 21 ++++ +/++
A 21 ++++ +/++
L 21 ++++ +
S 22 ++++ +
23 +++ ++
24 +++ ++
1 LH+6 + -/+
2 LH+7 ++++ +/++
3 LH+7 +++ +/++
4 LH+8 + -/+
5 LH+8 ++++ +
6 LH+8 ++++ +
7 LH+8 +++ +
8 LH+9 +++ +
9 LH+9 ++++ +
10 LH+10 ++++ ++
11 LH+10 ++++ +
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always appeared uniform throughout the glandular and luminal epithelium. Figure
4.4 shows examples of staining seen in recurrent miscarriage biopsies. Figure 4.4 (a) 
and (b) shows staining similar to that seen in normal fertile women, figure 4.4 (c) and
4.4 (d) shows staining weaker than that in normal fertile women and figure 4.4 (e) 
and (f) shows examples of variable epithelial staining seen in biopsies from recurrent 
miscarriage women. This variable pattern of staining was seen on each occasion that 
the immunocytochemistry was carried out.
Not all of the recurrent miscarriage biopsies were tested for all of the four cytokines. 
However, some of the biopsies were stained for more than one cytokine. Table 4.6 
shows all of the biopsies tested, which of the cytokines each biopsy was tested for 
and if the expression was similar or weaker than that in normal fertile women at the 
time of implantation. There are some biopsies which show normal staining intensities 
for all the cytokines tested and some which show low staining intensities for all 
cytokines tested. However, for the majority there are too many gaps in staining to 
assess whether when the expression of one cytokine is low, all the others are also 
decreased.
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Figure 4.4: Staining for IL -lp in endometrial biopsies from women who 
suffer unexplained recurrent miscarriages. Examples of 
(a and b) normal, (c and d) weak and (e and f) variable 
staining
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Table 4.6: Table to show which biopsies were tested for which cytokine.
NT= not tested, += normal staining and - = weak staining when 
compared to normal fertile women at the time of implantation
Biopsy Day LIF IL-6 IL-1ct IL-1 p
1 LH+3 + - NT NT
2 LH+3 + NT NT NT
3 LH+3 + NT NT NT
4 LH+4 + + NT NT
5 LH+4 + NT NT NT
6 LH+6 + + NT NT
7 LH+6 - NT - -
8 LH+7 + NT NT NT
9 LH+7 + NT NT NT
10 LH+7 + - NT NT
11 LH+7 NT NT - +
12 LH+7 NT NT + +
13 LH+8 - - NT NT
14 LH+8 - - NT NT
15 LH+8 - NT NT NT
16 LH+8 - NT NT NT
17 LH+8 NT + NT NT
18 LH+8 NT - NT NT
19 LH+8 + + NT NT
20 LH+8 NT - NT NT
21 LH+8 NT - NT NT
22 LH+8 NT - NT NT
23 LH+8 - NT + -
24 LH+8 - - NT NT
25 LH+8 NT NT - +
26 LH+8 NT NT - +
27 LH+8 NT NT + NT
28 LH+8 NT NT NT +
29 LH+9 NT + NT NT
30 LH+9 + + NT NT
31 LH+9 - NT e=+ s=- +
32 LH+9 + NT NT NT
33 LH+9 + NT e=+ s=- +
34 LH+10 - NT NT NT
35 LH+10 NT NT + +
36 LH+10 - NT + +
37 LH+10 - NT NT NT
38 LH+10 NT NT - NT
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4.4 Discussion
The results from this study suggest that expression of LIF, IL-6, IL -la  and IL-ip 
protein is decreased in the endometrium of some recurrent miscarriage women at the 
time of implantation. This agrees with previous work that has shown a decreased 
expression of IL-6 mRNA and protein and IL-ip mRNA (von Wolff et al., 2000; 
Lim et al., 2000) in recurrent miscarriage women compared to normal fertile women.
Protein expression was measured using immunocytochemical staining. Intensity was 
assessed using semi-quantitative analysis. In all cases the staining was carried out at 
least three times and a negative control run parallel to the sections whereby the 
antibody had been neutralised for 24h prior to incubation. Each time a set of slides 
with sections from recurrent miscarriage women was analysed, a section from a 
biopsy obtained at the same time in the cycle from a normal fertile women was 
included, to aid in comparison between the staining.
4.4.1 Leukaemia Inhibitory Factor and Interleukin-6
LIF expression was significantly weaker in 11 of the 16 (69%) recurrent miscarriage 
biopsies included in the experiment, mainly in epithelial cells. The results also 
showed a similar proportion of biopsies from recurrent miscarriage women had 
reduced epithelial IL-6 expression (9 of the 15 biopsies (60%)). These results 
therefore suggest that both endometrial LIF and IL-6 may be contributing factors to 
preventing recurrent miscarriage.
The results of the previous chapter show that changes in LIF and IL-6 occur through 
the menstrual cycle with maximum expression in the late secretory phase. A number 
of the endometrial biopsy samples from recurrent miscarriage women had retarded 
development, a phenomenon that is known to be associated with recurrent 
miscarriage. It is therefore possible that the reduced staining for LIF and IL-6 seen in 
some of the recurrent miscarriage women may be due to delayed endometrial 
development. However, the results in table 4.2 and 4.3 show that there is no 
relationship between LH day and intensity of staining and therefore this observed
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decrease in LIF and IL-6 staining appears independent of whether the endometrium 
is retarded or not.
4.4.2 Interleukin-la and Interleukin-1 p
In contrast to IL-6 and LIF a smaller proportion of recurrent miscarriage women 
showed lower epithelial expression of IL -la  (4 out of 12; 25%) and IL-ip (2 out of 
11; 18%). However, for IL-ip a very variable pattern of staining intensity was seen. 
The glandular epithelial staining in biopsies from normal fertile women was uniform 
throughout the sections from all biopsies tested. However, in some biopsies from 
recurrent miscarriage women the staining was very patchy in some glands and in 
some cases was entirely absent. In other cases it was seen in the luminal epithelium, 
but not in the glandular epithelium. The reason for this variation in staining is not 
known.
These results show that in some women who suffer recurrent miscarriage there is a 
decreased expression of more than one cytokine. Cytokines are known to be very 
redundant and it is therefore likely that the decreased expression of just one cytokine 
could not affect implantation. However, if more than one cytokine is affected it 
suggests a greater chance of implantation being unsuccessful and in these women 
may be a cause of pregnancy loss. Because of this redundancy, and the fact that 
recurrent miscarriage women are a very heterogeneous population, it would have 
been sensible to try and analyse all 4 cytokines in each biopsy sample. However, this 
was not possible, partly due to lack of planning, but also because there was a limited 
number of sections, which could be obtained from a single biopsy.
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Chapter 5 
Effect of cytokines on endometrial MMP production
5.1 Introduction
One of the autocrine/paracrine actions of cytokines may be to control the expression 
of MMPs. MMPs are enzymes that are produced by the endometrium and are known 
to be important in the degradation process associated with menstruation. It is also 
thought that because MMPs are capable of degrading the extracellular matrix (ECM), 
they could play a role in the invasion of trophoblast cells into the maternal decidua 
(Bischof et al., 1995b; Hulboy et al., 1997). Although the pattern of expression of 
MMPs in normal cycling endometrium is understood, the precise regulation of these 
enzymes has yet to be fully elucidated.
The endometrial cytokines, IL-1, TNFa, IL-6 and LIF have been postulated to be 
involved in the control of implantation (Stewart et al. 1992; Hunt et al. 1992; 
Sharkey, 1998; Simon et al., 1998) and thus may affect the production of MMPs 
during this process. Studies have shown that IL-1 and TNFa affect MMP-2 and 
MMP-9 production by endometrial stromal cells (Rawdanowicz et al. 1994; Singer et 
al., 1999) and that IL-1, TNFa, LIF and IL-6 affect gelatinase production by 
cytotrophoblast cells (Bischof et al, 1995a; Meisser et al., 1999a; Meisser et al., 
1999b). To date there are no reports of effects of LIF and IL-6 on MMP-2 and 
MMP-9 production by endometrial cells and studies of the effects of any of these 
cytokines on MMP production by epithelial cells are limited.
Therefore the aims of this study were to compare the production of MMP-2, MMP-9 
and MMP-7 by cultured human endometrial epithelial and stromal cells and to 
determine if the cytokines LIF, IL-6, IL -la  or TNFa have any effect on the 
production of these MMPs in vitro. In particular, if LIF and IL-6 affect MMP-2 and 
MMP-9 production as they do in cytotrophoblast cells.
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5.2 Materials and Methods
5.2.1 Tissue culture
Endometrial biopsies were obtained from 12 normal fertile women as described in 
chapter 2. Primary epithelial and primary stromal cell cultures were prepared from 
each biopsy as previously described. Once the cells reached confluency, they were 
incubated for a further 48 hours, with either no additions, O.lng/ml, lng/ml or 
lOng/ml of either IL -la, TNFa, IL-6 or LIF. Epithelial and stromal cell cultures 
from three biopsies obtained on days 7, 17 and 25 of the menstrual cycle were 
incubated with LIF. Epithelial and stromal cell cultures from three biopsies obtained 
on days 9, 14 and 17 were incubated with IL-6. Epithelial and stromal cell cultures 
from three biopsies obtained on days 9, 14 and 17 were incubated with IL -la  and 
from biopsies obtained on days 14, 22 and 24 were incubated with TNFa. After 
incubation the supernatants were removed from the cells and stored at -20°C until 
analysed using zymography or ELISA.
5.2.2 Zymography
Zymography was used to analyse MMP-2 and MMP-9 activity in the supernatants of 
cultured endometrial cells, as described in chapter 2. Supernatants from each cell 
culture were run on gels on at least three separate occasions. In each gel, 
supernatants from cells cultured with 0, 0.1 ng/ml, 1 ng/ml and 10 ng/ml of each 
cytokine were run parallel to a marker and supernatants from the D3X cell line, 
which was used as a positive control. The bands representing MMPs were analysed 
visually and also using densitometric analysis, as described in chapter 2.
5.2.3 ELISA
The amounts of MMP-2, MMP-9 and MMP-7 produced from cultured endometrial 
epithelial and stromal cells was measured quantitatively using commercially 
available BIOTRA ELISA kits (Amersham Life Sciences), as described in chapter 2.
5.2.4 Statistical analysis
Data was expressed as group means ± SEM (n = 4, number of replicate wells from a 
single experiment). Results shown are those obtained from cells prepared from a 
single biopsy and are typical of those obtained on each of the 3 occasions that the
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experiment was repeated. Differences in the amounts of MMP produced in the 
presence of different cytokines were analysed using ANOVA.
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5.3 Results
5.3.1 Basal production of MMP-2, MMP-9 and MMP-7
Analysis of supernatants from endometrial epithelial (figure 5.1a) and stromal (figure 
5.1b) cells, cultured without cytokines, by gelatin zymography showed between 2 
and 6 bands of gelatinase activity, with molecular weights of 234, 116, 90, 84, 70, 
and 66kDa (Figure 5.1). A summary of the results obtained from cells prepared from 
all twelve biopsies is shown in Table 5.1. Bands of molecular weights 90kDa,
84kDa, 70kDa and 66kDa showed the greatest activity. It is likely that these bands 
represent the pro and active (cleaved) forms of MMP-9 (90kDa and 84kDa) and 
MMP-2 (70kDa and 66kDa) and this is supported by results from the D3X cell 
supernatants, which also show bands at 90kDa, 70kDa and 66kDa. The band at 
84kDa is not present in D3X cell supernatants, but its position in the gel and 
molecular weight, suggest that it is active MMP-9. The identity of the higher 
molecular weight bands is not known, but may represent MMP-2 and MMP-9 bound 
to TIMPs. Bands corresponding to proMMP-2 and proMMP-9 were seen in all cell 
supernatants while the band corresponding to active MMP-9 was much weaker than 
that for pro MMP-9 and was only seen in some cell supernatants. Bands for active 
MMP-2 were seen in all supernatants from all cultured epithelial cells, but only in 
some supernatants from cultured stromal cells. Although similar band sizes for 
MMP-2 were seen in supernatants from stromal and epithelial cells, the bands for 
MMP-9 produced from stromal cell cultures were smaller than that seen in epithelial 
cell supernatants.
Basal production of MMP-2, MMP-9 and MMP-7 was also measured using ELISA 
(Table 5.2). This analysis showed that total MMP-2 (i.e. both pro and active forms 
were detected by the antibody), pro-MMP-9 and pro-MMP-7 were present in 
epithelial cell supernatants. However, under basal conditions only MMP-2 was 
detected in stromal cell supernatants and the amounts present were higher than those 
present in epithelial cell supernatants. None of the MMPs were detected in 
unconditioned CDMEM. These results confirm the zymography results showing that 
basal stromal cell production of MMP-9 is very low, and that epithelial cells produce 
both MMP-2 and MMP-9.
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Figure 5.1: Zymography gels showing gelatinase activity in supernatants from
unsupplemented (a) epithelial and (b) stromal cells. Lane 1 contains the 
molecular weight marker; and lanes 2-6 contain supernatants from different 
cell cultures. In (a) lanes 2 and 5 contain supernatants from cells prepared 
from proliferative endometrium, while lanes 3, 4 and 6 contain supernatants 
from cells prepared from secretory endometrium. In (b) lanes 2, 5 and 6 
contain supernatants from cells prepared from proliferative endometrium, 
while lanes 3 and 4 contain supernatants from cells prepared from secretory 
endometrium. Arrows indicate the 6 bands of gelatinase activity seen at 234, 
116, 90, 84, 70 and 66kDa.
a)
205 kDa
97.4 kDa 
84 kDa
55 kDa
234
116
9084
7066
b)
205 kDa
97.4 kDa 
84 kDa
55 kDa
116
90
.70
66
1 1 6
Table 5.1: Semi-quantitative analysis of bands of gelatinase activity in supernatants 
from unsupplemented cultured (a) epithelial and (b) stromal cells, +++ = 
high gelatinase activity, ++ = moderate gelatinase activity, + = low 
gelatinase activity and - = no gelatinase activity.
a)
Time in Band 1 2 3 4 5 6
Biopsy Cycle MW 234 116 90 84 70 66
1 P - - ++ -/+ + +
2 P - - -/+ - + -/+
3 P - -/+ ++ - ++ +/++
4 P -/+ - + - ++ -/+
5 P -/+ - +/++ -/+ ++ -/+
6 P - - -/+ + -/+ +
7 S -/+ - ++ - +++ ++
8 S - - + - ++ -/+
9 S - - + - ++ ++
10 S - - ++ - ++ +
11 S - - -/+ - ++/+++ -/+
12 S + -/+ ++ - +++ +/++
b)
Time in Band 1 2 3 4 5 6
Biopsy cycle MW 234 116 90 84 70 66
1 P - - -/+ - + -/+
2 P -/+ - -/+ - +/++ -/+
3 P - -/+ -/+ -/+ +++ -
4 P - - -/+ - ++/+++ -
5 P - - -/+ - ++ -
6 P - - + - ++ +/++
7 S - -/+ -/+ - +/++ -/+
8 S ++ -/+ ++ +/++ + ++
9 S -/+ - + - ++ +
10 S - - -/+ - +/++ -
11 S - - -/+ - ++/+++ -
12 S - -/+ -/+ -/+ +++ -
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Table 5.2: Basal production of MMP-2, MMP-9 and MMP-7 by endometrial 
epithelial and stromal cells. Values shown are ranges from cells 
prepared from 12 different biopsies.
Epithelial
(ng/ml/24h)
Stromal
(ng/ml/24h)
Total MMP-2 24 .8- 503.2 59 .2- 742.2
Pro MMP-9 0 .86- 100.1 < 0.6
Pro MMP-7 2 .9-693.2 < 0.16
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ELISA measurements showed that basal levels of pro-MMP-9 in epithelial cell 
supernatants and total MMP-2 in stromal cell supernatants were similar in cells 
prepared from both proliferative and secretory endometrium. However, differences 
were seen in total MMP-2 and pro-MMP-7 in epithelial cell supernatants between 
cells prepared from proliferative and secretory endometrium (Figure 5.2). Epithelial 
total MMP-2 levels were significantly higher (p<0.01) in supernatants from cells 
prepared from the secretory phase compared to cells from the proliferative phase.
Zymography also suggested that pro-MMP-2 was higher in supernatants from 
epithelial cells prepared from secretory endometrium (band 5, Table 5.1a), compared 
to that from cells prepared from proliferative endometrium. In contrast pro-MMP-7 
levels in supernatants from epithelial cells were significantly lower (p<0.01) in cells 
prepared from secretory phase endometrium compared to proliferative phase 
endometrium.
5.3.2 Effects of cytokines on pro-MMP-9 production
Results from zymography (Figure 5.3) and densitometric analysis (Table 5.3) 
showed that levels of proMMP-9 in supernatants from epithelial cells were increased 
in the presence of TNFa but not IL-la, whereas both IL -la  and TNFa caused an 
increase in proMMP-9 levels in supernatants from stromal cells. ELISA 
measurements showed that IL -la  caused a concentration dependent increase in 
stromal proMMP-9 production (p<0.001) (figure 5.4b) and TNFa caused a 
concentration dependent increase in both epithelial (p<0.01) (figure 5.4c) and 
stromal (pO.OOl) (figure 5.4d) proMMP-9 production. No significant difference in 
epithelial proMMP-9 production was seen following incubation with IL -la  (figure 
5.4a).
Visual analysis of the zymographs (figure 5.5) suggested that LIF and IL-6 had no 
significant effect on proMMP-9 levels in supernatants from epithelial and stromal 
cells and this was confirmed by densitometric analysis (table 5.3). In addition, no 
significant effects of LIF or IL-6 on proMMP-9 production were detected when the 
supernatants from epithelial and stromal cells were analysed using ELISA (figure 
5.6).
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Figure 5.2: Production of total MMP-2 and pro-MMP-7 by unsupplemented
endometrial epithelial cells, prepared from secretory and proliferative 
endometrium. Values are ± SEM (n=6 proliferative, n=6 secretory). ** = 
significantly different to cells from proliferative endometrium at p<0.01
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Figure 5.3: Zymography gels showing the effect of (a and b) IL -la  and (c and d) TN Fa 
on gelatinase secretion by cultured (a and e) epithelial and (b and d) 
stromal cells. Lane 1 contains the supernatant from D3X cells and lanes 2-5 
supernatants from cells incubated with 0, 0.1,1 and lOng/ml of each 
cytokine. Examples shown are from cells prepared from secretory 
endometrium
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Table 5.3: Densitometric analysis of MMP-2 and MMP-9 activity bands following
stimulation of cells with cytokines. Values shown are percentage change in 
net intensity when compared to control bands from the same gel
Epithelial ProMMP2 Stromal ProMMP2 Epithelial ProMMP9 Stromal ProMMPS
IL-1 0.1 -1.1 -0.06 9.2 520.1
ng/ml 1 5.2 ■4.6 3 523.9
10 12.3 -7.8 0.7 512.7
TNF 0.1 1.7 -8.4 38.1 643.8
ng/ml 1 11 3.2 86.5 1159.3
10 -21.8 19 63.9 1385.5
LIF 0.1 -5.4 -11.3 -25.1 8.5
ng/ml 1 8.5 -1.3 12.3 12.5
10 0.5 0.53 9.4 2.6
IL-6 0.1 4.5 -2.5 -7.1 -6.3
ng/ml 1 -24.3 6.9 -12.2 -4.8
10 -15.3 15.6 -14.5 -2.1
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following stimulation with (a and b) IL-la and (c and d) TNFa. Values are 
mean ± SEM (n = 4). ** = significantly different to controls at p<0.01, *** = 
significantly different to controls at p<0.001. Results shown are from cells 
prepared from a single biopsy and are typical of that seen in 3 different 
biopsies. All graphs show results from biopsies obtained during the secretory 
phase of the menstrual cycle
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Figure 5.5: Zymography gels showing the effect of (a and b) LIF and (c and d) IL-6
on gelatinase secretion by cultured (a and c) epithelial and (b and d) stromal 
cells. Lane 1 contains the supernatant from D3X cells and lanes 2-5 
supernatants from cells incubated with 0, 0 .1 ,1 and lOng/ml of each 
cytokine. Examples shown are from cells prepared from secretory 
endometrium
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Figure 5.6: Pro MMP-9 production by (a and c) epithelial and (b and d) 
stromal cells following incubation with (a and b) LIF and (c 
and d) IL-6. Values are mean + SEM (n = 4). Results shown are 
from cells prepared from a single biopsy and are typical of 
that seen in 3 different biopsies. All graphs show results from 
biopsies obtained during the secretory phase of the menstrual 
cycle
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5.3.3 Effects of cytokines on MMP-2 production
The effects of cytokines on MMP-2 production were less dramatic than that seen for 
MMP-9. No effect of IL -la  on either stromal or epithelial pro-MMP-2 levels was 
seen using zymography (Figure 5.3) even after densitometric analysis (Table 5.3). 
However, a small significant increase (P<0.05) in epithelial total MMP-2 levels was 
seen at higher concentrations of IL-la, using ELISA (Figure 5.7a). ELISA also 
suggested a significant decrease (P<0.05) in stromal total MMP-2 production at 
lng/ml IL -la  (figure 5.7b). Again the effect of TNFa on MMP-2 production was 
small. However, a significant decrease in total MMP-2 levels in epithelial cell 
supernatants (PO.Ol) was seen using ELISA (Figure 5.7c) and zymography showed 
a decrease in both the pro and active MMP-2 bands in supernatants from epithelial 
cells cultured with TNFa (Figure 5.3). No significant effect of TNFa on stromal cell 
MMP-2 production was seen. The effects of both TNFa and IL -la  on MMP-2 
production as assessed by both zymography and ELISA, although significant, are 
small and therefore the physiological significance of this response is questionable.
Zymographic (Figure 5.4) and densitometric analysis (Table 5.3) suggested that LIF 
and IL-6 had no effect on pro or active MMP-2 levels in the supernatants of either 
epithelial or stromal cells. This was confirmed using ELISA (Figure 5.8), which 
showed that neither LIF nor IL-6 had a significant effect on epithelial or stromal total 
MMP-2 production.
5.3.4 Effects of cytokines on pro-MMP-7 production
Levels of pro-MMP-7 in supernatants from epithelial cells following incubation with 
IL -la, TNFa, LIF and IL-6 were measured using ELISA only. TNFa caused a 
significant increase in pro-MMP-7 production by epithelial cells, but only at 1 Ong/ml 
(p<0.01). IL -la, LIF and IL-6 had no significant effect on pro-MMP-7 production 
(Figure 5.9).
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Figure 5.7: Total MMP-2 production by (a and c) epithelial and (b and d) 
stromal cells following incubation with (a and b) IL-1a and (c 
and d) TNFa. Values are mean + SEM (n = 4). * = significantly 
different from controls at p<0.05,**=significantly different from 
control at p<0.01. Results shown are from cells prepared from 
a biopsy and are typical of that seen in 3 different biopsies. All 
graphs show results from biopsies obtained during the 
secretory phase of the menstrual cycle
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igure 5.8: Total MMP-2 production by (a and c) epithelial and (b and d)
stromal cells following incubation with (a and b) LIF and (c and 
d) IL-6. Values are mean + SEM (n = 4). Results shown are from 
cells prepared from a single biopsy and are typical of that seen 
in 3 different biopsies. All graphs show results from biopsies 
obtained during the secretory phase of the menstrual cycle
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Figure 5.9: Pro MMP-7 production by epithelial cells following incubation 
with (a)IL-1a, (b)TNFa, (c)LIF and (d)IL-6. Values are mean 
+SEM (n=4). **= significantly different from controls at p<0.01, 
Results shown are from cells prepared from a single biopsy 
and are typical of that seen in 3 different biopsies. All graphs 
show results from biopsies obtained during the secretory 
phase of the menstrual cycle
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5.4 Discussion
In this study zymography and ELISA were used to detect MMP secretion by human 
endometrial cells in vitro. It was shown that pro and active MMP-2 and MMP-9 were 
secreted by both epithelial and stromal cells, although basal stromal MMP-9 
production was very low, while pro-MMP-7 was secreted from epithelial cells only. 
Supplementation with various cytokines caused a concentration dependent 
modulation of proMMP secretion. In particular, TNFa and IL-1 a  caused a large 
increase in pro-MMP-9 production, while having smaller stimulatory or inhibitory 
effects on MMP-2 production. In contrast to previous studies using cytotrophoblast 
cells (Bischof et al., 1995a; Meisser et al., 1999a; Meisser et al., 1999b) addition of 
LIF and IL-6 had no effect on MMP production.
5.4.1 Basal production of endometrial MMPs
Gelatin zymography showed the presence of gelatinase activity at 6 different 
molecular masses in the endometrial cell culture supernatants. The most intense 
bands seen were the pro form of MMP-9 and the pro and active forms of MMP-2. 
This is supported by the presence of bands at the same molecular weight in D3X cell 
supernatants, which are known to produce both MMP-2 and MMP-9 (Laird et al., 
1999). A less intense band was also seen in epithelial cell culture supernatants at 84 
kDa and although this was not seen in the D3X cell supernatants, its molecular 
weight suggests that it is active MMP-9. Both zymography and ELISA analysis 
showed that MMP-2 was produced by both stromal and epithelial cell cultures under 
basal conditions. The production of MMP-2 by epithelial cells is controversial. In 
vivo studies have suggested its presence only in stromal cells (Freitas et al, 1999; 
Rodgers et al., 1994), while other in vivo and in vitro studies have shown its presence 
and production by both stromal and epithelial cells (Martelli et al., 1993; Zhang et 
al., 2000).
The secretion of MMP-2 by epithelial cells seen in this study could possibly be due 
to contamination with stromal cells or leukocytes. However, epithelial cells prepared 
in this way are essentially pure and free of stromal and leukocyte contamination 
(Laird et al, 1993). The finding that epithelial cells are the major source of MMP-9 
agrees with that reported in a number of other studies (Frietas et al, 1999; Skinner et
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al., 1999; Jeziorska et al., 1996). In particular it has been shown that basal 
production of MMP-9 by cultured stromal cells is very low (Huang et al., 1998).
The results also suggest that MMP-2 production by epithelial cells, but not stromal 
cells, is significantly higher in cells obtained from secretory endometrium compared 
to cells from proliferative endometrium. These in vitro findings agree with previous 
in vivo studies which have shown a higher concentration of MMP-2 in endometrial 
flushings taken during the secretory phase compared to those obtained during the 
proliferative phase (Laird et al, 1999) and more MMP-2 mRNA in secretory 
endometrium compared to proliferative endometrium (Irwin et al., 1996). However, 
other studies have suggested that endometrial stromal cell MMP-2 production does 
not change significantly throughout the cycle (Hulboy et al., 1997). Also in contrast 
to others, who have shown an increase in MMP-9 secretion (Jeziorska et al., 1996) 
and immunostaining (Skinner et al., 1999) during the peri-implantation period, our 
results showed that MMP-9 secretion by epithelial cells in vitro was similar in cells 
prepared from proliferative and secretory phase endometrium. This may be due to the 
fact that in this study only 2 biopsies were obtained during the peri-implantation 
period and thus differences at this time in the cycle were not observed.
The presence of MMP-7 in supernatants of endometrial epithelial cells, but not 
stromal cells, found in this study agrees with other in vivo and in vitro studies, where 
MMP-7 mRNA and protein were found predominantly in the epithelial compartment 
(Rogers et al., 1993; Rogers et al., 1994; Osteen et al., 1994). The results from this 
study suggest that more MMP-7 is produced from cells prepared from proliferative 
endometrium compared to cells prepared from secretory endometrium. Other studies 
have suggested that endometrial MMP production is suppressed during the secretory 
phase of the menstrual cycle due to the action of steroid hormones which may 
influence cytokine secretion (Marbaix et al., 1992; Marbaix et al., 1995). The results 
from this study suggest that MMP-7 production may also be decreased in the 
secretory phase of the cycle.
131
5.4.2 Effects of cytokines on endometrial MMP production
Both zymography and ELISA results show that of the four cytokines studied, TNFa 
has the most dramatic effect on MMP production. The stimulatory effect of TNFa on 
MMP-9 production by stromal cells agrees with previous reports (Rawdanowicz et 
al., 1994; Singer et al., 1999) and is similar to the effect of TNFa on 
cytotrophoblastic cells (Meisser et al., 1999a). In this study IL-1 a  also increased 
MMP-9. A similar effect of IL-1 a  on MMP-9 production by endometrial stromal 
cells (Rawdanowicz et al., 1994; Huang et al., 1998) and cytotrophoblast cells has 
been reported (Meisser et al., 1999a). The importance of IL-1 a  in MMP production 
has also been suggested by other studies, where the stimulatory effect of IL-1 a  on 
MMP-1 expression by endometrial fibroblasts was blocked by anti-IL-1 antibodies 
(Singer et al., 1997). In this study, the results show that TNFa stimulates MMP-9 
production by epithelial cells and that IL-1 a  stimulates MMP-2 production by 
epithelial cells, suggesting that cytokines may also be important in the control of 
MMP production in epithelial cells.
In contrast to IL-1 a  and TNFa, IL-6 and LIF had little effect on MMP production by 
endometrial cells. This is surprising as both LIF and IL-6 have been shown to affect 
gelatinolytic production by trophoblast cells (Bischof et al., 1995a; Meisser et al., 
1999b) and increased MMP-11 expression was seen in response to IL-6 in 
endometrial stromal cells (Singer et al., 1999). LIFR, IL-6R and gpl30 are 
expressed by both stromal and epithelial endometrial cells (Tabibzadeh et al., 1995a; 
Senturk and Arid, 1998), suggesting that the differences in response to these 
cytokines by cytotrophoblast and endometrial cells are not due to differences in the 
expression of their receptors, but may be due to differences in intracellular signalling 
pathways.
In this study the cells were incubated in media containing fetal calf serum which was 
not further supplemented with steroids, both prior to and during incubation with 
cytokines. Previous studies have shown the importance of combined oestradiol and 
progesterone in the control of MMP production. Steroid withdrawal stimulates MMP 
production both in vitro and in vivo (Schatz et. al., 1999; Salamonsen et al., 1997; 
Keller et al., 2000) and progesterone can prevent IL-1 stimulation of MMP
132
production by endometrial stromal cells (Singer et al., 1997; Keller et al., 2000). In 
addition, the fact that differences in MMP-2 and MMP-7 secretion were seen in this 
study in cells prepared from secretory and proliferative endometrium, also suggest an 
influence of steroids. It may therefore be possible that the increases in MMP 
production seen on addition of cytokines may be due to the effects of steroid 
withdrawal. The experiments should therefore be repeated in the presence of 
oestradiol and progesterone. The fact that stimulatory effects on MMP production 
were specific for IL-1 a  and TNFa and not seen for LIF and IL6, and that differences 
were seen in the effects of TNFa and IL-1 a  on MMP-2 and MMP-9 production, 
suggest that the effect is not just a general effect of steroid withdrawal. It is also 
possible that steroid exposure in vivo prior to surgery and cell preparation may also 
affect the response of cells to cytokines. However in this series of experiments each 
cytokine was added to cells prepared from biopsies obtained both during the 
secretory and proliferative phases of the cycle with no differences in response seen.
These results therefore show that both stromal and epithelial cells are capable of 
producing MMP-2 and MMP-9, although basal production of MMP-9 by stromal 
cells is very low. In contrast, MMP-7 is only produced by epithelial cells. The results 
also suggest that TNFa and IL-1 a, but not IL-6 and LIF, play an important role in 
the regulation of MMP-2 and MMP-9 production by both endometrial stromal and 
epithelial cells. This pattern of MMP stimulation is different to that seen for 
cytotrophoblast cells. As the interaction between cytotrophoblast and endometrial 
cells is important in the control of embryo implantation, an understanding of the 
different control mechanisms may result in an increased understanding of this 
process and thus to treatments for conditions, where implantation is defective such as 
infertility and recurrent miscarriage.
133
Chapter 6 
Interleukin-11 in the human endometrium
6.1 Introduction
Recent studies in mice have suggested the importance of IL-11 and IL-1 IR a in 
embryo implantation (Robb et al., 1998; Bilinski et al., 1998). Both of these studies 
have shown that IL-1 IR a expression is essential for normal decidual development. 
Female mice with either an inactive or null mutation for the IL-1 IR a chain are fertile 
and their blastocysts implant and elicit an initial decidual response. However, only 
small decidua form due to reduced cell proliferation, resulting in progressive 
degeneration of the decidua. Consequently, embryo-derived trophoblast cells 
generate a network of trophoblast cells but fail to form a chorio-allantoic placenta, 
showing that the decidua is essential for normal feto-placental development (Bilinski 
et al., 1998). The presence of IL-11 and IL-1 IR a has been shown in mice 
endometrium, with increased expression around the time of decidualisation 
(Davidson et al., 1997).
Previous studies have shown that IL-11 production by other cell types is controlled 
by other cytokines. IL-1 a  and TNFa synergistically stimulate rheumatoid synovial 
fibroblasts to produce IL-11 at the mRNA and protein levels (Mino et al., 1998) and 
IL-1 a  has also been shown to stimulate IL-11 production from lung epithelial cells 
(Elias et al., 1994a). Transforming growth factor beta (TGFP) has also been shown 
to stimulate IL-11 production in vitro from a number of other different cell types 
including lung epithelial cells (Elias et al., 1994a), fibroblasts (Elias et al., 1994b), 
osteoblasts (Elias et al., 1995; Morinaga et al., 1997), chondrocytes (Maier et al., 
1993) and breast cancer cells (Lacroix et al., 1998).
These previous results have suggested the importance of endometrial IL-11 in the 
murine decidual response; and it is possible that IL-11 may also play an important 
role in implantation and decidualisation in humans. The expression of IL-11 in the 
human endometrium throughout the menstrual cycle was therefore studied. The
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effects of IL-1 a , TNFa and TGFp on IL-11 production by cultured human epithelial 
and stromal endometrial cells in culture was also investigated.
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6.2 Materials and Methods
Immunocytochemistry was used to determine the expression of IL-11 in sections 
taken from endometrial biopsies obtained throughout the menstrual cycle. Staining 
was then evaluated by semi-quantitative analysis. Endometrial epithelial and stromal 
cultures were grown and the effects of IL-1 a, TNFa and TGFp on IL-11 production 
measured using ELISA.
6.2.1 Endometrial sections
Serial cryostat sections of 15pm were taken from endometrial biopsies obtained from 
normal fertile women, as described in the materials and methods section. For this 
study one biopsy was obtained from the early proliferative phase (days 0-5), two 
during the mid-proliferative phase (days 5-9), four during the late proliferative phase 
(days 10-14), five during the early secretory phase (days 15-19), five during the mid 
secretory phase (days 20-24) and two from the late secretory phase (days 25+). The 
sections were fixed as described in chapter 2. Dating of the biopsies was calculated 
from the time of the last menstrual period.
6.2.2 Immunocytochemistry
All sections were stained according to the protocol previously described in chapter 2. 
The antibodies used in this experiment were as follows: two primary antibodies for 
IL-11 were used, a goat anti-human IL-11 polyclonal antibody (Santa Cruz 
Technology Inc, U.K.) and a mouse anti-human IL-11 human monoclonal antibody 
(R+D Systems, Abingdon, U.K.), both at a concentration of lOpg/ml and incubated 
for 24h at +4°C. The secondary antibodies were a rabbit anti-goat immunoglobulin 
at a dilution of 1:100 (18 pg/ml) in 10% normal rabbit serum for the polyclonal 
primary antibody, and a rabbit anti-mouse immunoglobulin at a dilution of 1:25 (140 
pg/ml) in 10% normal rabbit serum for the monoclonal antibody. Both were obtained 
from DAKO, Ely, U.K. and incubated for 30min at room temperature. Binding was 
visualised using PAP antibodies and DAB colour reagent as previously described.
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6.2.3 Quantification of staining
All staining was assessed using the semi-quantification method.
6.2.4 Cell culture
All cell cultures were prepared as previously described. For this experiment biopsies 
were used from nine different women and both epithelial and stromal cell cultures 
were prepared from each biopsy. IL-1 a  (0.1-10ng/ml) was added to replicate wells of 
epithelial and stromal cells prepared from three biopsies, which had been obtained on 
days 9, 16 and 17 of the menstrual cycle. TNFa (0.1-10ng/ml) was added to cells 
prepared from three biopsies obtained on days 16, 22 and 24 of the menstrual cycle 
and TGFp (0.1-10ng/ml) was added to cells prepared from biopsies obtained on days 
7, 17 and 21 of the menstrual cycle. Again the timing of the biopsies was calculated 
from the last menstrual period. Control wells containing no additions were included 
in each experiment. After incubation for 48h the supernatants were removed and 
stored at -20°C until analysed for IL-11 by ELISA (see chapter 2 for details).
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6.3 Results
6.3.1 Human endometrial expression of IL-11 in vivo
Immunocytochemical staining showed that IL-11 was present in the human 
endometrium throughout the menstrual cycle in both epithelial and stromal cells. 
Results obtained were similar when using both the goat anti-human IL-11 and mouse 
anti-human IL-11 antibodies. Figures 6.1 and 6.2 show staining obtained in sections 
from four biopsies taken during the proliferative, early secretory, mid secretory and 
late secretory phases of the cycle, with either the goat anti-human IL-11 (figure 6.1) 
or the mouse anti-human IL-11 (figure 6.2) antibodies. No true negative control was 
used for these experiments, however a section was run parallel to each section, 
whereby the primary antibody was emitted from the protocol, and instead the 
sections incubated with just normal rabbit serum.
6.3.2 Expression throughout the menstrual cycle
Glandular epithelial IL-11 staining was strong throughout the cycle, with a small 
increase in expression during the late proliferative -  early secretory phase. Although 
luminal epithelium was not observed in sections from all biopsies, when it was 
observed, it also stained intensely and in some cases showed slightly stronger 
staining than that seen in the glandular epithelium of the same section (see Figure 
6.2d). In both luminal and glandular epithelial cells staining was particularly intense 
at the luminal side of the cell, particularly during the secretory phase of the cycle 
(see Figure 6.2a), suggesting that the IL-11 produced is secreted. During the 
proliferative and early to mid secretory phases of the cycle, stromal IL-11 expression 
was weak and it remained relatively constant throughout the cycle, with only a small 
increase during the late proliferative phase. However stromal cell staining increased 
during the late secretory phase of the cycle (Figure 6. Id, 6.2c and d) and its 
expression at this time was similar to that seen in the epithelium.
6.3.3 Semi-quantitative analysis of IL-11 staining
The semi-quantitative analysis of staining intensity in sections obtained from 19 
biopsies is summarised in Table 6.1. These results were obtained using the mouse
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Figure 6.1: Immunocytochemical staining for IL-11 in sections obtained from
endometrial biopsies during the (a) proliferative, (b) early secretory, (c) 
mid secretory and (d) late secretory phases of the menstrual cycle. A 
negative control is also shown (e). Results shown were obtained using the 
goat anti-human IL-11 antibody.
a) b)
/y *
c) d)
e)
Magnification = X200, on all 
figures except (e) where the 
magnification =X400
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Figure 6.2: Immunocytochemical staining for IL-11 in sections obtained from
endometrial biopsies during the proliferative (a), early secretory (b), mid- 
secretory (c) and late secretory (d) phases of the menstrual cycle. A 
negative control is also shown (e). Results shown were obtained using the 
mouse anti-human IL-11 antibody.
a) b)
c) d)
e)
Magnification = X400
140
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Table 6.1: Semi-quantitative analysis of staining intensity for IL-11 in epithelial
and stromal cells of 19 biopsies from normal fertile women obtained
at different times throughout the menstrual cycle
Biopsy Day of cycle Epithelial staining Stromal staining
1 3 ++/+++ +
2 5 +++ +
3 7 +++ +
4 10 +++ +
5 11 +++/++++ +
6 12 +++/++++ +
7 14 ++++ +
8 15 ++++ +
9 15 ++++ -/+
10 16 +++/++++ -/+
11 17 +++ +
12 19 +++ +
13 20 +++ ++
14 20 +++ ++
15 21 +++ ++
16 22 +++ ++
17 23 +++ ++
18 26 +++/++++ ++/+++
19 33 +++ ++
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anti-human IL-11 antibody, however a similar pattern of staining was seen when 
using the goat anti-human IL-11 antibody.
6.3.4 Basal production of IL-11 from endometrial cell cultures
Basal production of IL-11 was measured in supernatants from cultured epithelial and 
stromal cells. The results agreed with the immunocytochemical staining and showed 
that IL-11 production was significantly lower in supernatants from cultured stromal 
cells when compared to that from epithelial cells (Figure 6.3). No differences were 
seen in IL-11 production by cells prepared from proliferative and secretory 
endometrium. However, only two of the nine biopsies used for cell culture in these 
experiments were obtained from proliferative phase endometrium and therefore 
absolute comparisons are difficult. The results shown here are a culmination of the 
controls used in the stimulatory experiments. Also the same biopsies were used for 
each of the stromal and epithelial cell cultures.
6.3.5 Effects of cytokines on IL-11 production from endometrial cell cultures
TNFa, IL-1 a  and TGFp all caused a concentration-dependent increase in IL-11 
production by both stromal and epithelial cells (Figure 6.4).
Significant increases in IL-11 production by epithelial cells were seen at 
concentrations of 1 (p<0.05) and lOng/ml (p<0.001) TNFa (figure 6.4a). While all 
concentrations of TNFa used caused a highly significant increase (p<0.001) in IL-11 
production by stromal cells (figure 6.4b). Epithelial cell IL-11 production was 
significantly increased following incubation with lng/ml (p<0.01) and lOng/ml 
(p<0.001) IL-1 a  (Figure 6.4c), and IL-11 in supernatants from stromal cells was also 
significantly higher (p<0.001) when cells were incubated with all concentrations of 
IL-1 a  (figure 6.4d). Like IL-1 a  and TNFa, TGFp caused a highly significant 
increase (p<0.001) in stromal (figure 6.4f) and also in epithelial (figure 6.4e) cell IL- 
11 production, at all concentrations of cytokine used.
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All three cytokines caused a greater stimulation of IL-11 by stromal cells than 
epithelial cells. The stimulated: basal ratio at lOng/ml of TNFa was 10:1 and 2:1 for 
stromal and epithelial cells respectively. Similarly the stimulated:basal ratio at 
lOng/ml of cytokine was 4:1 and 2:1 for stromal and epithelial cells in the presence 
of both IL-1 a  and TGFp.
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Figure 6.3 : Production of IL-11 in supernatants from unsupplemented 
epithelial and stromal cell cultures. Values are mean ± SEM (n=9 
epithelial, n=9 stromal). *** = significantly different to epithelial 
production at p<0.001.
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Figure 6.4: IL-11 production by (a, c and e) epithelial and (b,d and f) 
stromal cells following stimulation with (a and b) TNFa,
(c and d) IL-1 a and (e and f) TGFp. Values are mean +
SEM (n=4). Results shown are from cells from a single 
biopsy and are typical of that seen in 3 different biopsies 
for each cytokine. * = significantly different from controls 
at p<0.05, ** = significantly different from controls at p<0.01 
and *** = significantly different from controls at p<0.001 
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6.4 Discussion
6.4.1 Human endometrial IL-11 expression in vivo
This is one of the first studies that has investigated the expression of IL-11 protein in 
the human endometrium, although a recent report (Dimitriadis et al., 2000) has 
shown that IL-11 mRNA is expressed in the human endometrium. Our results clearly 
show that IL-11 is present in human endometrium throughout the menstrual cycle 
and is expressed by both stromal and epithelial cells, agreeing with the results from 
Dimitriadis et al (2000). The semi-quantitative analysis of intensity of staining 
suggests that until the late stages in the cycle, expression is greater in epithelial cells 
than stromal cells, but during the late secretory phase increased levels of stromal IL- 
11 are produced. No attempt was made to establish whether specific populations of 
stromal cells, such as the leukocytes, were staining particularly for IL-11. However, 
particularly in the late stages of the cycle, staining in the stromal compartment 
appeared fairly uniform, whereas leukocytes are present in discreet populations. 
There is a slight possibility that the staining may be due to IL-11 binding to its 
receptor. However the positioning in the cytoplasm of the cell suggests that it is 
produced by the cells themselves. In addition, the fact that there is more intense 
staining on the luminal side of the cytoplasm suggests that it is secreted.
Previous studies in mice have suggested that IL-11 is only expressed by decidualised 
cells in the pregnant endometrium and not during the non-pregnant cycle (Bilinski et 
al., 1998; Robb et al., 1998; Davidson et al., 1997). Our results, and those of 
Dimitriadis et al. (2000) suggest that in human endometrium it is also expressed in 
the non-pregnant cycle.
6.4.2 Human endometrial IL-11 production in vitro
In this study we also used our cell culture system to investigate the effects of other 
cytokines on endometrial IL-11 production. Immunocytochemical analysis has 
previously suggested that both the epithelial and stromal cell cultures are free from 
leukocyte contamination (Laird et al., 1993) and therefore the IL-11 in the cell 
culture supernatants is likely to originate from either stromal or epithelial cells. Basal
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production of IL-11 by epithelial cells was greater than basal stromal cell IL-11 
production and although care should be made in extrapolating between in vivo and in 
vitro, taken together these results suggest that epithelial cells produce more IL-11 
than stromal cells. The number of cells present at the end of the incubation was not 
calculated, so it is possible that the differences seen between epithelial and stromal 
IL-11 production could be due to a smaller number of cells being present in the 
stromal cell cultures. However, both the epithelial and stromal cell cultures were 
grown to confluency before stimulation and therefore it is unlikely that the 5 fold 
difference is due entirely to a difference in cell numbers. None of the nine biopsies 
used in the cell culture part of this study were obtained during the late secretory 
phase of the cycle, therefore the suggestion of an increase in production by stromal 
cells at this time, suggested by the immunocytochemistry results can not be 
confirmed by the cell culture results.
6.4.3 Effects of cytokines on endometrial IL-11 production
Our results suggest that IL-11 production by both stromal and epithelial endometrial 
cells is increased by IL-1 a, TNFa and TGFp, as has been shown for many other cell 
types. IL-1 a  and TNFa are known to be present in the human endometrium (Stewart 
et al., 1992; Simon et al., 1995b) and are postulated to have a role in implantation, 
possibly by affecting the production of other endometrial cytokines such as IL-6 and 
LIF (Laird et al., 1994). The results from this study suggest that IL-11 is also 
stimulated by IL-1 a  and TNFa. TGFp is also expressed by the endometrium in a 
menstrual cycle dependent manner (Arid et al., 1996; Casslen et al., 1998) and has 
been shown to affect proteinase and proteinase inhibitor production by endometrial 
stromal cells (Godkin et al., 1998).
IL-11 stromal cell production appeared to be more sensitive to stimulation by 
cytokines, as evidenced by higher stimulatedrbasal values. This greater effect of 
cytokines on stromal cell IL-11 production compared to epithelial cell production 
seen in this study is similar to that reported by others on the effects of IL-1 a  and 
TNFa on IL-6 and LIF production (Arid et al., 1995).
147
The work in transgenic mice provides strong evidence for a possible role for IL-11 in 
the decidual reaction, which is an essential response of the maternal endometrium for 
implantation and feto-placental development (Bilinski et al., 1998; Robb et al.,
1998). Decidualisation results in a change in morphology and functional activity of 
the stromal cells characterised by an increased secretion of prolactin (Schatz et al., 
1997). In addition stromal cell extracellular matrix (ECM) production is altered 
resulting in significant remodelling of the ECM (Church et al., 1996).
Decidualisation is initiated by the effects of progesterone on the oestradiol-primed 
endometrium and in humans is also seen in late secretory endometrium, even in the 
absence of an implanting embryo (Lockwood et al., 1997). The increased expression 
of IL-11 in the endometrial stromal compartment seen in this study may suggest that 
decidual cells also produce more IL-11 than non-decidual cells. An alternative 
explanation for the increased stromal staining at this time may be due to increased 
binding to the IL-11 receptor. Whichever explanation is correct the results suggest 
that IL-11 may also play a role in decidualisation in the human endometrium.
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Chapter 7 
Expression of Interleukin 11 Receptor in human 
endometrium and effects of IL-11 on endometrial cell 
function
7.1 Introduction
The work described in the previous chapter shows that IL-11 is produced by the 
human endometrium. However, the effects of IL-11 on endometrial function have not 
previously been reported in humans. In order for IL-11 to have an effect on 
endometrial cells in vivo the endometrium must express IL-1 IR a and gpl30.
Previous reports (Tabibzadeh et al., 1995a; Cullinan et al., 1996) have shown that 
gpl30 is expressed by the human endometrium. These studies showed that 
expression of gpl30 mRNA and protein is greater in the glandular and luminal 
epithelium than the stromal cell compartment and suggested that levels may increase 
during the secretory phase of the cycle. We therefore wanted to determine if IL-
I IR a protein is expressed in the human endometrium, and if the expression varies 
throughout the menstrual cycle. Any expression of IL-1 IR a would suggest that IL-
II is capable of functioning within the human endometrium by signalling through 
the IL-1 IRa/gp 130 complex.
Studies have shown that IL-11 is essential for normal decidualisation in mice (Robb 
et al., 1998; Bilinski et al., 1998), and IL-11 may also be important in human 
implantation and decidualisation. These processes involve remodelling of the 
endometrium and may be controlled by cytokines. The postulated role of MMPs in 
endometrial remodelling associated with embryo implantation has previously been 
discussed (Bischof et al., 1995b) and our results have shown that endometrial MMP 
production in vitro can be influenced by the presence of other cytokines, particularly 
IL-1 a  and TNFa. We therefore wanted to determine if IL-11 has any effect on 
endometrial MMP production.
Several studies have shown that IL-11 can affect cytokine production by other cells. 
Work on psoriasis, a chronic inflammatory skin disease has also shown that
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treatment with recombinant human IL-11 (rhIL-11) results in a decreased expression 
of disease-related genes including the cytokines IFNy, IL-8, IL-12, TNFa and IL-1 p 
and also an increased expression of endogenous IL-11. This resulted in amelioration 
of the disease as shown by reduced keratinocyte proliferation and chronic 
inflammation (Trepicchio et al., 1999). This indicates that pro-inflammatory 
cytokines can be selectively suppressed, in this disease, by rhIL-11 and suggests that 
IL-11 may play a role in the regulation of these cytokines in other tissues. Therefore, 
we wanted to determine if IL-11 would effect the production of pro-inflammatory 
cytokines from cultured endometrial cells.
The aims of this study were therefore to determine the expression of IL-1 IR a in 
human endometrium throughout the menstrual cycle using immunocytochemistry 
and to study the effects of IL-11 on production of MMP-2, MMP-9, MMP-7, TNFa 
and IL-1 p by cultured human endometrial epithelial and stromal cells. We initially 
investigated whether cultured endometrial stromal and epithelial cells in vitro 
expressed the IL-11R and therefore had the potential to respond to IL-11.
150
7.2 Materials and Methods
Immunocytochemistry was used to determine the expression of IL-1 IR a in sections 
taken from endometrial biopsies obtained throughout the menstrual cycle. 
Immunostaining was also used to show expression of IL-1 IR a in cultured stromal 
and epithelial cells. Staining in the endometrial sections was then evaluated by semi- 
quantitative analysis.
Endometrial epithelial and stromal cells were cultured and the effects of IL-11 on 
MMP-2, MMP-9, MMP-7, TNFa and IL-1 p production measured using ELISA.
7.2.1 Endometrial sections
Cryostat sections of 15 pm were taken from nineteen endometrial biopsies obtained 
from normal fertile women. For this study, one biopsy was obtained from the early 
proliferative phase (days 0-5), one during the mid-proliferative phase (days 5-9), four 
during the late proliferative phase (days 10-14), four during the early secretory phase 
(days 15-19), seven during the mid secretory phase (days 20-24) and two from the 
late secretory phase (days 25+). The sections were fixed as previously described in 
chapter 2. Dating of the biopsies was calculated from the time of the last menstrual 
period.
7.2.2 Cell culture
Endometrial stromal and epithelial cells were grown in chamber slides, until 
confluent. The cells were then fixed and stained as described for endometrial 
sections.
7.2.3 Immunocytochemistry
All sections and cells were stained according to the protocol previously described. 
The primary antibody used in this experiment was a goat anti-human IL-1 IR a 
polyclonal antibody (Insight Biotechnologies, Wembley, U.K.) at a concentration of 
lOpg/ml and an incubation time of 24h at +4°C. A parallel section was included, 
where the section was incubated with 10% normal rabbit serum instead of the
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primary antibody, but no negative control (i.e. goat IgG) was included in these 
experiments. The secondary antibody was a rabbit anti-goat immunoglobulin at a 
dilution of 1:100 (18 pg/ml) in 10% normal rabbit serum (DAKO, Ely, U.K.) and an 
incubation time of 30min at room temperature. The binding was visualised using 
PAP antibodies and DAB substrate.
7.2.4 Quantification of staining
Staining in the endometrial sections was assessed using the semi-quantification 
method.
7.2.5 Cell culture
All cell cultures were prepared as described in chapter 2. For these experiments, 
endometrial biopsies were used from five different women and both epithelial and 
stromal cell cultures were prepared and grown from each biopsy. The timing of each 
biopsy was calculated from the time of the last menstrual period. Cells were prepared 
from biopsies obtained on days 7, 10, 12, 17 and 21 of the menstrual cycle and each 
biopsy was taken from a different woman. At confluency, the cells were either 
stimulated with IL-11 at concentrations of O.lng/ml, lng/ml and lOng/ml, or 
incubated with no additions for a further 48h. The supernatants were then removed 
and stored at -20°C until analysed for MMP production by ELISA. Epithelial and 
stromal MMP-2 production was measured in cell cultures prepared from the biopsies 
obtained on days 7, 12 and 17 of the menstrual cycle. Epithelial and stromal MMP-9 
production was measured in cell supernatants prepared from the three biopsies 
obtained on days 7, 10 and 17 of the menstrual cycle and epithelial MMP-7 and 
TNFa production was measured in supernatants of cell cultures from all five 
biopsies.
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7.3 Results
7.3.1 Human endometrial expression of IL -llR a
Immunocytochemical staining showed that IL-1 IR a was present in the human 
endometrium obtained throughout the menstrual cycle in both epithelial and stromal 
cells. Figure 7.1 shows staining obtained from four biopsies taken during the 
proliferative, early secretory, mid secretory and late secretory phases of the cycle. A 
negative control has been included where the primary antibody was replaced with 
normal rabbit serum. Figure 7.2 shows the expression of IL-1 IR a in cultured 
epithelial (figure 7.2a) and stromal (figure 7.2b) cells.
7.3.2 Expression throughout the menstrual cycle
Expression of IL-1 IR a in the glandular epithelium was strong, with little variation 
between the different phases of the menstrual cycle. However, slightly more intense 
staining for IL-1 IR a was seen during the late proliferative and secretory phases 
compared to the early-mid proliferative phases of the menstrual cycle. Although 
luminal epithelium was not observed in sections from all biopsies, when it was 
observed, it also stained intensely and showed similar staining to that seen in the 
glandular epithelium of the same section (Figure 7. Id). Staining of the stromal 
compartment also remained relatively constant throughout the cycle, with only a 
small increase during the late proliferative and early secretory phases. However 
stromal cell staining was less intense than that seen in the epithelium at all times.
7.3.3 Semi-quantitative analysis of IL-11 staining
The semi-quantitative analysis of staining intensity in sections obtained from 19 
biopsies is summarised in Table 7.1.
7.3.4 Effects of IL-11 on endometrial MMP production
The basal production of MMP-2, MMP-9 and MMP-7 in these experiments was 
similar to that described in chapter 5 and showed that epithelial MMP-2 was
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Figure 7.1: Immunocytochemical staining for IL-1 IR a  in sections obtained from
endometrial biopsies during the (a) proliferative, (b) early secretory, (c) 
mid secretory and (d) late secretory phases of the menstrual cycle. A 
negative control is also shown (e).
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Figure 7.2: Immunocytochemical staining for IL -llR a  in cultured (a) epithelial 
and (b) stromal cells. A negative control is also shown (c).
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Table 7.1: Semi-quantitative analysis of staining intensity for IL -llR a  in
epithelial and stromal cells of 19 biopsies obtained at different times
throughout the menstrual cycle
Biopsy Day of cycle Epithelial staining Stromal staining
1 3 ++ +
2 5 ++ +/++
3 10 ++ +/++
4 11 ++ +/++
5 12 +++ ++
6 12 +++ ++
7 15 +++ ++
8 16 ++++ ++
9 17 ++/+++ ++
10 19 ++/+++ ++
11 20 ++/+++ ++
12 20 +++ ++
13 20 +++ ++
14 21 +++ ++
15 22 +++ +/++
16 23 +++ +/++
17 23 ++++ +/++
18 25 +++ +/++
19 27 +++ ++
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produced from both epithelial and stromal cells, but that stromal MMP-2 production 
was greater than epithelial production. MMP-9 production was predominantly seen 
in epithelial cells and MMP-7 production was only seen in epithelial cell cultures.
7.3.5 MMP-2 production
The effects of IL-11 on epithelial (figure 7.3a,c and e) and stromal (figure 7.3b, d and 
f) MMP-2 production by cells prepared from biopsies obtained on days 7 (figure 7.3a 
and b), 12 (figure 7.3c and d) and 17 (figure 7.3e and f) of the menstrual cycle are 
shown in figure 7.3. IL-11 significantly increased MMP-2 production in supernatants 
from epithelial cell cultures prepared from two of the three biopsies used (figure 7.3a 
and e). Stromal MMP-2 production was significantly increased in supernatants from 
cells prepared from only one of these experiments (figure 7.3f), with IL-11 having no 
significant effect on MMP-2 production by stromal cells prepared from the other two 
experiments (figure 7.3b and d).
7.3.6 MMP-9 production
Figure 7.4 shows the effects of IL-11 on MMP-9 production from epithelial cells in 
vitro. In this experiment cells were prepared from biopsies obtained on days 7 (figure 
7.4a), 10 (figure 7.4b) and 17 (figure 7.4c) of the menstrual cycle. IL-11 caused a 
significant decrease (p<0.05 at lOng/ml) in epithelial MMP-9 production in cells 
prepared from two of the three biopsies (figure 7.4b and c). However, the decreases 
seen were only very small. In the stromal cell culture supernatants levels of MMP-9 
were below the level of detection of the ELISA kit, both in the presence and absence 
of IL-11, showing that IL-11 did not cause a large increase in MMP-9 production by 
these cells (data not shown).
7.2.7 MMP-7 production
The effect of IL-11 on epithelial MMP-7 production in cells cultured from five 
different biopsies is shown in figure 7.5. The biopsies were obtained on days 7 
(figure 7.5a), 10 (figure 7.5b), 12 (figure 7.5c), 17 (figure 7.5d) and 21 (figure 7.5e)
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Figure 7.3: Effect of IL-11 on MMP-2 production from (a, c and e) 
epithelial and (b, d and f) stromal cells in vitro. Values 
are mean + SEM (n=4). *= significantly different from 
controls at p<0.05, **= significantly different from 
controls at p<0.01. Each graph represents the results 
obtained from cells prepared from a single biopsy 
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Figure 7.4: Effect of IL-11 on MMP-9 production from epithelial cells 
in vitro. Values are mean + SEM (n=4). *= significantly 
different from controls at p<0.05. Each graph represents 
results obtained from cells prepared from a single biopsy
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Figure 7.5: Effect of IL-11 on epithelial MMP-7 production in supernatants 
from cell cultures of biopsies obtained on (a) day 7, (b) day 10, 
(c) day 12, (d) day 17 and (e) day 21 of the menstrual cycle. 
Values are mean + SEM (n=4). *=significantly different from 
controls at p<0.05. Each graph represents results from cells 
prepared from a single biopsy.
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of the menstrual cycle. The results suggest that IL-11 had no significant effect on 
MMP-7 production by endometrial epithelial cells prepared from four of the five 
biopsies, and although a significant decrease (p<0.05) in MMP-7 production was 
seen in cells prepared from the other biopsy (figure 7.5b), the effect was not dose- 
dependent.
7.3.8 Effects of IL-11 on endometrial cytokine production
7.3.8.1 Tumour Necrosis Factor a
Production of TNFa from epithelial cells was seen to decrease following incubation 
with IL-11. Figure 7.6 (a) shows the results from cells prepared from a single biopsy, 
when levels of TNFa in cell culture supernatants were measured using ELISA. IL-11 
caused a dose-dependent decrease in TNFa production with significant decreases 
seen at 1 and lOng/ml. A similar decrease was seen in 3 of the other 4 experiments 
carried out. In the other experiment, IL-11 had no effect on TNFa production. 
Changes in levels of TNFa measured by bioassay showed strong correlation with 
that seen when TNFa was measured by ELISA. Figure 7.6 (b) shows the dose- 
dependent decrease in TNFa production by epithelial cells as is seen in figure 7.6 
(a). Figures 7.6 (a) and (b) show the results from the same cell culture experiment 
measured using the two methods, and similar patterns of TNFa levels were seen in 
all experiments when analysed by bioassay and ELISA. Differences in the amount of 
TNFa measured using the two different methods is due to the bioassay only 
measuring unbound/active TNFa, whereas ELISA will also measure any TNFa that 
is bound to the soluble form of the receptor, therefore producing higher 
measurements of TNFa present. No differences were seen in responses of cells 
prepared from the proliferative and secretory endometrium.
7.3.8.2 Interleukin-1 P
The effect of IL-11 on IL-1 p production from cultured epithelial and stromal cells 
was also investigated. However, in both epithelial and stromal cell cultures the 
concentration of IL-1 p in the supernatants was below the level of detection of the
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Figure 7.6: Effect of IL-11 on endometrial TNFa production by cultured 
epithelial cells. TNFa was measured by (a) ELISA and (b) 
bioassay. Values are mean + SEM (n=4). *= significantly 
different from controls at p<0.05, ** = significantly different 
from controls at p<0.01 and *** = significantly different 
from controls at p<0.001. The results shown are from 
a single biopsy, but similar results were seen in the other 
four exeriments.
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ELISA kit. The levels of IL-1 p remained below the level of detection following 
incubation of the cell cultures with IL-11.
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7.4 Discussion
This study is one of the first to investigate the presence of IL-1 IR a protein in the 
human endometrium. The results clearly show that IL-1 IR a is expressed in the 
endometrium throughout the menstrual cycle. This agrees with a previous recent 
study which showed, using RT-PCR, that IL-1 IR a mRNA was expressed in the 
human endometrium throughout the menstrual cycle with minimal variation 
(Dimitriadis et al., 2000). The results suggest that IL-1 IR a expression in epithelial 
and stromal cells remains relatively constant throughout the menstrual cycle, with 
epithelial expression being greater than stromal expression at all times in the 
menstrual cycle. The intensity of staining in the epithelial cells appeared to be 
slightly greater during the early secretory phase of the menstrual cycle. The presence 
of IL-1 IR a in the human endometrium taken together with results from other 
studies, which have shown the presence of gp 130 in the human endometrium 
(Dimitriadis et al., 2000; Tabibzadeh et al., 1995a), suggests that IL-11 should be 
capable of functioning within the human endometrium. It has been shown that mice 
with either a null or inactivating mutation in the IL-1 IR a gene were infertile, as they 
had an impaired decidual response, which resulted in pregnancy loss (Robb et al., 
1998; Bilinski et al., 1998). Therefore, IL-1 IR a may also play an important role in 
the decidualisation process in humans. The results also show that cultured epithelial 
and stromal cells express IL-1 IRa. Thus the cells in culture should be able to 
respond to IL-11.
MMPs are thought to be involved with the endometrial remodelling associated with 
implantation of the embryo in humans. It has previously been shown that MMP-2, 
MMP-9 and MMP-7 are produced by epithelial cells and that other cytokines, in 
particular, IL-1 a , TNFa can affect endometrial MMP production in vitro (data 
shown in chapter 5). We therefore wanted to determine if IL-11 had any effect on 
endometrial MMP production. The results show varying effects of IL-11 on 
endometrial MMP-2 production in vitro. In some cases significant increases were 
seen, while in others no effects were seen. Even when significant increases were seen 
the effects were not dose-dependent and therefore, there is little convincing evidence 
for IL-11 affecting stromal or epithelial MMP-2 production. The results suggest that
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IL-11 may have a slight inhibitory effect on MMP-9 production at lOng/ml. It is 
possible that higher doses of IL-11 may cause a further decrease. This was not tested 
as we have previously found that cytokines have their effects at the concentrations 
used in these experiments (0.1-10ng/ml). Levels of stromal MMP-9 production were 
below the level of detection of the ELISA kit. This is expected for the basal values of 
MMP-9, but because the levels were still below the level of detection following 
incubation with IL-11 it suggests that IL-11 has no significant stimulatory effect on 
stromal MMP-9 production.
The results show considerable variation in basal MMP-7 production from cells 
cultured from biopsies obtained at different times in the menstrual cycle. Overall, 
basal MMP-7 concentrations were highest in supernatants from cells cultured from 
biopsies obtained in the proliferative phase of the menstrual cycle, which agrees with 
that seen in previous studies (Rodgers et al, 1993; Rodgers et al., 1994) and results 
obtained in chapter 5. The results showing the effect of IL-11 on epithelial MMP-7 
production were also very varied and the standard error bars were very large. The 
reason for the high level of variation for MMP-7 in this series of experiments 
compared to those described in chapter 5 is not known. As in chapter 5 these 
experiments were carried out without the addition of steroids to the cell culture 
media and in media containing fetal calf serum. This may have accounted for the 
lack of effect of IL-11 on the cells and for the variation seen. However, as discussed 
in chapter 5, consistent responses to IL-1 a  and TNFa were seen when cells were 
cultured in the same conditions. In these experiments the levels of MMPs were not 
assessed by zymography. The results described in chapter 5 show that similar effects 
are seen by zymographic analysis and ELISA analysis, and as ELISA is more 
quantitative than zymography, only this type of analysis was chosen.
The results suggest that IL-11 significantly decreases TNFa production from most 
endometrial epithelial cells. No attempt was made to measure TNFa levels in 
stromal cell supernatants as they do not produce TNFa (Laird et al., 1996). An 
attempt to measure any effect of IL-11 on epithelial and stromal IL-1 p production 
was made, but the amounts of IL-1 p measured were below the level of detection of 
the ELISA kit both before and after addition of IL-11. It would be difficult to
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hypothesise a possible reason for this effect of IL-11 on TNFa production, however, 
it may be that it acts as a feedback mechanism to prevent over-production of TNFa.
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Chapter 8
General Discussion
8.1 Introduction
This study has concentrated on the expression of cytokines in the human 
endometrium and the possible role that they may play in normal endometrial function. 
The role of these cytokines in recurrent miscarriage has also been investigated. 
Although much previous work has concentrated on ThI and Th2 cytokines in 
successful pregnancy outcome, this study has concentrated on the pro-inflammatory 
cytokines, IL-1, TNFa, LIF and IL-6, as previous studies have suggested that these 
are important in endometrial function. During this period of study, the work with IL- 
11R knockout mice was published (Bilinski et al., 1998; Robb et al., 1998), 
suggesting the importance of IL-11 in successful pregnancy outcome. As IL-11 
belongs to the same family of cytokines as IL-6 and LIF this was also studied.
The main techniques used were immunocytochemical analysis of cytokines in 
endometrial biopsies and cell cultures, and some attempt was made to measure 
cytokine mRNA by RT-PCR analysis. Immunocytochemistry has the advantage of 
enabling detection of cytokine production in the in vivo situation, and in particular, in 
determining which cell populations are involved. However, quantification using this 
technique is difficult and it is not possible to study mechanisms of actions of 
cytokines in human endometrial function in this way. Cell culture has the advantage 
of enabling control mechanisms to be investigated, but care should be taken in 
extrapolating the results obtained to the in vivo situation, as influences of other cells, 
either structurally or functionally have been removed. If it had been successful, the 
RT-PCR results would have shown expression of mRNA, which confirms synthesis, 
rather than presence of cytokines in the tissue. Showing the presence of both mRNA 
and protein would also have strengthened this study. The reason for the lack of 
success of the RT-PCR is probably due to the way the biopsies were collected and 
due to the impurity of the RNA samples following the RNA extraction procedure. It 
is however, unlikely that the lack of success is a result of inadequate optimisation of 
the PCR reactions as the reactions were optimised, as discussed previously in chapter 
3.
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The results from these studies clearly provide more evidence for the presence of 
cytokines, in particular LIF, IL-6, IL-1, TNFa and IL-11 in the human endometrium. 
With the exception of TNFa all of these cytokines have been localised in human 
endometrium using immunocytochemistry, and in this work, cultured endometrial 
cells were shown to express TNFa and IL-11. LIF and IL-6 have previously been 
shown to be produced from endometrial cells cultured using the same cell culture 
technique (Laird et al., 1994; Laird et al., 1997).
8.2 Human endometrial cytokine expression
8.2.1 In vivo expression of endometrial LIF, IL-6, IL-1 and IL-11
The results from this work agrees with that from others (Chamock Jones et al., 1994; 
Tabibzadeh et al., 1995a; Tabibzadeh and Sun, 1992; Simon et al., 1993a; Dimitriadis 
et al., 2000), in demonstrating that LIF, IL-6, IL-la, IL-1 p and IL-11 are expressed 
by the human endometrium throughout the menstrual cycle. The most significant 
findings are that LIF and IL-6 expression, in the epithelial glands, is maximal during 
the secretory phase of the cycle, when implantation occurs. Previous studies have also 
reported a similar increase in epithelial LIF expression (Chamock Jones et al., 1994; 
Vogiagis et al., 1996; Arici et al., 1995) and epithelial IL-6 expression (Tabibzadeh et 
al., 1995a) in the secretory phase of the menstrual cycle. This increased expression 
suggests that LIF and IL-6 may therefore be important in the implantation process in 
humans, particularly as LIF has previously been shown to be essential (Stewart et al.,
1992), and it has been suggested that IL-6 may also play an important role 
(Tabibzadeh et al., 1995a), in implantation in mice.
IL-11 is a member of the IL-6 family of cytokines, and also signals through the signal 
transducing receptor gpl30. Although the expression of IL-11 in the human 
endometrium was not seen to increase as drastically as LIF and IL-6, at the time of 
implantation, epithelial expression was slightly increased during the secretory phase 
of the cycle. As previous studies have shown that mice with a null or inactivating 
mutation for IL-1 IR a are infertile as a result of inadequate decidualisation (Bilinski
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et al, 1998; Robb et al., 1998), it is possible that IL-11 may be important in the 
decidualisation process in humans. This provides a possible explanation as to why 
stromal IL-11 expression is increase^ during the mid-late secretory phase of the 
menstrual cycle. Further evidence to support this possibility are the results showing 
that IL-1 IR a is expressed in the epithelial and stromal compartment of the human 
endometrium, although there appears to be little variation throughout the menstrual 
cycle.
Expression of IL-1 a  and IL-1 p was seen to remain relatively constant throughout the 
menstrual cycle in both stromal and epithelial cells. This agrees with a previous 
report of human endometrial IL-1 expression (Tabibzadeh and Sun, 1992). However, 
other studies have suggested that IL-1 p expression is only seen during the mid-late 
secretory phase of the menstrual cycle (Kauma et al., 1990; Simon et al., 1993a). 
Although the results from this study showed that expression of IL-1 p in epithelial 
cells was maximal at the time of implantation, it was also present at all other times in 
the menstrual cycle. The differences in staining seen between these studies is not 
known, but may be due to different antibodies being used in each of the experiments.
8.2.2 Differences in cytokine expression of normal fertile women and women 
who suffer recurrent miscarriage
The results from this study showed that LIF expression was decreased in 11 out of 24 
women who suffer unexplained recurrent miscarriage when compared to normal 
fertile women at the time of implantation. Expression of IL-6 was also decreased in 9 
out of 15 biopsies obtained from recurrent miscarriage women and IL-1 a  was 
decreased in at least 4 out of 12 biopsies obtained from recurrent miscarriage women 
when compared to staining seen in normal fertile women at the time of implantation. 
IL-1 P expression was only decreased in 2 out of 11 biopsies obtained from women 
who suffer recurrent miscarriage, however of the remaining biopsies that were used in 
this experiment, there was some variable staining. In some biopsies, epithelial glands 
stained the same intensity in recurrent miscarriage biopsies when compared to those 
obtained from normal fertile women, but the staining was not uniform throughout the 
sections, some glands showed a complete absence of IL-1 p. In other biopsies the
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luminal epithelium stained normally but there was no staining present in any of the 
glands.
These differences seen between recurrent miscarriage women and normal fertile 
women were greater for LIF and IL-6 than for IL-1 a  and IL-1 p. Previous studies 
have reported a similar decreased endometrial expression of both IL-1 p (von Wolff et 
al., 2000) and IL-6 (von Wolff et al., 2000; Lim et al., 2000) mRNA transcripts in 
women with habitual abortion when compared to normal fertile women during the 
mid secretory phase of the cycle.
Having determined the pattern of expression of IL-11 in the endometrium throughout 
the menstrual cycle, the expression of IL-11 needs to be investigated in women 
suffering recurrent miscarriages. This work would determine if there are any 
differences in endometrial IL-11 expression between these two groups of women, 
particularly at the time of implantation and provide a greater understanding of the 
possible role of IL-11 in human endometrial function.
The results have shown the limitations of using immunocytochemistry to determine 
expression of cytokines in the endometrium, particularly when comparing results 
between the two groups of women. It might prove useful to use a more quantitative 
method to investigate this further. The measurement of protein in endometrial 
flushings has previously been used to compare production of endometrial proteins in 
normal fertile women and recurrent miscarriage women (Dalton et al., 1995; Hey et 
al., 1995) and provides a more quantitative assessment of differences. However, 
cytokine concentrations are very low in flushings and although attempts have been 
made to compare endometrial LIF production in various groups of women in this 
way, the levels present were close to the detection limit for the assay (Laird et al., 
1997). However, more sensitive assays for IL-6, IL-1 and IL-11 are now available 
and therefore this approach may prove productive in the future.
8.2.3 In vitro production of cytokines by cultured endometrial cells
The work presented here shows that cultured epithelial and stromal cells express IL- 
1 IR a and produce IL-11. TNFa was also shown to be produced by epithelial cells,
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but not stromal cells. Other experiments attempted to measure IL-1 p production by 
cultured endometrial cells, however, the levels of IL-1 p in supernatants from cultured 
epithelial and stromal cells were below the level of detection of the ELISA kit, 
suggesting that if IL-1 p is secreted by these cells, it is only in very small amounts. 
Previous studies in this laboratory have shown that cultured epithelial, but not stromal 
cells produce IL-6 and LIF (Laird et al., 1994; Laird et al., 1997). The results above 
suggest that the cell culture system used acts as a good in vitro model when studying 
epithelial and stromal cells, as cytokines that are expressed in vivo can be detected in 
the cell cultures. However, when studying the endometrium in vitro, it can not be 
assumed that the results obtained would be an exact reflection of what is happening in 
the in vivo environment. These studies showed differences between in vivo and in 
vitro IL-1 p production, agreeing with other work that has also shown that IL-1 p is not 
produced by cultured endometrial cells (Simon et al., 1998). We know that cytokines 
act in an autocrine and paracrine manner and it may be that in cell cultures, the 
paracrine action of some cytokines is altered due to the absence of other cells that 
would be present, and therefore would be influential, in the in vivo environment.
When studying cultured endometrial cells it is essential to determine the purity of the 
cell cultures, as contamination with leukocytes, stromal or epithelial cells would 
produce inaccurate results. Immunocytochemical analysis of vimentin (stromal cell 
marker), cytokeratin (epithelial cell marker) and CD45 (leukocyte marker) expression 
by stromal and epithelial cells prepared and cultured in this way has shown that the 
cells are essentially pure (>90%) and free of leukocyte contamination (Laird et al.,
1993).
8.3 Investigations into endometrial cytokine function
Epithelial and stromal cell cultures were used to study the effects of cytokines on 
MMP-2, MMP-9, MMP-7, IL-11 and TNFa production. In these experiments 
cytokines were added to confluent cells and were further incubated for 48 h. Effects 
of cytokines on cell growth were not investigated and it is therefore possible that the 
changes seen may be due to effects on cell number. However, previous published 
(Laird et al., 1994; Laird et al., 2000) and unpublished work has shown that neither
171
IL-1, TNFa, IL-6 and LIF have any effect on 3H-thymidine uptake into either stromal 
or epithelial cells, suggesting that the effects seen are independent of cell growth. 
Initial studies in the effect of IL-11 on H-thymidine uptake into stromal and 
epithelial cells, also suggest that the effects of this cytokine are independent of cell 
growth (personal communication, S.M.Laird).
8.3.1 Basal endometrial MMP production
The production of MMP-2, MMP-9 and MMP-7 from cultured epithelial and stromal 
cells was measured using ELISA. The results showed that MMP-2 was produced 
from both epithelial and stromal cells, MMP-9 was produced mainly from epithelial 
cells, with only small amounts present in supernatants from cultured stromal cells and 
MMP-7 was produced from epithelial cells only. Epithelial MMP-2 production was 
seen to be significantly increased in supernatants from cells cultured from secretory 
endometrium when compared to that in supernatants from proliferative endometrium. 
Whereas epithelial MMP-7 production was significantly decreased in supernatants 
from cells cultured from secretory endometrium compared to proliferative 
endometrium. These findings are not surprising because it has previously been shown 
that progesterone and oestrogen are capable of influencing endometrial MMP 
production (Salamonsen et al., 1997; Singer et al., 1997; Schatz et al., 1999; Keller et 
al., 2000). Therefore the cyclical changes in steroid production would be expected to 
influence MMP production.
8.3.2 Effects of cytokines on endometrial MMP production
The results from this study have shown that cytokines, in particular, IL-1 a  and TNFa 
are capable of modulating endometrial MMP production. In this study, cells prepared 
from only three endometrial biopsies were incubated with each cytokine and therefore 
it cannot be determined if the effects of the cytokines were dependent on the time in 
the cycle that the biopsy was obtained. The fact that differences in basal MMP 
production was seen in cells prepared from biopsies obtained at different times in the 
cycle, suggests that differences may be seen. Subsequent studies investigating the 
effects of cytokines at particular times in the cycle, in particular at the time of
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implantation, would prove useful in order to establish the relationship between 
cytokines and MMPs in the implantation process.
The most surprising aspect of this study was the fact that IL-6 and LIF had no effect 
on MMP production by either stromal or epithelial cells. Both IL-6 and LIF have 
been shown to affect gelatinase production by cytotrophoblast cells (Bischof et al., 
1995a; Nachtigall et al., 1995; Meissier et al., 1999b). IL-6 receptor, LIF receptor and 
gpl30 signal transducing receptor are all expressed in epithelial and stromal cells in 
vivo (Tabibzadeh et al., 1995a; Sharkey et al., 1999). Although there are no reports of 
their expression by cultured epithelial cells, loss of cytokine receptor expression is 
not characteristic of cultured cells. Taken together these results suggest that MMP 
production from embryonic and maternal cells are controlled by different 
mechanisms.
In contrast to IL-6 and LIF, IL-1 a  and TNFa seem to be capable of modulating MMP 
production by both embryonic and maternal cells (Meissier et al., 1999a). IL-11, like 
LIF and IL-6, had little effect on endometrial MMP production by either stromal or 
epithelial cells. This is perhaps not surprising as all three cytokines signal through 
gpl30 and thus would be expected to have similar effects.
8.3.3 Effects of cytokines on endometrial IL-11 production
Previous studies have shown that IL-1 and TNFa stimulate endometrial LIF (Arici et 
al., 1995) and IL-6 (Laird et al., 1994; Laird et al., 2000) production and that IL-1, 
TNFa and TGFp are capable of stimulating IL-11 production in other cell types 
(Elias et al., 1994a; Morinaga et al., 1997; Mino et al., 1998). Therefore, we have 
used cultured stromal and epithelial cells to investigate the effects of IL-1 p, TNFa 
and TGFp on endometrial IL-11 production in vitro. The results showed that all three 
cytokines significantly increased IL-11 production from both stromal and epithelial 
cell cultures.
These results show the production of IL-11 by cultured endometrial cells for the first 
time and also indicate differences between IL-11, IL-6 and LIF production, in that IL-
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11 is produced by both stromal and epithelial cells, whereas previous studies have 
shown that LIF and IL-6 are only produced by cultured epithelial cells (Laird et al., 
1994; Arici et al., 1995).
The effect of TGFp on cell growth has not been investigated and as a result, this may 
explain the increased expression of IL-11 in the presence of TGFp. However, the 
cells were only incubated with TGFp for 48h and the significant increase in IL-11 
production seen in the cell cultures particularly stromal cells, is unlikely to be 
accounted for by an increase in cell number over 48h. Therefore the results suggest 
that the effects of all three cytokines on IL-11 production are independent of growth.
The results suggest that IL-11 production can be controlled by other cytokines in the 
endometrium, including IL-1, TNFa and TGFp. Effects of IL-1 and TNFa on 
endometrial LIF and IL-6 production have been reported (Laird et al., 1994; Arici et 
al., 1995). Effects of TGFp on endometrial cytokine production have not been 
reported and would warrant further study.
8.3.4 Effect of IL-11 on endometrial cytokine production
The endometrial expression of IL-1 IR a shown in this study and the fact that previous 
studies have shown expression of gp 130 in the endometrium (Tabibzadeh et al., 
1995a; Cullinan et al., 1996), suggests that IL-11 may have a role in endometrial 
function. In this study, the effect of IL-11 on cytokine production from cultured 
endometrial cells was also investigated. However, only TNFa production from 
epithelial cells could be measured because epithelial IL-1 p and stromal IL-lp and 
TNFa levels were below the level of detection of the ELISA kits. TNFa production 
was significantly decreased following incubation of the cells with IL-11. Taken 
together with the findings that TNFa stimulates epithelial IL-11 production in vitro, 
this suggests that IL-11 may provide a possible negative feedback mechanism for the 
control of epithelial TNFa production in the human endometrium (figure 8.1). Thus 
IL-1 and TNFa stimulate epithelial production of not only IL-11 but also IL-6 and 
LIF; which becomes maximal at the time of implantation. Increased IL-11 production
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Figure 8.1: Postulated function of IL-11 to provide a negative feedback 
mechanism for the control of endometrial epithelial TNFa 
production
Epithelial
Cell TNFa
IL-11 EpithelialCell »
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appears to feedback onto the epithelial cells and inhibits TNFa production, thus 
turning off one of the major stimulants of its production. The effects of IL-6 and LIF 
on TNFa and IL-1 production have not been reported, but initial studies have 
suggested that IL-6 and LIF have no effect on TNFa production by epithelial cells 
and thus the feedback effect may be specific for IL-11.
8.4 Overall conclusion
In summary this study has shown the presence of LIF, IL-6, IL-1, TNFa and IL-11 in 
the human endometrium and provided evidence that they play a major role in human 
endometrial function. LIF and IL-6 in particular appear to be important in 
implantation, as expression is greatest at the time of implantation and is decreased in 
some women who suffer recurrent miscarriage. However, functional studies suggest 
that IL-1 and TNFa are also important, as it is these cytokines that produce more 
dramatic effects on cytokine and MMP production from endometrial cells in culture. 
More extensive research is required before the exact role of cytokines within the 
human endometrium can be determined. However, results from this study along with 
those previously reported by others show that cytokines are undoubtedly important 
mediators of endometrial function.
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